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Thesis Summary 
Obesity and its accompanying comorbidities play a crucial role in the pathogenesis of endothelial 
function which is a pre-cursor to atherosclerosis, subsequently leading to increases in cardiovascular 
risk. However, amelioration of these risk factors and improvements in endothelial function have 
never been fully explored in functional assessments of the retinal and peripheral microcirculations. 
The aim of this thesis was therefore to investigate the presence and impact of weight-loss 
interventions in overweight and obese individuals and also the relationships between functional 
measurements of different vascular beds. 
 
The principle findings of this work were: 
1. The relationship between retinal and peripheral vascular function in healthy individuals with 
low cardiovascular risk 
• Participants with higher peripheral vascular reactivity indices had a higher amplitude change 
from maximum to minimum and also showed enhanced reaction times to flicker 
provocation, which correlated to the degree of peripheral vascular function.   
 
2. The effects of physical training on retinal and systemic microvascular function 
• Physical exercise positively influenced the retinal microcirculation through improvements in 
dilation and constriction reaction times to flicker provocation 
 
3. The long-lasting effects of fasting during the month of Ramadan on retinal and peripheral 
vascular function 
• Participants during fasting had a higher capacity to reach maximum dilation and also a 
greater percentage increase from baseline diameters. The retinal veins were also 
significantly less variable during baseline corrected measurements 
 
4. The effect of bariatric surgery on retinal vessels structure and systemic microvascular function 
• Increases were recorded for the diameter of retinal arteries but also for the veins. Peripheral 
vascular function was significantly improved and arterial stiffness was decreased. CVD risk 
was significantly decreased and also correlated with retinal vessel calibre measurements. 
 
5. Is there an improvement in anterior ocular health after bariatric surgery? 
• Anterior surface health doesn’t necessarily cause ocular health problems in obese 
individuals nor can it be improved or ameliorated through bariatric surgery 
 
 
 
Keywords: Overweight, Obesity, Weight-loss, Retinal vessel reactivity, Peripheral vascular reactivity, 
Cardiovascular disease, Endothelial function 
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1. Introduction 
1.1. General background  
Obesity has been recognised as a health issue for thousands of years. Early documents show that the 
privileged classes of roman society were affected by obesity1. The writer Gaius Plinius Secondus 
known as “the Elder”, describes in his book2 that the son of the consul Lucious Apronius complained 
that his excessive stature made him clumsy and heavy, and chose to have surgical removal of his skin 
and subcutaneous fat. The consul expressed the opinion that the operation would have physical and 
psychological health benefits for his son and would improve his ability to perform his professional 
duties1 2. Hippocrates also recognized that “sudden death is more common in those who are 
naturally larger than their leaner counterparts”3. 
The technological advances in farming during the 18th Century  translated in a gradual increase of 
food supply and in a better quality and variety of food; this, in turn, led to an increased longevity and 
body size. Corpulence and increased “flesh” were a desirable attribute and a sign of beauty, as 
reflected in arts, literature, and medical opinions of those times4.  
In 1832, Adolphe Quetelet (1796-1874), a Belgian mathematician, astronomer, and statistician 
developed a formula for estimating body fat, called the quetelet index. His pioneering cross- 
sectional studies of human growth led him to conclude that ‘weight increases as the square of the 
height’5. The need for a normative value index was also recognized in the early 19th century when 
actuaries noted an increased death claims among their obese policy holders6.  As obesity gradually 
became a medical concern following the Second World War, the pursuit for a reliable and practical 
index for relative weight began5. One of the first studies to confirm the validity of the quetelet index 
was the Framingham study5 7 and  this index was renamed the body mass index (BMI)8. This index is 
still used today.  
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Even though the impact of obesity on health was being recorded from the late 18th century and 
recognized as a cause of ill health by the mid-19th century4, its morbid complications and impact on 
increased mortality was  documented only in  mid-20th century3 9-11. Obesity has seen an exponential 
increase in the west most probably due to sedentary lifestyles, longer working office hours and the 
commodity of fast food.  
Obesity has been described as a chronic disease in the same sense as hypertension and 
atherosclerosis3. In the past few decades it has reached epidemic proportions. Obesity has become 
one of the leading causes of disability and death, affecting not only adults but of varying ages, 
including children worldwide12. In 2014, more than 1.9 billion adults were overweight, 600 million of 
them were obese. Forty two million children under the age of 5 were overweight or obese in 201313. 
Obesity has also been shown to decrease life expectancy by 7 years at the age of 4014. This increased 
risk of death declines progressively with each unit of BMI but remains substantial until about the age 
of 7515 16. The World Health Organization (WHO) has declared obesity as a global epidemic and 
world-wide public health crisis. WHO has characterized obesity as a medical condition in which 
excess amounts of body fat have accumulated, leading to health problems and reduced life 
expectancy13.The WHO has declared obesity as the largest global chronic health problem in adults 
which is increasingly turning into a more serious problem than malnutrition17. The WHO world 
health statistics report in 2015 shows that in the European region the overall obesity rate among 
adults is 21.5% in males and 24.5% in females. The same report states that the prevalence for 
overweight among children under the age of 5 is 12.4%18 (ref WHO 2015). It has been further 
projected that 3.3 billion people, could be overweight (2.2 billion) or obese (1.1 billion) by 2030 if 
these trends continue, equating to roughly 60% of the world’s population17 19. 
Throughout the world, obesity is more common amongst women; they also have a mean BMI higher 
than men, possibly due to biological reasons, such as estrogen and insulin resistance20. The 
department of health (UK) estimates that men with a BMI of 25 kg/m2 have a reduced life 
13 
 
expectancy of 2 years, and given the progressive nature of obesity, life expectancy will be reduced 
by 5 years in 205016.  
1.2. The role of adipose tissue 
Historically adipose tissue has been has been viewed as one of the least complex organs in the body. 
The perspective was that the organ was simply for fat storing purposes in which excess calories were 
deposited after a meal and from which fuel would be released during episodes of increased energy 
demands, fasting and prolonged food deprivation21. Adipose tissue in normal weight persons can 
account for between 18% and 24% of total body weight and in contrast in obesity it can account for 
between 52% and 74%22. Adipocytes secrete cytokines, hormones and bioactive peptides that have a 
key impact on skeletal muscle and liver function to regulate energy, and maintain homeostasis as 
well as used in metabolism23.  Adipose tissue has a dense network of micro-vessels ensuring 
sufficient exchange of nutrients and oxygen. The adipose tissue delivers lipids to their storage depot 
in the adipocytes and also exports nutrients in response to metabolic need. Adipokines and other 
vasoactive mediators are secreted from adipocytes and other cellular elements from the tissue, such 
as macrophages and via the tissue microvascular network are delivered into the blood stream to 
exert their remote effects. In obesity however, insufficient adipose tissue perfusion may result in 
local hypoxia which induces the levels of hypoxia inducible factor (HIF) in adipocytes and can lead to 
increased synthesis of various inflammatory adipokines that include tumor necrosis factor (TNF), 
Leptin, interleukin (IL)-6 and resistin24-26. 
Newer studies and further developments have demonstrated essential distinctions between the 
roles of white adipose tissue (WAT) and brown adipose tissue (BAT)21. BAT is specialized for the 
generation of heat, fuelled primarily by the oxidation of fatty acids through the presence of a specific 
mitochondrial uncoupling protein (UCP-1)27 28. This generation of heat is mainly responsible for the 
dissipation of excess calories as a mechanism for maintenance of energy balance and body weight29 
30. In contrast WAT is responsible for fuels storage and provides a substrate to other tissues during 
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periods of high energy demands and fasting21.  Further studies demonstrate that in some cases it 
appears to be that both types of adipose tissue can interact in a coordinated and compensatory 
manner31 with little differentiation that makes this organ much more complex.  Nonetheless, 
adipose tissue is a key endocrine organ with autocrine regulation32.  Adipocytes are the signature cell 
of adipose tissue and are primarily the focus of cellular studies21. Indeed it has been realised that the 
cells (adipocytes) within adipose tissue become inflamed and this inflammatory state leads to the 
initiation and progression of the major obesity associated diseases33-35 and has a central role in the 
development of complications associated with obesity that include dyslipidemia, insulin resistance, 
metabolic syndrome and low grade chronic inflammation that leads to an increased risk of 
cardiovascular disease32 36.   
Other adipose constituents include Adipokines such as adiponectin, leptin, resisten, vascular 
endothelial growth factor (VEGF)23 37-39 and also proinflammatory cytokines such as TNF, IL-1, IL-640 41 
and monocyte chemoattractant protein (MCP1)42. Adiponectin is thought to have a positive effect on 
vascular function43. In obesity the circulating levels of adiponectin are reduced23 while the 
concentrations of leptin, TNF IL6, and MCP137 42 44 are increased. A study by Greenstein et al, has 
found that healthy adipose tissue around human small arteries secretes adiponectin that causes 
vasodilation by increasing nitric oxide (NO) bioavailability45. However, adiponectin from perivascular 
fat in obese subjects with metabolic syndrome lose its dilator effects45. Leptin is a hormone with 
appetite regulating properties which primarily acts on the hypothalamic neurons to activate 
catabolic and inhibit anabolic pathways resulting in weight reduction46 and lower levels of leptin 
have been found to be associated with higher risk of weight gain in healthy young adults47. In many 
obese subjects, leptin secretion was found to be significantly higher than in lean subjects, indicating 
leptin resistance rather than insufficient leptin production48, which can alter vasomotor function 
from the adverse effects of circulating levels of leptin23. In a study by Knudson et al, pathological 
concentrations of leptin attenuated dilation to acetylcholine (Ach) in coronary arteries, whereas 
physiological concentrations had no effect49.  
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Resistin is another adipokine and is expressed almost exclusively in adipocytes and resistin levels 
elevate in obesity50. Elevated serum levels of resistin have been correlated with inflammatory 
markers including TNF and IL-6 along with increased coronary artery calcium score51. Verma et al, 
showed within endothelial cells, resistin increased the expression of endothelin-1 (ET-1) a potent 
vasoconstrictor52. Another study showed decreased eNOS levels in coronary endothelial cells which 
were incubated with resistin53. TNF is also secreted by adipocytes and its expression in adipose 
tissue is increased in obesity54 55, which correlated with the severity of insulin resistance56 57 It has an 
important role in the development of endothelial dysfunction in obesity54 58 59. Recently a study 
carried out found that obese individuals express almost 3 times higher TNF in adipose tissue relative 
to lean controls35 56. Recent reports provide evidence that TNF inhibits endothelium dependant NO 
mediated dilation of coronary arterioles59 60. In obesity, adipose tissue is infiltrated with a large 
number of macrophages61, and can account for 40% of the cells within the adipose tissue when 
compared to normal adipose tissue62. Macrophages within adipose tissue were shown to contribute 
to the substantial release of TNF and Il663.  
Apart from the cerebral artery and pulmonary vessels various quantities of perivascular adipose 
tissue (PVAT) surround blood vessels throughout the body64. PVAT provides mechanical protection 
for the blood vessels but also secretes vasoactive adipokines65. The adipokines secreted from PVAT 
can easily reach the adjacent blood vessels wall sicne there is no anatomical barrier between PVAT 
and adventitia66. They play an important role in the regulation of vascular tone and vessel wall 
remodelling via their paracrine or endocrine effects. Adipokines released from PVAT have been 
shown to be more inflammatory, proliferative and angiogenic compared to other adipose depot 
profiles such as visceral or subcutaneous adipose tissues in humans67-70. It has been shown in 
coronary artery disease (CAD) that inflammatory and proliferative adipokine expression or release 
such as IL6, il1, resistin, MCP1, Leptin and TNF are increased where as ant-inflammatory and anti-
proliferative vasodilator such as adiponectin are decreased71 72. This imbalance between pro/anti-
inflammatory adopikines can play a major role in cardiovascular diseases such as atherosclerosis and 
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hypertension by increasing vascular tone, inflammatory processes and vascular smooth muscle cell 
VSMC proliferation and migration66. Total quantity of PVAT around coronary arteries is strongly 
related to atherosclerotic plaque73 74. It has been demonstrated that adipose tissue quantity is 
negatively correlated with microvascular coronary vasodilation response and also coronary flow 
hyperaemia75. More recently, the role of TNF on the NO/ET-1 imbalance in PVAT has been 
investigated in small arteries of visceral abdominal fat from obese subjects. The results have 
suggested that PVAT can have a role in endothelial dysfunction76.  
Weight-loss procedures such as bariatric surgery have been shown to improve vascular response by 
restoration of the vaso-relaxant effect of PVAT and also reversal of endothelial dysfunction77 78.  
PVAT is associated with an increased vascular expression of ET-1 and endothelin receptors. In 
addition, the increase of TNF in obsese subjects proposed to be responsible for NOS uncoupling and 
decreased NO release due to NADPH oxidase activation and increased reactive oxygen species (ROS) 
generation76. Arteries surrounded by PVAT from obese subjects release less NO compared to PVAT 
from controls. Thus the vaso-relaxant effects of PVAT in physiological conditions transforms into an 
inflammatory pro-contractile state in obesity54 76.  
It is well known that proliferation and migration of vascular smooth mucle cells (VSMC) plays a 
pivotal role in vascular remodelling which is observed during pathogenesis of atherosclerosis and 
hypertension66. These proliferative factors of PVAT include the adipokines resistin and TNF79 80 were 
found to be VSMC growth factors. Adipokines play a role not only in in VSMC proliferation but also 
endothelial cell proliferation. Studies have demonstrated that leptin and chemerin could promote 
endothelial cell proliferation and migration and mediate the formation of blood vessels to a similar 
extend as VEGF in human endothelial cells75 81-83. Similarly resistin and visfatin have induced 
angiogenesis by promoting VEGF via metalloproteinase84 85 and increase endothelial cell 
proliferation, migration and expression of cell adhesion molecules in human endothelial cells86 87. In 
contrast adiponectin supresses human endothelial cell migration and proliferation88 89. This 
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imbalance of proliferative and anti-proliferative adipokines observed in obesity is proposed to lead 
to the development of cardiovascular diseases.  In addition, most of the overweight/obese 
individuals have deviant lifestyle habits , including smoking , and these issues are discussed below. 
1.3. Lifestyle and cardiovascular risk 
The relationship between CVD and lifestyle habits have been explored with accumulating evidence 
that environmental factors, personal behaviour and genetic pre-disposition are indirect causes of 
CVD mortality.  A review of studies on these inter-relationships are presented in Table 1.3 
1.3.1. Sedentary lifestyle 
Adults in the western population devote at least half their employed hours in sedentary 
behaviours90. The term sedentary behaviour refers to any waking behaviour characterised by low 
energy expenditure while in a sitting or reclining posture91 92 and is completely separate from not 
participating in physical activity. After work, adults usually are continuing their sedentary behaviour 
at home watching television. Television itself has been shown to occupy a large amount of an adults 
leisure time93, and is predominantly prevalent in older adults who watch up to 5 hrs a day94. This 
accumulative sedentary behaviour can eventually lead to increased health problems and television 
viewing has been associated with snacking on energy dense foods95, poor self-rated health, low 
household income, and low education91. Excessive TV viewing has is also associated with an  
increased rates of cardiovascular disease and all-cause mortality96-99, depression100, type 2 
diabetes101, systemic hypertension98, and a high level of total cholesterol (CHOL)98.  Sedentary 
lifestyle first contributes to gaining weight, usually in the abdominal area.  If continued, the 
individual will become overweight. Sedentary lifestyle is also associated with poor nutrition, excess 
alcohol consumption and smoking, all contributors to a high level of cardiovascular risk102.  
Office workers are also at higher risks of developing routines which could easily lead them to a 
sedentary lifestyle103 104. The only way around this problem is to incorporate physical activity before 
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or after work and in most cases there are only few which that can manage this due to feeling of 
exhaustion and fatigue mentally as well as physically. In particular, office workers are at higher risk 
of developing metabolic syndrome, which incorporates an abdominal obesity, systemic 
hypertension, impaired glucose tolerance, low HDL levels, all of which increase the risk of future 
cardiovascular events. Previous studies have well documented the risk for obesity, diabetes, and 
cardiovascular disease through sedentary and office style work environments103-107. 
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Table 1.3 Overview of potential lifestyle and environmental relationships with cardiovascular disease 
  Author  Year Participants Purpose Main findings 
Li
fe
st
yl
e 
Stampfer108 2000 84,129 
To assess the effect of a combination of lifestyle practices on 
the risk of coronary heart disease 
82% of coronary events could be prevented by maintaining a healthy 
lifestyle. 41% of coronary events were attributed to smoking.  
Chiuve109 2008 43,685 
To examine the impact of stroke risk that is attributable to 
unhealthy lifestyle choices 
64% of all coronary events were avoidable if patients adhered to a low-risk 
lifestyle 
Akesson110 2007 24,444 
To determine the benefit of combining healthy dietary and 
lifestyle behaviours in preventing MI in women 
Low risk behaviour was associated with 92% risk reduction of Myocardial 
infarction 
C
ir
ca
d
ia
n
 r
h
yt
h
m
 
Knutson111 2006 298 
To determine the relationship between impaired sleep and 
glycaemic control 
Sleep duration and quality were predictors of HbA1c. Data suggests that 
sleep duration should be examined as an intervention to improve glucose 
control. 
Kohatsu112 2006 990 
To determine whether short sleep duration is related to BMI 
and obesity in a rural population 
Sleep duration was negatively correlated with higher BMI after adjusting for 
cofounding variables. 
Gangwisch113 2006 4810 
to analyse the relationship between sleep disorders and 
duration with the incidence of hypertension 
Participants with sleep disorders that are >32 yrs and <59 yrs were at 
higher risk  of developing hypertension even after correcting for obesity 
and diabetes 
Kawachi114 1995 79109 
To examine the relationship between shift work (including 
nights) with CHD in women 
Shift work for at least 6 years contributed to an increased risk of CHD in 
women 
Morris115 2016 14 
to determine the impact of acute circadian misalignment on 
CVD risk 
Shift workers are possibly more susceptible to hypertension, inflammation 
and CVD risk due to circadian misalignment increasing BP and inflammatory 
markers. 
A
lt
it
u
d
e
 
Fujimoto116 1989 65 
to Investigate risk factors for occlusive arterial disease in 
Tibetan highlanders 
Tibetans showed lower serum lipids, phospholipids and BP. They also had 
lower apo-B levels when matched to controls without any CVD 
De mendoza117 1979 230 
To assess the relationship between altitude and serum 
cholesterol levels 
High altitudes of 1000m resulted in  significantly lower total cholesterol 
levels 
Mohanna118 2006 82 
To assess the relationship between altitude, lipid profile, WC 
and BMI 
altitudes at 4100m in Peru Revealed that subjects had higher levels of 
cholesterol, WC and BMI particularly in women  
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En
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ro
n
m
e
n
t 
Critchley119 2004 100,000 
To assess the increase in CHD mortality with CVD risk factors 
in Beijing, China 
CHD mortality rates increased by 50% in men and 27% in women. Majority 
can be explained by rise in total cholesterol through "western diet" 
influences. 
Pekka120 2002 180,000 To determine dietary and lifestyle changes on CVD risk 
Environmental changes and education through local councils showed a 
decrease in ischaemic heart disease by 73% 
Zatonski121 2005 100,000 
To determine the decline in mortality from CHD to changes in 
food consumption and economic policy. 
Changes in dietary polyunsaturated to saturated fat resulted in a 24% drop 
in coronary mortality. 
Aspelund122 2010 100,000 
To determine the decrease in mortality attributed to surgical, 
medical, and dietary changes 
73% reductions in mortality were attributable to smoking, cholesterol, 
blood pressure and physical activity.  
Ford123 2007 100,000 
To determine the factors that have contributed to the decline 
of CHD 
There have been substantial decreases in CVD risk factors through patient 
education and a revolution in the treatments for vascular disease that are 
available 
patel124 2006 600 To determine whether migration effects CHD risk factors 
Western diet was associated with disproportionate levels of dyslipidaemia 
and hypertension compared to the country they migrated from 
Hedlund125 2007 1534 
To analyse the prevalence of CHD in migrants to Sweden 
compared with co-twins from Finland 
Emigration to Sweden reduced the prevalence of CHD possibly due to 
physical activity, dietary habits and psychosocial factors. 
Se
as
o
n
al
 
Marti-Solar126 2014 237979 
To assess the seasonality of CVD risk factors in a large set of 
population based studies 
Seasonal patterns of CVD risk factors tend to be higher in the winter 
months with increased BP, HDL, LDL and HbA1c in patients 
Tung127 2009 4162 
To examine whether seasonal variations affect acute 
coronary syndromes in patients receiving statin therapy 
Authors suggested lipoprotein metabolism may be regulated depending on 
the season as a significant amount of participants were able to achieve 
their LDL target in the summer 
Spencer128 1999 259,981 
To determine whether cases of acute myocardial infarction 
varied by season 
53% more cases were reported during the winter months. This was the 
same for all sub groups and with different geographic areas. 
Ostro129 2010 21,900 
To assess the association between temperature and hospital 
admissions and whether air condition (AC) usage attenuated 
this association. 
10F difference in one day resulted in increased hospital admission in 
patients’ with CVD, respiratory disease and diabetes. Ownership of AC's 
significantly reduced these effects 
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1.3.2. Smoking 
The substances in cigarette smoke include: carcinogens, respiratory toxicants, cardiovascular 
toxicants, and reproductive or developmental toxicants130. All of the above play vital roles in the 
pathogenesis of many diseases. The high concentration of carcinogens in cigarette smoke leads to 
the release of free radicals and the formation of oxidants. This damages tissue and depletes the 
body’s plasma and tissue antioxidant levels131.  Nicotine, being the chief addictive constituent of 
cigarette smoke, is also notorious for depressing the body’s immune system, increasing susceptibility 
to illness and disease, as well as making it more difficult to heal and repair wounded tissues132-134. 
Smokers are more susceptible to an increase in lipoprotein concentration and accumulation135. 
Lipoproteins are particles that transport triglycerides (TG) and CHOL in the blood stream. They are 
essential components to cell structure and metabolism that aren’t soluble in aqueous solutions136. 
Low density lipoproteins (LDL) “bad fat” are by-products of VLDL metabolism and are the primary 
carriers of plasma cholesterol.  High density lipoprotein (HDL) “good fat” particles are created by the 
liver and intestine and mature to become enhanced with other apolipoproteins and lipids136. LDL 
levels are higher in smokers and HDL levels are markedly reduced, adding to the negative effects 
that lead to CVD and an increase in atherosclerotic events135. Further impedance of blood 
distribution caused by smoking is due to the effects on NO mediated blood flow regulation. NO was 
first discovered to be an endothelium derived relaxing factor (EDRF) and named as such. It transmits 
inhibitory infomation from vascular endothelial cells to smooth muscle cells137 (ref toda 2010) and is 
responsible for the maintenance of the vascular tone, blood flow, peripheral vascular resistance and 
systemic blood pressure138 . The vasoactive substances released from the endothelium are described 
in detail in section 1.7.2. Briefly, endothelium nitric oxide (eNO) causes vasodilation, increased blood 
flow, lower blood pressure, platelet aggregation and adhesion with reduced smooth muscle 
proliferation, thus contributing to a reduction in athlerosclerotic events139.  
For the past decades it has been will established and  documented that smoking cigarettes is a major 
modifiable risk factor for CVD’s and the world health organization has attributed to 10% of all CVD 
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cases in the world140 141. The exact mechanisms of the relevant constituents in tobacco are still 
unclear as to how they initiate, progress and determine cardiovascular health through endothelial 
dysfunction. It is more likely that not a single compound of toxicants is responsible but rather a 
mixture of the elements that are responsible for cardiovascular outcome which are discussed below. 
Since then many studies have analysed the effect of smoking on serum lipids. In 1989 Craig et al142 
showed a statistically significant correlation between smoking and increased total serum CHOL, 
very–low-density lipoprotein (VLDL), LDL, and TG concentrations140. Additionally, they found that 
HDL and apolipoprotein A1 levels to be decreased in smokers. Similar conclusions were described by 
subsequent clinical studies, all validating that smoking modifies serum lipid profiles in a pro-
atherogenic manner143 144. Smoking was also found to cause changes within the biomolecules of 
lipids themselves. Free radicals and oxidants present in cigarette smoke as well endogenous 
produced oxidants and radicals (resulting from the smoke chemical induced alteration in the cellular 
redox system)140 causes a pro-oxidative environment145. Findings of increased lipid peroxidation in 
the serum of smokers and oxidative modification of LDL (oxidative stress) has been reported by 
many studies suggesting an impairment of antioxidant systems within the body146-149. It is known 
that oxidative modified LDL are recognized by macrophage scavenger receptors, they are taken up 
and transformed into foam cells which are essential elements in lipid deposition and plaque 
formation140, this results in the progression of atherosclerosis.  
Smoking is also known to have influences on the immune system both locally and systemically 
through inflammation which is an essential element in atherogenesis140 150 151. Smokers have a 
significantly elevated white blood cell (WBC) count, which is positively correlated to the formation of 
atherosclerotic plaques152. This was more recently confirmed by Lavi et al153 which reported smokers 
with increased levels neutrophils and lymphocytes when compared to controls. In addition, smokers 
were also found to have increased levels of pro-inflammatory cytokines, such as tumor necrosis 
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factor-@ and interleukin-1B154. Another marker of inflammation which is widely accepted is C-
reactive protein (CRP), this was also found to be increased in smokers155 156.  
Systemic immunologic alterations were found on smokers and that they correlate with 
atherosclerotic plaque within the vessel wall, characterized by inflammation and increased 
expression of matrix metalloproteinases157. In addition, leukocyte recruitment facilitated by 
endothelial adhesion molecules is a key element in the initiation of atherosclerosis is amplified by 
smoking140. Cavusoglu et al158 showed that smoking increases the plasma concentration of soluble 
vascular cell adhesion molecule-1 in patients with CVD.  
Clinical data on smoking has clearly shown a pro-oxidative environment in which smoking increases 
serum levels of oxidative stress markers, oxidative modification of LDL, lipid peroxidation, and lipid 
deposition in the vessel wall leading to plaque development and proression159. Additionally, Orosz et 
al160 showed in vivo a link between smoking-induced increase in reactive oxygen species and the 
expression of pro-inflammatory cytokines, interleukin-1b, 6 and TNF-ɑ, in the vascular wall by 
activation of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH).  
One of the first studies to document smoking induced vascular changes was in 1993 by Celemajer et 
al161. This study shows that continuous smoking decreased forearm flow mediated dilation (FMD) in 
a dose dependant manor. This was also confirmed in another study which showed the reduced 
dilative capacity of coronary arteries162 in smokers. Leading to smoking as an early marker of 
atherogenesis and vascular dysfunction. Oxygen free radicals, particularly superoxide anion is known 
to reduce the bioavailability of NO by the formation of peroxynitrite163.  This reduction of NO in the 
vascular wall in smokers results from an imbalance in oxididant-reducing and oxidant generating 
cellular systems164 165. Compounds within smoke have also been proven to decrease eNOS activity 
and increase eNOS acetylation166-168. As well as leading to adhesion molecue expression on the 
surface of endothelial cells and release of proatherogenic cytokines165, which result in increased 
number of platelets and a prothrombotic and procoagulative state within the vascular wall of 
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smokers169.  Several experimental studies also concluded that apart from causing endothelial 
dysfunction, smoking also causes physical damage to the vascular endothelium. Contraction of 
endothelial cells or endothelial cell death mediated by oxidation and collapse of the tubulin 
system140, could be responsible for the reduction in FMD165. This reduction leads to reduced 
endothelial functions and can promote thrombogenic events and inflammation. It was presented 
that cigarette smoke and interleukin-1b in combination contributed to endothelial junction 
disassembly154. Several studies found that smoking also induces smooth muscle cell proliferation. 
Proliferation of smooth muscle cells are mediated through activation of the platelet derived growth 
factor protein Kinase C signalling cascade170 171. In addition, compounds within cigarette smoke, 
specifically polycyclic aromatic hydrocarbons were shown to activate aryal hydrocarbon receptor, 
which induces iNOS (responsible for NO production), leading to intimal thickening172, as well as 
encouraging the transcription receptors for chemokines and adhesion molecules, thus intensifying 
the inflammatory signals to the vascular endothelium173.  
The key developments in smoking induced atherogenesis commencement are endothelial 
dysfunction and damage leading to reduced bioavailability of NO, increase in oxidation and of 
proatherogenic lipids, as well as decrease of HDL, stimulation of inflammation, and the alteration 
toward a pro-coagulant state in the circulation. Of important note is that these affects have not only 
been shown in active smokers but also patients exposed to second hand smoke155. Taken as a whole 
cigarette smoking still remains the most important modifiable risk factor for CVD outcome. 
1.3.3. Hypertension 
Obese individuals more often exhibit upper levels of office as well as ambulatory blood pressure (BP) 
from childhood to old age; moreover they exhibit higher BP levels than non-obese individuals even 
in the normotensive range174. This evidence indicates that excess adiposity and weight gain are 
major causes of human essential hypertension, possibly accounting for as much as 65–75% of the 
risk175 for the development of hypertension. Despite this, the mechanism through which obesity 
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directly causes hypertension is still an area of research and is being intensively studied, even though 
the relationship between obesity and hypertension is well established in both adults and children176 
177. Nevertheless, one should not assume that every obese person is hypertensive but that weight 
gain increases the probability of becoming hypertensive, by shifting the distribution frequency of 
arterial pressure towards higher BP values178-180. Current research in experimental studies propose 
essential roles for reduced renal-pressure natriuresis (excessive sodium excretion) due to physical 
compression of the kidneys and activation of the Renin-Angiotensin-Aldosterone-System (RAAS) and 
SNS which are discussed below. 
Increased visceral and retroperitoneal adiposity could increase BP by physical compression of the 
kidneys. Excess fat amassing in and around the kidneys is linked with impaired pressure natriuresis, 
amplified intrarenal pressures and hypertension181. In patients with visceral obesity, intra-abdominal 
pressure rises in proportion to sagittal abdominal diameter, reaching levels as high as 35–40 
mmHg175 182. These elevated pressures compress the renal veins, renal parenchyma and lymph 
vessels. Moreover, retroperitoneal fat often encapsulates the kidney, adheres securely and occupies 
the renal capsule and sinuses, causing further compression and elevated intrarenal pressures181. 
During obesity, increases in retroperitoneal and renal sinus fat are associated with hypertension. The 
Dallas Heart Study that showed that retroperitoneal fat was uniquely correlated with incident 
hypertension183. In addition it was reported that renal sinus fat was associated with stage II 
hypertension184. Compression of the kidneys through retroperitoneal and renal sinus fat may cause 
inflammation and expansion of renal medullary extracellular matrix that could further impair renal 
function175.  Increased sodium reabsorption initiated by renal compression could secondarily 
contribute to glomerular hyperfiltration, renal vasodilation, and augmented renin secretion in obese 
subjects181. Rapid weight gain can’t account for the initial rise in BP due to renal compression, but it 
can explain why visceral obesity and increased renal fat are more closely associated with 
hypertension than subcutaneous fat175. As the metabolic and hemodynamic consequences of obesity 
are sustained over many years, renal damage progressively makes the hypertension more severe 
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and more resistant to therapy175. To date, the only established strategies to decrease visceral, 
retroperitoneal and their adverse effects on cardiovascular, metabolic and lifestyle modification are 
with dietary changes, increased physical activity and the latter stages of obesity through bariatric 
surgery. 
In patients with obesity, activation of RAAS modulates insulin resistance, renal sodium handling, SNS 
activation, which jointly contribute to cardiovascular dysfunction185-188.  Angiotensin II (ANG II) 
synthesis by intravascular and intrarenal RAAS can directly control vascular stiffness,  endothelial 
and renal function186 189. Angiotensinogen expression by adipose tissue in obesity supports a role for 
local RAAS activation190. Moreover, it was shown that increased ANG II production by perivascular 
adipose tissue contributes to impaired vascular function64 191. Aldosterone has been implicated in the 
modulation of vascular remodelling through enhanced smooth muscle reactivity186 and ED192. This 
result of increased plasma aldosterone levels in obesity are derived from adipose tissue that can 
stimulate adrenal aldosterone secretion193 194 in turn which can activate NADPH that promotes 
oxidative stress and decreases NO bio-availability195. Aldosterone also increases endothelial rigidity 
by modifying epithelial sodium channel expression on the endothelial cell surface and NO release195.  
Structural and functional changes in the kidney that activate the intrarenal ANG II are also important 
in the development of obesity related hypertension196. It was previously shown that components 
between the RAAS, specifically ANG II and aldosterone can regulate vasoconstriction independently 
of renal control185 197. This can be the case in lean patients with hypertension that presented with an 
increase in peripheral vascular resistance, whereas obese hypertensive patients are mediated, in 
part, by sodium absorption in the kidney, increased intravascular volume and cardiac output198.  
Activation of the RAAS in obesity also contributes to glomerular injury and nephron loss not only by 
elevating BP but also through intrarenal effects through constriction of efferent arterioles by ANG II 
exacerbating the rise in glomerular hydrostatic pressure caused by arterial hypertension181 to 
maintain sodium balance176 199. 
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Obesity induced hypertension is also associated with activation of the SNS in diverse tissues which 
include the kidneys, heart, and skeletal muscles200-202. Individuals who are obese, irrespective of BP 
have increased renal SNS activity compared with healthy individuals, indicated by an elevation in 
renal norepinephrine levels202. Increases in both renal and cardiac SNS activity could possibly be one 
mechanism that leads to the development of hypertension in obesity. Remarkably, individuals who 
have obesity but are normotensive have suppressed cardiac SNS activity, however those who have 
obesity and hypertension have increased cardiac SNS activity202. There are studies that suggest SNS 
activation alone might not lead to the development of hypertension. It was speculated that a 
division between SNS activity and peripheral vascular tone can protect a small proportion of obese 
individuals from ever developing hypertension203. Increased alpha-adrenergic mediated vascular 
tone has been reported in overweight men with hypertension204 however, rather than being 
overweight, it was more likely plausible that hypertension could account for the increase in SNS 
activity. Alternatively, In individuals who are normotensive and obese, sympathetic outflow to the 
forearm musculature did not lead to an increase in peripheral sympathetic vascular tone203.  
Increased leptin secretion from dysfunctional adipose tissue is also an important modulator of SNS 
activity205. Another factor by which Leptin is secreted by white adipose cells and its production 
correlates positively with the percentage of body fat206. In experimental studies it was shown that 
acute and chronic leptin infusion increased blood pressure and heart rate207 208 despite decreases in 
food intake. However, leptin also has counterbalancing cardiovascular effects, the leptin receptor is 
expressed in endothelial cells209 which induces the release of NO210. This influence of leptin on blood 
pressure homeostasis may be the result of a balance between the action through sympathetic 
activation and the endothelium dependant hypotensive effect of leptin179. Consequently, any factor 
that impairs endothelial function in obesity may dilute the vasodilative capacity of leptin. 
Advancement to a chronic hypertensive obese state can possibly be preceded by a loss of nocturnal 
BP dipping211 212.  A non-dipping configuration of circadian BP increases the risk of CVD and Chronic 
kidney disease (CKD)212 213. The exact mechanisms for this non-dipping pattern of BP  is unknown but 
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is possibly a combination of  insulin resistance, autonomic nervous system (ANS) dysfunction, and 
increased SNS activity212 214. 
Endothelial dysfunction and arterial stiffness are thought to precede the development of 
hypertension which is the early manifestation of vascular dysfunction in obesity215-218. Vascular 
smooth muscle dysfunction219 and changes in the extracellular matrix220 contribute to arterial 
stiffness; there is also evidence suggesting that ED also contributes to vascular stiffness though the 
association with insulin resistance215 221. Impaired vascular reactivity to insulin in prehypertension 
can be seen in spontaneous hypertension222 suggesting that insulin resistance is an early event in 
obesity-related hypertension development. 
1.3.4. Metabolic syndrome 
Obesity is a risk factor for the development of the metabolic syndrome which encompasses 
diabetes, hypertension, and dyslipidaemia that can occur simultaneously resulting in vascular 
complications223. However, epidemiological studies specify that the preferential accumulation of 
intra-abdominal (visceral) fat224, neighbouring the gastrointestinal organs poses a superior 
cardiovascular risk than in other forms of obesity in which fat is amassed under the skin 
(subcutaneous) in the gluteal region225.  
To date the exact mechanism by which obesity results in diabetes and increased cardiovascular risk 
has yet to be elucidated; though a common denominator in this relationship is the link between 
excess adipose tissue and insulin resistance i.e. ( the inability of insulin to exert its metabolic effects) 
and thus leads to increased glucose within the blood. A chronic low grade inflammation and an 
activation of the immune system are observed in abdominal obesity and may have a role in the 
pathogenesis of obesity related metabolic disorders226-230. Indeed, white blood cell counts and 
plasma levels of coagulation factors (fibrinogen and plasminogen activator inhibitor 1(PAI-1)), 
proteins like C-reactive protein (CRP);pro-inflammatory cytokines (tumor necrosis factor-alpha (TNF-
ɑ), interleukin (IL-1B) and (IL-6)) are elevated in obese and diabetic patients. When these patients 
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are engaged in rigorous activity and undergo lifestyle changes, these systemic markers of 
inflammation reduce41 226 231-235.   
Increased expression of TNF-@ in adipose tissue of obese individuals and its direct role in obesity 
induced insulin resistance was first described by Hotamisligil and colleagues56. Over time 
accumulating data has shown an over-production of inflammatory cytokines in enlarged adipose 
tissue228 and was considered a crucial event leading to metabolic syndrome (MS), diabetes mellitus 
and atherosclerotic CVD’s. More recently, adipose tissue has been associated with an accumulation 
of immune cells which causes an infiltration of macrophages in adipose tissue63 227 236. Indeed, their 
recruitment correlates with the degree of obesity and is linked to systemic inflammation, and insulin 
resistance63. Infiltration of macrophages have similarly been described within skeletal muscles, 
particularly in the inter-muscular adipose depots, and have been a major site of local insulin 
resistance in obesity and diabetes mellitus226.   
The development from obesity related insulin resistance to diabetes mellitus is a failure of the 
pancreatic b-cells in the islets of Langerhan to recompense effectively, leading to chronic 
hyperglycaemia.  Inflammation was shown in the pancreas of patients with diabetes with presenting 
infiltration of macrophages, fibrosis and increased levels of pro-inflammatory cytokines63. This 
increase in inflammation can be seen before the onset of diabetes in obese individuals which can 
reduce insulin secretion and trigger b-cell death leading to a decrease in islet mass226. 
In the vasculature two components of insulin signalling exist: metabolic and growth factor 
signalling237. Metabolic signalling involves insulin receptor substrate-1 (IRS-1), phosphoinositide 3-
kinase, protein kinase B (AKT), and endothelial nitric oxide synthase (NOS)237; growth factor 
signalling functions via the extracellular signal regulated kinases (ERK)1/2 and (ET-1) pathways185 237-
240. 
In insulin resistant conditions, metabolism is compromised owing to serine phosphorylation of IRS-1, 
which leads to reduced NO bioavailability and impaired vascular dilatation238. Equally, in this state, 
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upregulation of the ET-1 pathway contributes to increased vascular contraction238. Coupled in the 
obese state, metabolic changes in adipose tissue can also lead to altered adipokines secretion and 
impaired adiponectin levels241 within the blood plasma of obese individuals which promotes insulin 
resistance187 188 242. Together these factors contribute to the deleterious effects of metabolic 
syndrome which predispose the individual to hypertension, insulin resistance, atherosclerosis and 
ED which are all risk factors for the development of CVD. 
1.3.5. Cardiovascular disease 
Various studies have established the strong relationship of overweight and obesity with increased 
prevalence of most CVD’s that include CHD, CAD and atrial fibrillation243-246. Though the relationship 
between obesity and cardiovascular disease is to some extent complicated; some investigators have 
suggested an indirect association due to the increased prevalence of diabetes, dyslipidemia and 
hypertension although others have demonstrated and independent association between obesity and 
cardiovascular disease247-249.   
Weight gain and obesity lead to various alterations in body’s hemodynamics, including increased 
central blood volume, decreased systemic vascular resistance, a rise in cardiac output, and cardiac 
remodelling250-253. Obese individuals are more likely to have left ventricular (LV) remodelling, left 
atrial (LA) enlargement, and greater right ventricular mass and end-diastolic volume254-257. 
Interestingly, obesity’s association with heart failure (HF) has been with a preserved ejection fraction 
of greater than 50%258 259. The area of the heart which is responsible for pumping blood through the 
aorta has a normal range of roughly 50%-70%260. Many studies have established a strong association 
amongst overweight/obesity and HF. In the Framingham Heart Study, every 1 kg/m2 increment in 
BMI was found to increase the risk of HF by 5% in men and 7% in women244 261. In a separate analysis 
of the Framingham Heart Study it was revealed that obesity was associated with significant 
decreases in life expectancy and these results were similar to the control group which included 
smokers14. In addition, the risk of developing hypertension is 5x greater for obese individuals than 
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those of normal weight262.  Other parameters in obesity, such as WC or waist-to-hip ratio, are useful 
for predicting individual risk. In a meta-analysis of 28 prospective studies, every 10 cm increase in  
waist circumference (WC) was associated with a 29% higher risk of HF263. In addition,  a cross 
sectional study by Janssen et al264 compared BMI and WC in a total 14925 participants from the 
national health and nutrition examination survey. The study revealed that those with high WC values 
were at greater risk to have hypertension, diabetes, dyslipidaemia and metabolic syndrome 
compared to controls. This was also significant in the case of comparing BMI values across groups 
even after adjusting for confounding variables. A cross sectional population survey by Allison et al265 
suggested that more than 80% of hypertension arises in individuals with a BMI of >25kg/m2 and up 
to 2 thirds of cases of hypertension are linked to excess weight266. Two separate meta-analyses also 
exhibited that overweight and obese individuals are at increased risk of CVD and mortality even in 
the absence of metabolic abnormalities267 268. A study by Sims et al269 showed that in otherwise 
healthy young men without a family history of diabetes who were overfed for 6 months BMI 
increased to 28 kg/m2 and there were reversible rises in concentrations of triglycerides, insulin 
glucose, and impaired glucose tolerance. The risk of developing diabetes greatly increased by early 
weight gain270 especially in childhood and abdominal obesity. Furthermore, Stevens et al271 showed 
that 90% of individuals who develop type 2 diabetes have a BMI higher than 23kg/m2.  
Obesity and its accompanying comorbidities such as HTN, dyslipidemia, and diabetes play a crucial 
role in the pathogenesis of atherosclerosis, the hallmark finding of CHD244 272. It was shown that 
relatively young men, aged 15-35yr, who are obese have an association with accelerated coronary 
atherosclerosis273, and that dyslipidemia progressively develops as BMI increases from 21 kg/m2 
with a rise in small particle (LDL)15. This change increases the risk of coronary heart disease by 3-6 
fold, resulting in Low concentration of HDL and high concentrations of triglycerides270 274.  
Overweight and obese individuals tend to have a higher prevalence of CHD compared to their lean 
controls275. The Framingham Heart Study demonstrated that roughly 23% of CHD in men and 15% of 
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CHD in women were attributable to excess visceral adiposity246 even adjusting for covariates. In 
addition, sudden rupture of atherosclerotic plaque within the coronary arteries also known as Acute 
coronary syndromes (ACS) occur at earlier ages in overweight and obese individuals compared to 
those with a normal BMI244. A large retrospective cohort study showed that obese individuals with 
greater BMI than 30kg/m2 had the prospect of suffering from ACS 7 years earlier as compared to 
normal weight individuals. This trend had a positive and linear relationship276. 
The obesity “paradox” is now a well-established phenomenon across different types of CVDs. It is 
derived from a complex interaction between several potential mechanisms but this remains poorly 
understood and can occur regardless of ethnicity and age and severity of CVD252. However, growing 
evidence suggests that muscle mass, strength training and cardio respiratory fitness (CRF) are the 
major determinants of the prognostic implications of obesity in CVD277-279. Increased CRF through 
physical activity and strength training has been associated with improvement in cardiometabolic risk 
factors, metabolic syndrome and can prevent/delay the development of hypertension280-283 
ameliorating the risk for CVD prognosis.  Higher CRF has been associated with several changes in the 
cardiovascular structure and function, that include larger LV chamber size, improved diastolic 
function, and greater left atrial volume284 285. The FHS revealed that higher PA levels were associated 
with lower arterial stiffness286. In the Coronary Artery Risk Development in Young Adults (CARDIA) 
study higher baseline CRF even after 25 years was associated with better diastolic BP, and lower LV 
mass287 288. Broadly speaking, high CRF provides a cardio protective effect regardless of race, age and 
gender, and independent of other traditional risk factors, including smoking, DM, HTN, and BMI102 244 
289. 
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1.4. INTERVENTIONS TO REDUCE CVD RISK IN OVERWEIGHT AND OBESITY 
Having a healthy BMI within the range of 20-25kg/m2 usually does not require any interventions. 
Once overweight BMI >25 one should consider necessary lifestyle changes, this usually includes 
physical exercise and eating a healthy diet. This can be taken further by restricting your daily calorie 
intake anywhere between 250-500 calories than you would normally consume. Fasting is also an 
option but usually only required under certain circumstances and/or under appropriate supervision. 
Pharmacotherapy has been used within the last 40 years290 291 as a method of weight loss with 
promising results but is usually only prescribed once other methods have failed. Once the individuals 
BMI is >30kg/m2 and they have not achieved any results your primary care physician will likely refer 
you onto a nutritionist/dietician. They will advise you of the appropriate management which will 
probably include all of the above with special emphasis on the diet including a breakdown of the 
macro-micro nutrient intake as well as a tailored exercise regimen. The last stage of management is 
bariatric surgery, usually only provided in certain circumstances which patients are suffering from 
morbid obesity BMI >40 kg/m2 or BMI >35 kg/m2 with >1 comorbidities. 
1.4.1. Exercise and diet 
Exercise as a method of weight loss is the best option. Firstly, if one exercises routinely they are at 
less risk of becoming overweight. It is known that regular exercise and healthy food choices reduce 
stress and puts the individual in a better mind set. If the individual has become overweight, this can 
be due to a number of factors such as a sedentary life style, high fat and condensed rich calorie 
meals, one has to start exercising because eventually this path will lead you to becoming obese. 
There are a number of studies which have looked at exercise training on overweight and obese 
individuals and the results show significant improvements in anthropometric measurements. Many 
studies have also shown that participants who exercise 3-4x a week without focusing on their diet 
make improve but individuals who are careful with their diet achieve better results and are more 
likely to maintain their habits. This can be done on their own or some type of counselling by a 
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nutritionist or physician.  Fasting or a reduced calorie intake has shown to help individuals reduce 
their weight. Several studies have looked at reducing calorie intake roughly from 250-1000 a day. 
Other, studies have calculated the total calorie intake per person for the week and look at reducing 
it by roughly 5000 calories. Fasting is also a method of weight loss. Muslims fast during the month of 
Ramadan from sunrise to sunset and there are a few studies (table 1.4.1.1) which have looked at the 
benefits of this with promising results. Unfortunately it is very difficult for an individual to maintain 
this beyond Ramadan and eventually within a few weeks or so it has been shown that those 
individuals that have lost weight usually regain it back. There are also studies that looked at 
alternate day fasting. These studies usually looked at a complete fast for one day (table 1.4.1.1), with 
the exception of water, and alternate days of whatever the participants can fathom. It is important 
to note that the studies carried out saw reductions in weight and BMI but alternatively it is not 
something that most individuals can do on a regular basis due to the extreme will power one must 
contain within themselves. Tables 1.4.1 and 1.4.1.1 show the studies that have previously looked at 
physical exercise and reduced calorie intake for weight-loss management. 
1.4.2 Pharmacotherapy for weight management 
Pharmacological interventions have gained much attention even though the amount of weight-loss 
attributable is roughly 5kg a year292 293 and no drug so far has the ability on its own to help patients 
lose weight. Patients that do require drugs to lose weight must also appreciate that a reduced 
calorie intake of 500-1000 calories will be necessary as well as lifestyle and behavioural changes with 
regards to the specific type of foods they eat.  This brings the question into play as why is there a 
need for this since it has already been shown that maintaining a healthy diet, watching the type and 
quantity of calories you consume as well as regular exercise can help an individual shed the pounds 
while feeling better psychologically as well. The other aspect of using drugs to lose weight is that 
they have side effects, some of them which are life threatening, and there are numerous drugs in 
the past which have been banned for this reason. Nevertheless, they are being prescribed and newer 
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drugs are coming on the market every year but to this date no drug has been able to show weight 
loss without calorie restriction. Table 1.4.2 shows the studies which have investigated weight-loss 
interventions using pharmaceutical drugs. 
1.4.3 Bariatric surgery 
Bariatric surgery refers to the surgical techniques available for achieving weight-loss. The technique 
includes modification of the gastrointestinal tract to either reduce absorptive capacity or volume294. 
Currently there are a few techniques used worldwide which encompass Laporoscopic adjustable 
gastric band (LAGB), Laporoscopic sleeve gastrectomy (LSG), and vertical banded gastroplasty (VBG). 
LAGB is currently the most common surgical technique since 1996 and has now over taken the 
traditional stomach stapling procedure. The procedure is reversible and can be done in 
approximately 1 hour. The gastric band is an implantable device which consists of 2 parts, a round 
silicone band with an inflatable cuff that sits around the cardia and a reservoir that is placed over the 
fascia of the abdominal wall. The 2 parts are connected by silicon tubing. The gastric band is placed 
just below the gastrooesophageal junction (GOJ) around the gastric cardia, creating a 10–15 ml 
gastric pouch294.  The band forms a aperture of about 10-12 mm in diameter so that food entering 
the stomach is slowed down. With stretching of the stomach wall leading to early satiety through 
signals transmitted via the nucleus tractus solitarius to the appetite centres in the hypothalamus 
thus reducing appetite294.  
 The other techniques are not reversible and are permanent. LSG procedure restricts food intake by 
reducing the size of the stomach. The gut is also re-arranged which produces significant changes of 
several gastrointestinal hormones294.  The hormone Ghrelin, which is secreted by the 
neuroendocrine cells and acts on the hypothalamus to regulate appetite, is suppressed after LSG.  All 
other treatment options must be carried out first and, when unsuccessful, bariatric surgery is only 
indicated when the individuals BMI is >40 or >35 with comorbidities. Table 1.4.3 shows the studies 
that have been conducted on bariatric surgery for weight-loss management. 
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Table 1.4.1 Overview of weight loss management with exercise 
Author Year Participants Purpose/Summary main findings Disadvantages 
Ross295 2000 
52 obese men (11 
controls) 
To determine the effects of diet- or -
exercise induced weight loss and exercise 
without weight-loss on 
abdominal/visceral fat, and insulin 
sensitivity in men 
Weight loss induced by daily physical activity without calorie 
restriction significantly reduced obesity and insulin resistance. 
Exercise without weight-loss reduced abdominal fat and 
prevents further weight gain 
Due to random group assignment there were more participants 
that dropped out then calculated, this let to approximately 10 
people in each group. The calorie deficit among studies is usually 
500, this study had a deficit of 700. 
Ito296 2001 
12 obese participants, 
longitudional study 
to evaluate the effect of increased 
exercise and mild calorie restriction on 
heart rate vairability 
After 3 months the patients had significant improvements in 
BMI, waste circumference, total cholesterol, triglycerides, and 
an improvement in parasympathetic modulation  
As there were only 12 participants in the study they were not 
able to test the influences of systemic measures on their 
outcome measures due to a small sample size 
Facchini297 2003 
40 obese individuals ( 10 
male) 
To assess the impact of a 3 week 
integrated calorie restriction diet and 
high intensity exercise training in 
morbidly obese individuals 
Resting SBP, DBP, BMI and total % body fat were all reduced 
following the exercise program. The reduction in Heart rate 
and increase in parasympathetic activity contribute to a 
reduced risk of cardiovascular morbidity. 
The results were significant enough for a change in multiple 
parameters but no mention was made on the psychological 
aspect of the participants on a hypocaloric diet of 1200 calories 
and whether the participants can potentially to change after the 
study.  
Trombetta298 2003 
59 Obese women (24 diet 
alone) (25 diet + exercise) 
(10 controls) 
To evaluate the effects of weight loss 
induced by moderate exercise and 
hypocaloric diet on neurovascular 
control 
Diet and exercise significantly reduce BMI and %percent body 
fat, also increased resting forearm vascular conductance at 
rest and during exercise. Insulin sensitivity was also increased 
during the hypocaloric diet and even more so accompanied 
with exercise. 
No measurements were reported on SBP and DBP only MBP and 
this did not change in any of the groups. Along with visits to the 
dietician, patients were instructed on diet and calorie break down 
but not everyone adhered to the advised protocol 
Woo299 2004 
82 overweight children, 
longitudinal study 
To evaluate the reversibility of vascular 
dysfunction in children through exercise 
and diet 
Diet alone improved arterial endothelial function but the 
combination of diet and exercise had significant 
improvements in body fat, endothelial function and lipid 
profile 
The intensity of the exercise program was difficult to apply to 
obese children which possibly led to a selection bias of which 
group the patient should belong 
Ross300 2004 
54 obese women ( 10 
controls) 
To determine the effects of diet- or -
exercise induced weight loss and exercise 
without weight-loss on 
abdominal/visceral fat, and insulin 
sensitivity in women 
Daily exercise with no caloric restriction showed significant 
reductions in total fat, abdominal fat, and insulin resistance. 
Exercise without weight loss was also associated with 
reductions in total fat and abdominal obesity.  
The study was underpowered due to dropouts not wanting to 
participate in a randomized group. If being part of a weight loss 
study requires one to do nothing (control) then it’s difficult to 
have participants. 
figueroa301 2007 
28 obese women (10 
with type 2 diabetes 
mellitus) 
To evaluate the effects of moderate 
intensity endurance training in obese 
women with and without type 2 diabetes 
mellitus 
After 16 weeks of speed walking training, resting SBP and DBP 
was significantly reduced in both groups. Heart rate was also 
reduced in both groups following recovery after 20 mins post 
exercise. 
Heart rate did not differ when patients in both groups were 
tested at rest. There were no differences in BMI and Total body 
fat % after 16 weeks of training. 
Goulopoulou302 2010 
62 obese participants (26 
type 2 diabetes mellitus) 
To investigate the effect of aerobic 
exercise on cardiac function, body 
composition, central adiposity, insulin 
sensitivity, and lipid profile. 
The group without diabetes had significantly reduced BMI, 
waste circumference, and diastolic blood pressure. The results 
were also significant in the non-diabetic group with reductions 
in fasting glucose, insulin sensitivity and reduced LDL 
cholesterol.  
Unlike other studies that examined diabetics this study did not 
find anything significant after the intervention, Possibly due to 
their ingestion of a variety of oral glycaemic control medications 
and the intervention of 16 weeks. Diabetes effects endothelial 
function and other studies had only noticed improvements after 
12 months   
Blumenthal303  2010 
144 overweight/obese 
individuals 
To evaluate the effects of 4 months of 
dieting alone and dieting with exercise 
on participants with pre/stage 1 
hypertension that are not on medication 
The 2 different groups had significant improvements in SBP 
and DBP, reduced arterial stiffness and changes in overall 
aerobic fitness compared to controls. The results more 
significant if the participants included exercise. After the 
treatment period, the 2 groups were no longer classed as 
hypertensive 
The group that was exercising was also being trained 
psychologically. Based on cognitive behavioural therapy, this 
teaches the participants to learn when and how to eat. This was 
not done on the diet alone participants even though it would 
have been appropriate 
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Table 1.4.1.1 Overview of fasting/reduced calorie intake studies for weight loss management 
Author Year Participants Purpose/Summary Main findings Disadvantages 
Temizhan304 2000 
52 (25 M) 
normal/overweight 
participants 
To examine the effects of voluntarily fasting 
on blood lipid levels 
There were significant decreases in total cholesterol, 
triglycerides, HDL, and LDL cholesterol. While there 
was an increase in glucose levels after 30 days. 
The study showed that both groups had reductions in blood lipids though 
they reported that women had better results even though they did not lose 
any weight. That’s slightly different in the table they reported showing a 
significant difference in weight after 30 days 
Harvie305  2011 
107 
0verweight/obese 
women 
To compare the feasibility and effectiveness 
of 25% energy restriction 2 days a week 
compared to 25% restriction 7 days a week 
on insulin sensitivity, weight loss, and 
metabolic disease risk factors 
After 6 months both groups had Significant reductions 
in body weight, insulin sensitivity, serum leptin and 
increases in plasma adiponectin with no differences 
between groups. 
Both groups had comparable reductions in total and LDL cholesterol, 
triglycerides, SBP and DBP but these weren't significant. As a cardiovascular 
disease risk factor a calculation on the long term risk might have provided 
added information to the study; such as the calculation of the framingham 
risk score before and after 6 months of calorie restriction 
Teng306  2011 
25 healthy 
overweight 
participants 
to conduct a 3 month pilot study to 
investigate the effect of calorie restriction 
on quality of life, food intake and body 
composition 
In the calorie restriction group compared to controls 
there were significant decreases in body weight, BMI, 
Body fat % and depression with participants in the CR 
group reporting increased energy levels. There were 
no differences in the levels of stress and sleep quality 
The control group had also reduced their daily calorie intake even though 
they were advised not to make any changes. Which could have possibly 
narrowed the gap between measurements within the groups. The groups 
chosen didn't differ by age but the participants were above 50 as the 
experimenters believed they were more likely to follow fasting guidelines 
than younger counterparts  
Varady307 2013 
32 (16 control) 
overweight 
participants 
To examine the effect of ADF on body 
weight and coronary heart disease risk in 
overweight participants 
There were significant decreases after 12 weeks in 
terms of body weight, BMI, Body fat %, C-reactive 
protein (CRP), and leptin, while adiponectin increased 
compared to controls. 
The fasting regimen included alternate days of calorie restriction and days of 
ad libitum intake but there were no documents on the quantity and quality of 
food participants were allowed to eat because they could have made up the 
excess in calories on the alternate day, which could represent why there were 
no differences if LDL and HDL cholesterol between the groups 
Bhutani308  2013 
64 obese 
participants 
to investigate the effect of ADF with 
endurance exercise on endothelial function, 
relative to ADF end exercise alone 
In the ADF group BMI decreased and in the 
combination group body weight decreased, waste 
circumference as well as plasma leptin levels. The 
increase in Endothelial function was only significant in 
the ADF group and not in the combination group. 
Alternate days of fasting included ad libitum intake with no measures of 
calories consumed and the equality of food ingested. The baseline 
characteristics did not differentiate between ages as endothelial function is 
known to reduce with age. 
Eshghinia309 2013 
15 overweight 
participants 
To examine the effects of modified ADF diet 
on BMI, waste circumference, SBP, DBP and 
cardiovascular risk factors 
After 8 weeks significant decreases in total body 
weight, BMI, waste circumference, Fat mass %, SBP, 
and DBP were achieved. Total cholesterol and 
triglycerides were reduced but were not significant. 
This study like others had no control group and included limited subjects with 
only 8 weeks duration. The study also found that men had significantly 
decreased LDL cholesterol while women has an increase but combined the 
results were not significant. 
Norouzy310 2013 
82 participants <35 
yrs, 158 
participants 36-70 
yrs 
to determine whether fasting during 
ramadan has any effect on body weight and 
composition relative to age and sex 
Significant reductions in both groups in body weight 
and BMI but more so in males <35 yrs. Waist and hip 
circumference decreased in all except women >35 yrs. 
Percentage body fat only decreased in males. Dietary 
intake was similar but males reported decreased 
protein intake 
Physical activity was not assessed so any changes observed couldn’t be 
attributable to energy expenditure. There was only a sub group of 
participants who kept a food log and thus the analysis was only done on sex 
but not age. It is not known whether the changes persisted in individuals after 
the study as it is known for subjects reverting to their baseline values within a 
few weeks after ramadan 
Varady311 2015 
121 
overweight/obese 
participants 
To examine the characteristics, namely age, 
sex, baseline body weight/BMI that can 
predict weight loss success with alternate 
day fasting (ADF) 
After 8 weeks of ADF; subjects aged 50-59 achieved 
the greatest weight loss. There were no differences 
between men and women but Caucasians achieved 
greater weight loss than other races. Baseline body 
weight and BMI did not predict outcome of success. 
The study didn’t perform a regression analysis to assess the independent 
contributions of age, sex and BMI on predicting weight loss even though that 
was their aim. The participants were allowed to eat whatever they chose on 
the alternate day but no record of what they ate nor was the amount of 
calories determined.   
Antoni312  2016 
10 (3F) 
overweight/obese 
participants 
The aim of the study was to characterise 
the early metabolic response to varying 
degrees of energy restriction 
Total energy restriction led to significant reductions in 
levels of fasting plasma glucose and triglycerides the 
following day. Partial energy restriction let to higher 
amounts of fat metabolism. 
The women in the study showed an impairment of glucose tolerance but 
there were only three participants. Moreover, participants showed a 
prolonged period of decreased insulin sensitivity after the first day. 3 days is 
not long enough to determine the profile of participants. Ideally the study 
should have lasted for 3-4 weeks.  
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Table 1.4.2 Overview of weight loss management using pharmocotherapy     
Author Year Participants Purpose/Summary main findings Disadvantages 
Munro313 1968 
108 obese women, 
randomized placebo 
controlled, double blind 
study 
To assess the effect of 
phenturmine on obese 
women after 36 weeks 
The mean weight loss was 12.5 kg in patients taking 
the drug and 4.5 kg in the placebo group. The 
combination of calorie restriction and phenturmine 
produced promising results 
The group which alternated the drug and placebo every 4 
weeks had similar results to the group using the drug during 
the whole experiment. During the last 16 weeks of the trial 
there was no statistically significant change in weight loss 
between the three groups.   
Alien314 1975 
110 patients, randomized 
placebo controlled, double 
blind 
To assess the use of 
Diethylpropion in conjunction 
with calorie restriction and 
exercise on obese patients 
At 12 weeks there were significant reduction in 
weight compared to the placebo group, on average 
patient lost between 4-7Kg. Systolic and Diastolic BP 
were significantly lower as the 2 and 8 week follow 
up.  
The drug group lost the most weight but the placebo group 
lost a significant amount as well. This study was only 12 
weeks and possibly not long enough for obese patients to 
settle in a healthy weight range 
Baird315 1977 
38 patients, randomized 
placebo controlled, double 
blind 
To assess the use of mazindol 
and calorie restriction on 
obese patients 
At 12 weeks there were significant changes in body 
weight and waste circumference. Patients lost 
roughly 11.5 kg after treatment 
The study did not find any significance between the 2 
groups. This is probably because the 1000 calories a day 
would make anyone lose weight and be difficult to test the 
efficacy of the drug  
Brun316 1988 
44 patients, randomized 
placebo controlled, double 
blind study 
To assess the effects of 
fenfluramine in 
hypertriglyceride obese 
subjects 
Following 12 weeks follow up. Patients on the drug 
had decreased levels of LDL cholesterol and 
increased levels of HDL cholesterol, weight loss was 
roughly 3kg and was considered significant 
Weight loss was only 3 Kg after 12 weeks, that's 0.25 Kilos a 
week which can be easily accomplished with diet and 
exercise. This drug has a potential to be used as a lipid 
lowering medication but not for weight loss.  
Darga317  1991 
45 obese patients, 
randomized placebo 
controlled, double blind 
study 
To assess the combined 
effect of fluoxetine and diet 
after 52 weeks  
The combined effect resulted in a mean loss of 12.5 
kg after 26 weeks and 4.5kg for the placebo group 
There was no information regarding the total caloric diet. 
The placebo group on the diet retained their weight loss 
from 26 to 52 weeks, while the drug group gained 5 Kg. 
Towards the end of the study. After 52 weeks there was no 
difference between the 2 groups 
Van 
Gaal318 
2005 
1507 patients, randomized 
placebo controlled, double 
blind 
To assess the effect of 
rimonabant on bodyweight 
and cardiovascular risk 
factors in overweight/obese 
patients after 52 weeks 
Rimonabant 20mg was significantly associated with 
reduction in body weight, waste circumference and 
% BF. Patients lost a total of roughly 6 kg 
Patients taking Rimonobant 5mg had some promising 
results but did not differ significantly from the placebo 
group. The 20mg dose reduced weight but all participants 
were put on 600 a day calorie deficit. 
Hsieh319 2005 106 (55) controls 
To assess the influence and 
effect of Orlistat on 
parameters of metabolic 
syndrome but without 
patients suffering from 
chronic diseases 
There was a significant reduction in BMI, waste 
circumference and % BF in the drug group. At one 
year follow participants lost roughly 6 KG 
Originally had 180 patients which only 106 completed the 
study. The participants were also given a specific diet to 
follow which included caloric restriction and daily exercise. 
This could possibly alter the effects of the drug in question 
Fidler291 2012 
4008 patients, randomized 
placebo controlled, double 
blind 
To evaluate the effects of 
locraserin on body, weight 
cardiovascular risk factors 
and safety in 
obese/overweight patients. 
There was a significant reduction in body weight, 
decreased body fat content and improved quality of 
life. At one year follow up participants lost roughly 4-
6 KG 
The placebo group that exercised and had a calorie 
restriction diet improved as well but the analysis only 
compared the drug groups to placebo. A within measures of 
the placebo group should have been carried out 
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Table 1.4.3 Overview of weight-loss management with bariatric surgery     
Author Year Participants Purpose/Summary main findings Disadvantages 
Sjostrom3
20  
2004 
4047 obese 
participants 
To assess the long term benefits of 
bariatric surgery. At 2 years and at 10 
years. 
After 2 years there was a 24% decrease in weight and 16% at 
10 years. The participants which benefited the most kept 
physically active. All systemic plasma measure were reduced 
against the controls however there was no difference 
between the groups in total cholesterol. 
The study could have calculated the framingham risk before 
and after surgery and at subsequent visits. Throughout the 
study obese controls were used for comparison. It would 
have been better to compare the surgery with age matched 
normal BMI controls to differentiate their actual risk.  
Torre321 2008 
45 Obese 
participants & 
9 controls 
To analyse the relationship between 
weight and circulating (VEGF-a) in 
morbidly obese subjects before and 
after bariatric surgery 
After surgery there was a significant decrease in leptin and 
insulin concentrations. Adiponectin also showed an increase 
after surgery. Participants lost an average of25% of their 
body weight after 9 months. 
The study carried out was only done on women and they 
can’t make generalisations about the surgery without 
including men. There were no BP measurements and no 
anthropometric data  
Mingrone
322 
2012 
60 obese 
participants 
Trial comparing the efficacy of bariatric 
surgery and conventional medical 
therapy in severely obese patients with 
type 2 diabetes. 
Both groups had significant changes in BMI, WC, fasting 
glucose, total cholesterol but there were no differences in 
systemic BP. Those that had bariatric surgery had a 75% rate 
of remission of diabetes at 2 year follow up.   
The study had 3 groups but the participants were not 
enough for the level of power. Sample size was small which 
led to differences in detecting important endpoints. Such as 
long term morbidity between the surgical procedures 
Miras323  2012 
84 
Participants 
with type 2 
diabetes 
To assess whether bariatric surgery 
procedures are safe for retinal and 
renal complications of type 2 diabetes. 
In the subgroup of participants with diabetic retinopathy 
17.8% of patients improved and the mean retinoscopy 
scores decreased significantly. The stabilization of 
microvascular complications were observed in the context of 
a reduction in medication usage within all surgery groups. 
There was only one grader for a total of 67 photos. 
Retinopathy was graded subjectively according to clinical 
protocol but no actual measurements were made of the 
photos and did not include the CRAE or CRVE or the AVR. 
Lammert3
24  
2012 
30 obese 
participants 
To assess the effect of bariatric surgery 
on retinal vessel as an early surrogate 
marker of atherosclerosis in morbidly 
obese participants. 
After 9 months, there was significant reductions in total 
cholesterol, 53% of participants had complete remission of 
impaired glucose metabolism, mean weight loss was 37.5%. 
The AVR improved significantly the results indicated 
widening of the arterioles and narrowing of the venules. 
The time to first postoperative visit was variable among the 
participants. There was also no mention of diet, eating 
behaviour and whether the participants were active in 
physical exercise. 
Varadhan3
25 
2012 
23 obese 
participants 
with type 2 
diabetes 
mellitus 
Was only a pilot study and all grading 
was done subjectively. None of the 
photos had actual software or manual 
calculations of retinal parameters.  
2 patients had new development of retinopathy, further two 
had progression of retinopathy and 2 patients had 
regression of retinopathy. Changes are unpredictable after 
surgery and patients should still be screened even though 
there is rapid improvement in glycaemic control 
Even though patients improvement in glycaemic control 
was measured, they should be more frequently assessed for 
retinopathy.  
Nerla326  2012 
50 obese 
participants 
To assess the effects of bariatric 
surgery on peripheral endothelial 
function and on coronary 
microvascular dilator function 
After 3 months there was an improvement in flow mediated 
dilation (FMD), Coronary blood flow (CBF) and the cold 
presser test (CPT). 17 participants were no longer classed as 
hypertensive and 15 participants had quit smoking. 
The study assessed short term effects at 3 months. It is 
important to note that participants are still in a liquid diet 
at that time. Yet, there was no mention of diet and the 
results of oral glucose tolerance test at the follow up visit. 
Johnson32
7 
2013 
2580 obese 
participants 
and 13371 
controls 
To examine the long term effects of 
bariatric surgery and compare the 
macrovascular and microvascular 
complications to nonsurgical controls 
Bariatric surgery was associated with a 5 year event free 
survival outcome. It is also associated with a 65% reduction 
in major macrovascular and microvascular events in obese 
patients with type 2 diabetes.  
There are some limitations in administrative data when 
combining studies and have been well documented. There 
was a lack of data on body weight and markers of glycaemic 
control. There was also a lack of information on the 
duration and severity of diabetic or obesity status.  
Aghamoh
ammadza
deh78 
2013 
20 obese 
participants 
To investigate the effects of bariatric 
surgery on small artery function and 
the underlying mechanisms  
6 months after surgery there were significant improvements 
in insulin sensitivity, inflammatory cytokines, and SBP 
together with increased Perivascular adipose tissue (PVAT) 
anti-contractile function, adiponectin and Nitric oxide (NO) 
bio-availability 
There was no monitoring of the patients exercise and 
dieting habits with regards to calorie restriction. The 
changes detected were only to subcutaneous gluteal PVAT 
after surgery and not necessarily represents all small 
functional arteries in different vascular beds 
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1.5. Obesity and anterior eye health 
Not much is known about the impact of obesity on anterior eye health. Dry eye syndrome is a 
multifactorial disease of the ocular surface which results in symptoms of discomfort, visual 
disturbance and tear film instability328. It can be brought upon by certain medications, poor 
nutritional diets, contact lens wear and also laser refractive surgery, but the direct association has 
still yet to be elucidated. Floppy eye syndrome (FES) is a condition where the upper lids are 
extremely lax and when the patient falls asleep the eye lids turn inside out which results in 
conjunctivitis, keratitis, corneal ulceration, and palpebral inflammation. It was first described by 
Cumbertton & Olster329 in 1981 and it was more prevalent in overweight/obese individuals. Since 
then there have been studies which have argued against the direct association but have now come 
to terms that being overweight/ obese is a risk factor for the development of FES. Xanthoma can be 
characterised as an ocular manifestation of hypercholesterolaemia. CHOL deposits can appear 
anywhere on the body, and when they appear around the eyelids, usually in the inner canthus, they 
are referred to as xanthelasma palpebrum. They are a result of high CHOL levels in the systemic 
system and present as deposits of fat that build up under the skin but are usually of no consequence 
and are not sight threatening.  This is the same when certain patients have a ring around their 
cornea, known as Arcus Senilis or Juvenilis. The former of which is due to the accumulation of lipids 
over a prolonged period of time and could represent serum hyperlipidaemia. The latter happens 
much earlier on in younger individuals and this definitely represents that there is an underlying 
problem. These cases are also more frequent when the individual is overweight and more so obese.   
It is unequivocal that obesity has perilous effects on the body, and the eye. A study by Caffery et al330 
looked at the diet within the western world and its influence on tear function. In this review more 
than 25 years ago, it was noted that the maintenance of a healthy tear film requires sufficient 
amount of protein and vitamin A. Within the Western world protein intake is not the problem as 
there is an abundant supply but the real problem lies with the vitamins and minerals which are part 
of a balanced diet and this was hypothesized to be the problem of maintaining a healthy tear film. 
41 
 
More recently, elevated amounts of serum lipids was associated with dry eyes in the Beaver Dam 
eye study331 and in the Taiwan nationwide population based survey332. The link between higher 
serum lipid levels and ocular deposition is well established for corneal arcus and xanthelasma333 334.  
However, the exact mechanism for the association between dry eye syndrome and obesity has yet 
to be elucidated. A study by Dao et al335 identified high serum lipid levels as a risk factor for the 
development of Meibomian Gland Dysfunction (MGD). However this was identified as elevated HDL 
levels. Table 1.5 provides a summary of obesity related complications and their effect on anterior 
eye health. 
The present research looks at both systemic and ocular circulation in relation to obesity and CVD 
risk.  Therefore, an understanding of the cardiovascular anatomy and physiology is, in this context, 
necessary. This is offered below. 
1.6. Anatomy of the cardiovascular system 
The cardiovascular system is composed of the heart and circulatory blood vessels. It is a complex 
system with regulatory feedback mechanisms to ensure rapid alterations in blood flow which can be 
adjusted based on the metabolic needs of various tissues and the transport of materials to and from 
all regions of the body. On leaving the heart, the blood is distributed between two principle 
cardiovascular pathways, namely the pulmonary circuit and systemic circuit336. The systemic 
circulation refers to the flow of blood from the left ventricle of the heart to the tissues of the body 
and back to the right atrium. All of the arteries which make up the systemic circulation are branches 
of the aorta. The aorta branches further into the ascending aorta, the aortic arch and the descending 
aorta. The arteries that arise from the aortic arch (the brachiocephalic trunk, the subclavian artery, 
and the carotid artery) ultimately supply blood to the upper limbs, shoulders, neck, eye, and the 
head336.
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Table 1.5 Summary of studies of obesity related ocular health and systemic influences 
Author Year Participants Purpose/Summary Main findings Disadvantages 
Caffery330  1991 Review Article 
To review the dietary habits 
of north Americans and its 
effect on dry eye syndrome 
and the ocular tear film 
Sufficient dietary intake of protein and vitamin A are 
essential. Fresh fruit and milk intake can be less than 
adequate in the western diet. Deficiencies in vitamin 
A, B6 and C, minerals, potassium, zinc, folate and 
linoleic acid have been identified in tear dysfunction.  
An enormous amount of studies had been reviewed but 
the studies that were carried out were not really defined 
in terms of protocol and methodology. This review is also 
25 yrs + outdated and since then many changes have to 
come light regarding dry eye disease. 
Moss331 2000 
3222 
population 
based cohort 
study (beaver 
dam study) 
The examine risk factors for 
the prevalence of dry eye 
syndrome 
Diabetes, Elevated amounts of total and HDL 
cholesterol were associated with dry eye syndrome. 
Women report dry eye more than men but after 65 
years of age there’s no difference.   
Dry eye was diagnosed by the patients self-report and no 
objective testing was conducted. This resulted in not 
differentiating between evaporative and aqueous 
deficiency.  It is also known that patients can have dry 
eye but not suffer from any symptoms which probably 
led to an underestimation.  
Mori337 2000 
70139 (60% 
M) 
participants 
To evaluate the association 
between IOP and obesity by 
cross sectional and 
longitudinal analysis in a 
Japanese population. 
BMI significantly correlated with IOP after controlling 
for age, sex, and BP. There was also a significant 
association between longitudinal change in IOP and 
weight, this also remained after controlling for 
variables.   
The variations were slight but in contrast all the values 
would still be considered normal and not pathological. 
Also at the last follow up visit there were only 2000 
participants. That’s almost a 96% drop out rate 
Dao335 2010 
46 (22 M) 
with 
meibomian 
gland 
dysfunction 
(MGD). 
To determine whether MGD 
is associated with 
dyslipidemia 
Patients with moderate to severe MGD have a higher 
incidence of dyslipidemia with regards to total and 
HDL cholesterol. No significant differences were 
noted for LDL cholesterol.  
The study could not age match the patient population 
with controls. As a result the participants were older and 
could have possibly affected the results owing to the fact 
that cholesterol builds up as one ages.  
Uchino338 2011 
2644 (1221 
M) 
To investigate the prevalence 
and factors associated with 
dry eye disease in Japanese 
cohort 
Low BMI and hypertension were risk factors for men 
having dry eye disease. Women were 2x more likely 
to have severe dry eye symptoms than men but were 
also more likely not to have dry eye disease if they 
were overweight. 
There was no objective testing of dry eye disease done, 
rather the information was self-reported. In diabetics 
because of peripheral neuropathy this can undermine dry 
eye symptomology resulting in an underestimation.    
Beis339 2012 
135 (51 
controls) 
obese/overwe
ight 
participants 
To investigate whether there 
is an association of floppy eye 
lid syndrome (FES) and BMI in 
Sleep apnea syndrome (SAS) 
patients and normal controls 
The presence of hyper elasticity in obese SAS 
individuals was significant compared to controls. But 
there was no direct association between FES and 
Obesity  
Other studies have found associations between BMI and 
FES and it was first noted in overweight individuals. This 
study probably didn’t find an association due to a 
number of control participants who were overweight and 
15 were obese.  
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Modulo340 2012 5 mice 
To determine in transgenic 
mice models of dyslipidemia, 
whether there is an 
association with dry eye 
syndrome (DES) 
Mice that were fed high lipid diets had reduced tear 
secretion but did not suffer from meibomian gland 
dysfunction.  
Did not have the tests sensitive enough to analyse 
cholesterol esters within the tear film. Mice live in a 
different environment and there were only 5 that were 
analysed. It’s very difficult to make generalisations. 
Wang341 2012 
12007 
patients with 
dry eye 
disease 
To investigate the 
comorbidities of dry eye 
disease in a nationwide 
population-based data in 
Taiwan. 
Patients with dry eye syndrome compared to 
controls were more likely to suffer from 
hyperlipidemia, hypertension, diabetes, cardiac 
arrhythmias and peripheral vascular disorders. 
Almost all patients being treated for mental illness 
had dry eye disease as well. 
The study had no medicinal information with regards to 
what patients were being treated for and if they were 
being treated for more than one condition. Such as 
diuretics, antihistamines, corticosteroids and 
antidepressants which are known to affect tear function.  
Pinna342 2013 
120 (63 
control) 
patients with 
MGD 
The aim was to investigate a 
possible correlation between 
MGD and 
hypercholesteremia in young 
and middle aged patients. 
Hypercholesteremia was found in nearly half of 
participants. After adjusting for confounding 
variables MGD was significantly associated with 
higher total cholesterol levels, HDL, and LDL levels. 
Only included patients of Italian ancestry and can’t be 
used for the general population. They showed an 
association between MGD and hypercholesteremia but 
not necessarily proven. Larger trials with multi-ethnic 
populations should be carried out. 
Wang343 2013 
2355 (960 
men) 
participants 
To assess the association 
between longitudinal changes 
in IOP, blood pressure and 
BMI (the Beijing eye study) 
A Higher IOP was significantly associated with a 
higher change in mean arterial pressure and a higher 
change in BMI.  
From the original cohort there was many drop outs. 750 
just did not want to attend and 158 died. Methods 
included a whole section on Visual acquity but did not 
report on it. Also would have been better to carry out 
Applanation tonometry as this is the gold standard. 
Pihlblad34
4 
2013 
30 (15 
control) obese 
Patients with 
keratoconus 
To investigate the prevalence 
of obesity and obstructive 
sleep apnea (OSA) in 
keratoconic patients 
The prevalence of OSA 24% and obesity 50% were 
higher in the keratoconic patients. Keratoconic 
patients also had increased lid laxity with a more 
rubbery tarsus further prolonging the symptoms of 
FES. 
There were 15 controls and they were referring to them 
as the normal population rather than Group etc. The 
study size was small and in a case control there was only 
one examiner which could have possibly lead to bias 
results. 
Dogan345 2016 
96 (29 
controls) 
morbidly 
obese 
participants 
To assess the ocular factors 
using OCT in morbid obesity 
and compare them against 
matched controls 
Intra ocular pressure (IOP) and central corneal 
thickness (CCT) were found to be significantly higher 
in obese subjects, while the retinal nerve fibre layer 
(RNFL) was found to be significantly thinner. There 
was a positive correlation between IOP and BMI.  
There were twice as many morbidly obese patients as 
there were controls. Patients that attended also had 
systemic measurements taken but none of which was 
included. A regression analysis could have elucidated an 
influence on measurements and could have been 
corrected for.  
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1.6.1 The heart 
The human heart consists of four chambers: the left and right atria and the left and right ventricle. 
The right atrium receives deoxygenated blood which is then pumped into the right ventricle and 
then into the pulmonary artery and the lungs. Oxygenated blood then returns to the heart, into the 
left atria from where is pumped into the left ventricle, aorta, and systemic circulation (Figure 1.6.1). 
Approximately 80 cm3 of blood is pumped out of the heart in each of its beats, making a total of 
approximately 5.5 litres of blood every minute346. 
 
 
FIG 1.6.1. Illustration of the heart. The heart comprises of four chambers. It is divided into a right and left, each with an 
atrium and a ventricle. The atria act as reservoirs for venous blood. The ventricles are the major pumping chambers, 
delivering blood to the pulmonary (right ventricle) and systemic (left ventricle) circulations. The left ventricle has to 
generate greater pressures than the right ventricle, and has a thicker and more muscular wall. Four valves ensure that 
blood flows only one way, from atria to ventricle (tricuspid and mitral valves), and then to the arterial circulations 
(pulmonary and aortic valves)346. Illustration sketched by author based on Ganong’s medical physiology336.  
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The hearts’ blood supply to the cardiac muscle is derived from branches of the aorta and the 
coronary circulation, mainly the right and left coronary arteries, which line of wall of the heart. The 
left coronary artery originates from the left side of the aorta and separates into three branches 
supplying the anterior wall of the heart and left ventricle. The right coronary artery originates on the 
right side of the aorta separating into two branches and supplies the right ventricle347 348. The 
coronary arterial blood supply to the cardiac muscle represents an “end circulation” since it is the 
only blood supply to the myocardium. As such any type of pathology (atherosclerosis) resulting in 
either blockage or dysfunction to the coronary arteries poses a significant threat that can lead to a 
heart attack or myocardial infarction349. 
1.6.2 The Carotid Arteries 
 
FIG 1.6.2 Illustration of the carotid artery and its branches. The brachiocephalic trunk arises from the aortic arch and 
divides into the right common carotid artery and subclavian artery. The left common carotid artery arises directly from the 
aortic arch. The internal carotid artery is a branch of the common carotid artery and is responsible for the main arterial 
blood supply to the eyes and brain while the external and its varying branches supply the head and face. Illustration 
sketched by author based Netter’s medical illustrations350. 
The right common carotid artery (Figure 1.6.2) arises from the branch of the aortic arch via the 
brachiacephalic artery, whereas the left common carotid artery arises directly from the aortic arch 
46 
 
itself. Both right and left common carotid arteries extend superiorly within the corresponding parts 
of the neck before branching to form the right and left, internal and external carotid arteries336. The 
examination of the carotid artery can be undertaken, due to its close proximity to the skin, with 
ultrasonography and involves measurements of the thickness of the vessel. An increase of carotid 
intimal media thickness can be regarded as one of the first anatomical signs of atherosclerosis which 
is a precursor to atheroma formation351. 
1.6.3 Brachial Artery 
 
FIG 1.6.3. Illustration of the brachial artery. The brachial artery is the major blood vessel of the upper arm, especially the 
tricep muscles. It continues from of the axillary artery, which is a branch of the subclavian, travelling downwards to 
the surface of the arm until it reaches the cubital fossa at the elbow. Blood pressure cuffs are often used to measure 
the blood pressure at this point. The brachial artery then divides into the radial and ulnar arteries which run down 
the forearm. Illustration sketched by author based on Netter’s medical illustrations350. 
 
The brachial artery, located in the upper arm, is formed from the subclavian artery which is a direct 
branch of the braciocephalic artery (Figure 1.6.3). Its location facilitates uniform compression and 
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the artery can be easily visualized with ultrasonography of reactive hyperaemic responses with the 
FMD technique or measurements of temperature rebound with the Endothelix. The brachial is in 
close proximity to the skin which allows for a non-invasive blood pressure assessment carried out 
routinely by a physician or using automated instruments that can allow for routine assessments in 
one’s own home. Currently the gold standard of measuring reactive hyperaemia, is FMD, involves 
and induced increase in blood flow through the artery, based on the principal that shear stress 
exerted on the endothelium would stimulate the release of NO and cause vasodilation. An impaired 
vasodilative response is indicative of a decreased bioavailability of NO352. Although, given the 
subjective nature of the FMD assessment, it has been prone to large inter and intra-observer 
variability, making this technique difficult to master, and usually requires two operators 
simultaneously. The endothelix is a new instrument which also relies on the principle of reactive 
hyperaemia but the advantage of it being that it is fully operator independent.  
1.6.4 Radial Artery 
 
FIG 1.6.4. Illustration of the radial artery. The radial artery arises from the bifurcation of the brachial artery in the cubital 
fossa. It runs distally on the anterior part of the forearm travels down the radial side of the forearm towards the wrist. This 
is where pulse rate can be measured. Just beyond the wrist branches of the ulnar artery join and form a network of vessels 
which supply the hand and fingers. Illustration sketched by author based on Netter’s medical illustrations350. 
 
As the brachial artery branches at the elbow it give rise to the radial artery that traverses along the 
radial side of the forearm to the wrist providing a site for pulse measurements as it approaches the 
skin surface353. Radial artery (Figure 1.6.4) elasticity is measured by pulse wave analysis. This 
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technique relies on pulse pressure waves that travel through the vasculature during cardiac 
contractions. However, it does not give an indication of how the artery interacts with the heart as 
part of an integrative system353. Typically, thicker arterial walls facilitate the dampening of pressure 
oscillations so that blood flows smoothly from the aorta to target tissues354. At inflection points in 
the vessel, pressure waves are reflected back to the heart to regulate the filling of coronary vessels 
during diastole. In individuals with impaired arterial elasticity, pressure wave forms return to the 
heart at a much quicker rate and this augments the pressure that the heart has to overcome in order 
to open the aortic valve. Stiffening of the arterial wall reduces elasticity355, and has been attributed 
to decreased production of nitric oxide, and loss of smooth muscle tone356. 
1.6.5 Blood vessel structure and function 
1.6.5.1 General considerations 
Blood vessels carry blood to every part of the body. They decrease in size as they move away from 
the heart357. From major arteries to arterioles and finally capillaries which are then collected in 
venules to veins and back to the atrium via the superior and inferior vena cava358. Arteries are 
vessels that are robust and elastic which have to carry blood away from the heart at high pressures. 
These arteries branch off and subdivide into arterioles. The artery vessel wall can be divided into 3 
distinct layers (Figure 1.6.5) which are separated by elastic connective tissue. The inner most layer 
known as the tunica intima is largely made up of simple squamous epithelium known as the 
endothelium. The role of the endothelium is to prevent coagulation and also regulate blood flow. 
The middle layer known, as the tunica media, makes up majority of the vessel wall and includes 
smooth muscle fibres and thick elastic tissue. The outer most layer known as the tunica adventitia is 
thinner than the middle layer and is mostly made up of connective tissue358. The walls of the aorta 
and other large diameter conducting arteries contain a large amount of elastic tissue within the 
laminas, either internally or externally. These walls are stretched during systole and recoil during 
diastole. Arterioles contain more smooth muscle and less elastic tissue. The smooth muscles 
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function as a constrictor through innervation by adrenergic nerve fibres and also dilate through 
innervation by cholinergic fibres336. Small changes within the lumen diameter of arterioles cause 
large changes in peripheral resistance; arterioles being the major site of blood flow resistance. 
Conducting arteries branch out further into smaller arteries such as the brachial and radial arteries 
which direct regional blood flow and divide into arterioles which are responsible for perfusion of the 
organ. Arterioles further divide into capillaries. Capillaries are semi-permeable and formed by a 
single layer of endothelial cells. Their main function is for nutrient, metabolite and gas exchange. 
The capillaries connect the arterial system to the venous system. The venules will branch together 
directing regional blood flow to the veins from which deoxygenated blood will travel through the 
peripheral veins and into the heart via the atrium and pulmonary circulation336. Veins can also be 
divided into 3 layers like their arterial counterparts but mainly have a larger lumen, smaller amount 
of smooth muscle cells and elastic tissue. Veins also contain valves which prevent back flow and are 
supported by skeletal muscle contractions to help return blood to the heart221 336. 
 
FIG 1.6.5. Illustration of the blood vessel types, structure and diameters. There are five classes of blood vessels within the 
circulatory system. Arteries, arterioles, capillaries, venules, and veins. Arteries deliver oxygenated blood to the organs 
through arteries and capillaries while de-oxygenated blood returns to the heart from the veins. Illustration sketched by 
author. 
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1.6.6 Anatomy and physiology of peripheral circulation 
 
The vasculature of the superficial skin is organized into two horizontal plexi of arterioles and 
venules; one located just below the papillary dermis (1-1.5 mm below the surface) and one at the 
dermal-subcutaneous junction (3-5 mm below the surface). The upper (superficial) plexus supplies 
the individual dermal papillae with nutritive capillary loops and the lower (deep) plexus provides 
supply to the hair follicles and sweat glands (Figure 1.6.6). The many neural, environmental and 
hormonal signals involved in temperature regulation are integrated in the pre-optic anterior 
hypothalamus359. The hypothalamus has a thermos-neutral zone of accepted core body 
temperature, and deviation from this point by ±0.2°C initiates reflex activity by a variety of negative 
feedback-controlled methods359. Warm and cold responses are both mediated by the sympathetic 
nervous system.  Blood flow to the cutaneous circulation has a remarkable range, from nearly zero in 
extreme cold to a total for the entire body surface of 7 l/min when body temperatures are high360. 
When expressed per unit volume of skin. Maximal skin blood flow can reach an estimated 300–400 
ml/min per 100g skin361-363. 
During warm temperatures blood flow increases to the skin and can be as high as 8L/min. This is an 
effective manner of heat loss; though it can cause problems in subjects with some degree of cardiac 
abnormalities who can’t increase their cardiac output sufficiently359. Cold temperatures result in 
reductions of blood flow to the skin. This response is mediated by aplha1-adrenoreceptors and 
peripheral alpha2-adrenoreceptors. These cause constriction of arteriovenous shunts in the skin 
(particularly fingers and toes), diverting blood away from the peripheries. This reduces the mass of 
tissue in the body that must be kept warm by reducing the size of the core. There can be a 
temperature difference of 6°C between the hands and core organs without damage to tissue or 
extra expenditure of energy359.  
Pathology-induced vascular dysfunction is evident in the cutaneous circulation364-367 and may mirror 
generalized systemic vascular dysfunction in magnitude and underlying mechanisms368-373. Deficits in 
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cutaneous vaso-reactivity are measurable early in the progression of hypertensive vascular 
disease366 367 374 375, and hypertrophy of the cutaneous resistance vasculature is predictive of future 
cardiovascular events376. 
 
 
FIG 1.6.6. Illustration representative of cutaneous circulation. Skin blood flow has, as a prime function, the regulation of 
core body temperature. The superficial plexus acts as a large thermal radiator and has a blood-flow range of 1ml/min per 
100g of tissue in the cold to 200 ml/min per 100 g tissue in the hot346. These extremes of flow are possible through the 
regulation of numerous arteriovenous communications by the ANS. The acral areas (hands and feet) in particular possess 
abundant direct connections between arterioles and venules; the vessels in these areas are controlled almost exclusively 
by sympathetic nerve fibers. Illustration sketched by author based on Netter’s medical illustrations350. 
 
1.7. Physiology of the cardiovascular system 
The principle function of the cardiovascular system is to maintain adequate blood flow to all tissues, 
ensuring their oxygen and nutrient demands are met and waste products removed. Blood flows 
through the cardiovascular system primarily as a result of the pressure produced by the contraction 
of the heart ventricles, referred to as the systemic BP336. Both systemic BP and heart rate (HR) are 
constantly regulated and controlled by the autonomic nervous system (ANS) in accordance with the 
hemodynamic needs of the body. The background and relevance of systemic BP and the ANS with 
regard to cardiovascular physiology is outlined in the following sections 
1.7.1. Systemic blood pressure 
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Blood pressure defines the force exerted by the blood against the vessel wall and is determined by 
both the volume of blood in the vessel and the distensibility of the vessel wall. It is commonly 
described in terms of systolic (SBP) and diastolic (DBP) blood pressure, with systolic being the 
highest measured pressure, corresponding to ventricular contraction and diastolic being the lowest 
measured pressure, corresponding to ventricular relaxation and refilling. It is measured in milligrams 
of mercury (mmHg) from the brachial artery in the upper arm using a sphygmomanometer.  The 
most recent World Health Organisation (WHO) and International Society of Hypertension guidelines, 
which are based on the 1999 publication for the classification of hypertension, are outlined in table 
1.7. 
 
Based on WHO and international society of hypertension377 
 
1.7.2. Endothelial function  
The endothelium is the most inner portion of the vessel. It comprises of almost single layered cells 
and lines the entire vasculature throughout the body.Its structure and phenotype depends on the 
vessel size and location378. The cell structure is important for the maintenance of the vessel wall and 
circulatory function379. Endothelial cells have the ability to regulate a number of complex 
physiological functions depending on the location of the vascular bed. Its main role is regulation of 
vascular tone and blood flowto  maintain homeostasis. It also regulates thrombosis, coagulation, 
platelet adherence and inflammation.  The endothelium releases vasoactive substances which act on 
the diameter of the vessel. These are usually brought on but not limited to stress, mechanical 
Table 1.7 Classification of hypertension
Category Systolic (mmHg) Diastolic (mmHg)
Optimal <120 <80
Normal 120-129 80-84
High normal 130-139 85-89
Hypertension
Grade 1- Mild 140-159 90-99
Grade 2- moderate 150-179 100-109
Grade 3-Severe >180 >110
Isolated systolic 
hypertension >140 <90
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irritation or chemical provocations. These active substances are commonly known as endothelial 
derived constricting or relaxing factors which play an important part in the regulation of ocular blood 
flow380. In diseased, the endothelium undergoes structural and functional changes making it more 
prone to atherosclerosis and thus becoming more susceptible to develop vascular disease381 382. 
More commonly known as endothelial dysfunction.  
The endothelium has a critical role as an active regulator of vascular tone383 384. Maintaning vascular 
homeostasis is brought upon by competing factors on the smooth muscle cell within the vessel wall 
from internal and external forces. These internal factors influence the smooth muscle cell within the 
vessel wall itself through the production of vasoactive substances such as NO and ET-1, which are 
the most potent vasodilating and vasoconstricting substances within our body385 386. External factors 
which act on the smooth muscle cell relate to innervation from the autonomic nervous system138 387. 
The endothelium also has a protective role within the vessel wall and regulates inflammation, 
inhibits the proliferation of smooth muscle cells, platelet aggregation, angiogenesis and thrombosis 
through its control on vascular permeability382 388 389. 
a. Endothelium derived relaxing factor 
The endothelium plays a key role in maintaining basal vascular tone throughout the body. The 
endothelium derived relaxing factor (EDRF) was first described in 1980 by Furgatt and Zawadzki139. 
Their study had shown that Acetylcholine which acts on muscarinic receptors within the endothelial 
cells provided a substance which acted upon the relaxation of smooth muscle cells. They also 
noticed that Acetylcholine had no effect on relaxation when endothelial cells were not present or 
damaged. However this EDRF was not known at the time of their study. Soon after it was recognized 
that this EDRF was NO385 390 391 and became an important research topic with regards to vascular 
physiology and has been investigated in depth.  
NO is produced from the oxidization of the  amino acid L-arginine to the L-citriline group by the 
enzyme Nitric oxide synthase NOS385 390. To date three isoforms have been identified, Neuronal 
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NOS1, inducible NOS2 and endothelial NOS3. NO synthesis has been mainly attributed by endothelial 
synthesis. When NOS1 and NOS3 are activated, NO is produced via the calcium/calmodulin complex. 
When NOS2 is activated NO production is independent of calcium392. Large amounts of NO, via 
NOS2, are produced and expressed only after immunological or inflammatory stimuli392 393. All the 
isoforms of NOS have been identified in the ocular circulation394. NO has a very short half-life of 
roughly 2-3 seconds. A single NO molecule can affect adjacent cells because of its ability to diffuse 
over large distances. NO has a key role in maintaining vascular tone in humans 138 and is a major 
regulator of systemic blood pressure395 396. Diffusion of NO into smooth muscle cells brings about 
vasodilation of the vessel through stimulation of the guanylate cyclise enzyme and increased 
production of cyclic guanine monophosphate (CGMP)397 398.  
NO plays an important role in the haemodynamics of the cardiovascular system, the regulation of 
physiological functions and the branches of the autonomic nervous system. In addition to its role as 
a relaxer it has many other functions including inhibition of thrombosis, cellular proliferation and 
inflammation. NO has also been identified at the ocular level as a mediator of vascular tone. NO is 
present in retinal vessels, in the endothelium of the optic nerve head and choroidal blood vessels399-
401. Retinal arterioles and capillaries are in a constant state of vasodilation which is maintained by a 
continuous release of NO138 402. Any disturbances to homeostasis can have detrimental effects on the 
vasculature and it has been shown that NO deficiency, through an impaired endothelium, can result 
in excessive vasoconstriction, inflammation, leukocyte activation and infiltration403. As such, any 
disturbance to NO can have an impact on systemic and ocular haemodynamics, resulting in 
endothelial dysfunction ED, usually from impaired NO bioavailability which results in 
vasoconstriction from stimulation of the vasoconstrictor (ET-1). This shift from a normal vasodilative 
state can influence the vasculature permanently leading to a greater chance of vascular disease.  
b. Endothelium derived constricting factor 
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Endothelium derived constricting factors (EDCF) were first described by Yanagisawa in 1988404, 
having potent vasoconstrictor capabilities which are also produced in the endothelium alongside NO. 
Three distinct isoforms of endothelins exist and have been identified, ET-1, ET-2 and ET-3. The 21-
amino acid peptide ET-1 is considered as the most potent isoform in controlling vascular tone405. 
Endothelins are formed via a 39-amino acid intermediate which is then processed by a family of 
endothelin converting enzymes392 406. Under physiological conditions, ET-1 is produced in very low 
concentrations within endothelial cells and there release is inhibited by the production and 
continual release of NO. However, under pathophysiological conditions, the production of 
endothelins is stimulated in a large number of different cell types such as smooth muscle cells, 
endothelial cells and inflammatory cells such as leukocytes and macrophages which can be 
measured in plasma407.  
There are two classes of endothelin receptors ET-a and ET-b, separated by pharmological receptor 
subtypes. The ET-a receptor is mainly located within smooth muscle cells and mediate the potent 
vasoconstriction affect. The ET-b receptor has been further divided into ET-b1 & ET-b2 based on 
their responses408. Stimulation of ET-b1 receptor cells induces vasodilation in generally low doses 
probably because they are formed within endothelial cells, but at higher concentrations of the 
peptide, vasoconstriction dominates. The ET-b2 receptor located within vascular smooth muscle 
cells when stimulated cause direct vasoconstriction. The total effect of endothelins may vary 
considerably from different vascular beds, which depends on the localization of the ratio of ET-a and 
ET-b receptors. This varies considerably within veins as they tend to have a lower receptor ratio 
compared to arteries409. In pathological states there is a predominantly ET-1 vasoconstrictive 
induced effect. This is because there is an upregulation of ET-b receptors on vascular smooth muscle 
cells and down regulation of ET-b receptors on endothelial cells410.  
Increased amounts of ET-1 due to a reduced bioavailability of NO have been implicated in a number 
of cardiovascular diseases including CAD, systemic hypertension and exasperation of 
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atherosclerosis411 412. Endothelin receptors ET-a are found at the ocular level within the retina and 
choroid and optic nerve head while Receptor ET-b sites are localized to the neural and glial 
substance of the retina413 414. Within the ocular circulation there have been numerous studies that 
have shown ET-1 being involved primarily in the regulation of vascular tone mainly exhibiting its 
vasoconstrictor effects on the microvessels406 415 416. The role of ET-1 in regulating ocular blood flow 
can be seen as it was shown that during exercise ET-1 is produced to counteract the effect of 
increases in ocular perfusion pressure413 417. But when the receptor ET-a antagonist BQ-123404 was 
administered the vasoconstrictive role of ET-1 was ameliorated. Due to the role of ET-1 regulatory 
capacity of blood flow throughout the body it can be envisaged that any imbalance in vascular tone 
through cardiovascular disease, systemic or ocular, can result in retinopathy and future 
cardiovascular events. 
1.7.3. The relationship between the Autonomic Nervous System and the 
endothelial function 
In a normal state, the ANS and the endothelium work together to maintain vascular tone. There is a 
tonic balance between the release of vasodilating factors from the endothelium and vasoconstricting  
factors from the sympathetic nerve terminals418. The balance between these forces acts on the 
vascular smooth muscle cells to maintain the appropriate vessel tone419. Activation of b-adrenergic 
receptors on vascular smooth muscle cells contribute to vasodilation420, whereas activation of a1-
adrenergic and a2-adrenergic receptors on smooth muscle cells contributes to smooth cell 
contraction402 420 421. PSNS stimulation of muscarinic receptors on smooth muscle cells also results in 
contraction138. The release of NO from the endothelium stimulates smooth muscle cells which in 
turns causes dilation422 (Figure 1.7.3). This endothelium-dependant vasodilatory effect of a2-
adrenergic receptor activation counteracts the vasoconstricting effects of a1-adrenergic receptor 
stimulation of the vascular smooth muscle421 423. In addition, the SNS can stimulate the release of 
endothelium derived contracting factors, such as ET-1419 424. Endothelial cells also possess receptors 
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for the primary PSNS neurotransmitter acetylcholine and activation of these receptors produces 
endothelium-dependant relaxation of human coronary arteries 425. Although endothelial cells in the 
microvasculature may receive ANS input, endothelial cells along the major conduit vessels do not 
receive direct neural innervation from the ANS419. Therefore the effects of neurotransmitters on 
endothelial function must be exerted by circulating levels or by diffusion through the smooth muscle 
cell layer without degradation422 (figure 1.7.3).  
 
FIG 1.7.3. Illustration of ANS and endothelium and its effects on vascular diameters. There is a tonic balance between the 
release of vasodilating factors from the endothelium and vasoconstricting factors from sympathetic nerve terminals. The 
endothelium releases vasodilating factors, such as NO, which stimulates the smooth muscle cells causing vasodilation. The 
endothelium also releases contracting factors, such as ET-1 and ANGII, which stimulates vasoconstriction. Sympathetic 
activation of B-adrenergic receptors of smooth muscle cells contributes to vasodilation, whereas a-1adrenergic receptors 
contributes to vasoconstriction. Parasympathetic stimulation of muscarinic receptors on smooth muscle cells also results in 
vasoconstriction138. Illustration sketched by author. 
 
Much of the evidence linking ANS activity and endothelial function comes from pathological states 
associated with impairments in both systems. Chronic diseases such as hypertension and diabetes 
have been independently associated with ANS and endothelial function426-430. It is unclear though, 
whether the ANS and endothelial systems are negatively affecting one another, or whether both 
systems undergo dysregulation as a consequence of the disease process422. An impairment in 
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endothelial function can cause irregularities within the ANS, through alterations in neurotransmitter 
release from the SNS may result from decreased NO release431. Conversely, an impairment in ANS 
function can cause irregularities in the endothelium. This can happen through an exaggerated SNS 
and can enhance endothelium mediated atherogenic processes418 as well as it may also increase the 
uptake of low density lipoprotein by endothelial cells432. 
 
1.7.4. Vascular tone 
In healthy individuals, the ANS works closely with the vascular endothelium to insure a stable 
vascular tone. In response to local factors, the vascular endothelium continuously releases 
vasodilating factors (e.g., NO, endothelium-derived hyperpolarizing factor, prostacycline, substance 
P, acetylcholine) which counteract the vasoconstrictor effect of the sympathetic activation occurring 
as a result of a more systemic requirement 418. Although the vascular endothelial cells do not receive 
direct ANS innervation, it still can be influenced through the activation of its own alpha2 and beta- 
adrenoreceptors  that results in NO release and vasodilation 420. In addition, the parasympathetic 
nervous system can contribute to acetylcholine release and vasodilation 433, while the sympathetic 
nervous system can stimulate the release of endothelium-derived vasoconstrictors such as ET-1 434. 
More recently, Seddon et al. has demonstrated that neuronal NO synthase (nNOS) also contributes 
directly to the regulation of human vascular tone 435. 
 
Blood flow is autoregulated in proportion to tissue demand for oxygen and other nutrients436. 
Therefore, during the night, the lack of physical activity together with a decreased demand for 
oxygen results in a low blood flow and an increased peripheral resistance 436 437. In addition, the 
frequency of peripheral vasoconstriction is dependent on the stage of the sleep, being higher during 
REM than during non-REM sleep 438. Endothelium-dependent vasodilation represents a protective 
mechanism against time-dependent changes in the body’s haemodynamics. Any disturbances in this 
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mechanism could represent an important risk factor for circulatory ischaemic events 439. Assessment 
of endothelial function, can therefore provide both a valuable insight into the pre-clinical phase of 
ischaemic diseases and an early marker for this type of circulatory disturbance. Moreover, due to a 
circadian variation in the occurrence of systemic and local circulatory ischaemic events, the rhythm 
of the endothelial function is equally important to assess. In healthy individuals, the vascular 
diameter is smaller in the morning. However, this status is accompanied by a normal dilation 
capacity should the body need it 440. In addition, it has been demonstrated that the systemic 
secretion of NO has a peak early in the morning 441, possibly to buffer the concomitant increase in BP 
due to a high sympathetic tonus. Moreover, in normals, circadian rhythm of (ET-1), the most potent 
vasoconstrictor of the human body is characterized by two peaks (at 8h and 20h) and low levels 
during the night when the body should rest 442.  Therefore, maintaining a balance between all these 
factors is crucial for an appropriate perfusion with blood and any disturbance that occurs in either 
ANS or endothelial function is ultimately reflected in impairments that occur in both systems 418. 
Indeed, disorders such as diabetes, cardiovascular disease, hypertension and congestive heart 
failure, have been associated with both abnormalities of ANS regulation 430 443 444 and abnormalities 
of endothelial function 445-447. It is difficult to determine, however, whether a dysfunction in one 
system may have driven a dysfunction in the other and if so which occurred first, or whether both 
systems have developed a dysfunction independently as part of the disease process. In young 
patients with essential hypertension, both ET-1 levels and sympathetic activation were higher (ref 
kulinska 2010).  Moreover, in patients with congestive heart failure, studies have found that ET-1 
levels correlate negatively with some measures of HRV 448 and in patients with diabetes associations 
have been found between lower HRV and higher levels of von Willibrand factor (vWF), a marker of 
endothelial dysfunction 449. Nevertheless, other external influences, such as the level of oxidative 
stress and the ageing effect on the vascular function, should also be considered when studying the 
complex interaction between ANS and endothelial function in health and disease.  Indeed, an altered 
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vascular tone may result in higher vulnerability of various organs including the eye to damage from 
free radicals or inflammatory stress450. 
 
1.8. Anatomy and physiology of the retinal vessels and retinal circulation 
The blood supply that nourishes the retina and ocular structures primarily arises from the internal 
carotid artery which is a direct branch of the aorta. The internal carotid artery (ICA) branches into 
the ophthalmic artery (OA), which further divides into the central retinal artery (CRA), and posterior 
ciliary arteries (PCAs). These vessels are known as retro bulbar vessels as they provide nourishment 
to the posterior segment of the eye. 
1.8.1 The ophthalmic artery 
The OA if the first major branch of the ICA arising just after the cavernous sinus. It travels anteriorly 
passing within the optic canal and piercing the dura meter infero-laterally reaching the optic nerve 
until it enters the orbit451. There are normal anatomical variations, such as OA piercing the orbital 
canal but not the protective dura sheeth, and other variations such as the OA entering the optic 
canal superiorly, medially, and nasally but in most cases it enters inferiorly452 453 and is situated 
beneath the superior oblique muscle. As such, the anatomy will be discussed according to what is 
most frequently observed.  
1.8.2 The central retinal artery 
The CRA represents a direct branch of the ophthalmic artery. It commonly originates on the infero-
medial side of the ophthalmic artery about 8.4mm distal to the orbital end of the optic canal454. It 
pierces through the optic nerve behind the globe. It then travels along the centre of the optic nerve 
before appearing at the surface of the disk through the lamina cribrosa. The central retinal artery 
further divides into 4 intra retinal arterioles; supplying each quadrant of the retina. 
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1.8.3. The ciliary arteries 
The ciliary arteries can be divided into three groups; the short posterior, long posterior, and anterior 
ciliary arteries. Anatomical variations exist but there are roughly between 1-5 posterior ciliary 
arteries that arise from the ophthalmic artery. They branch from the ophthalmic artery, grouped 
into medial trunks situated on either side of the ophthalmic nerve and pierce the sclera laterally, 
medially (infrequently inferiorly, and superiorly) and serve as the main source of blood supply to the 
ocular structures and optic nerve head455. Short posterior ciliary arteries can range from 12-20 in 
number depending on the subdivision before reaching the sclera. They divide into the para-optic 
ciliary arteries which supply parts of the optic nerve head and distal ciliary arteries which supply the 
choroid. Long posterior ciliary arteries, run a course, and pierce the sclera medial and laterally 
forward to the iris. The anterior ciliary arteries leave the ophthalmic artery and run a course through 
the medial and lateral rectus muscles; then travel forward to the ciliary muscle and also to the major 
arterial circle of the iris, supplying the anterior uveal tract456. 
1.8.4 The retinal circulation 
There are 2 main sources of blood for the retina. The CRA and its branches supplying the inner retina 
and the choroidal blood vessels which maintain and nourish the outer retina. Branches of the 
posterior ciliary arteries, are the main source of blood to the corresponding parts of the optic nerve 
head, peripapillary choroid, the circle of Zinn and Haller, and serve recurrent branches to the 
retrolaminar optic nerve head455. These short posterior ciliary arteries further divide into smaller 
segments and supply a corresponding segment of the choroid. Each terminal arteriole supplies a 
lobule of the choriocapillaries455 457 458. The choriocapillaries (a network of choroidal capillaries 
located beneath the retinal pigment epithelium) are extremely small vessels and are arranged 
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distinctly within the inner portion of the choroid. One of its major roles is to supply blood and 
metabolites to the retinal pigment epithelium and the outer neurosensory retina459.  
The retinal capillary network is organized into an inner and outer parapapillary radial network. The 
inner capillaries underlying the radial peripapillary network from the superficial layer and the outer 
capillaries form the deep plexus layer460. This capillary network extends towards the edges of the 
retina with the exception of a capillary free zone in the macular region461.  Majority of blood that 
flows for the maintenance of the retina is through the choroid and its circulation and is 
approximately 40 times greater than that of the retinal vasculature462. Generally the retinal 
circulation is characterized by a low level of flow with a high level of oxygen extraction463 464. The 
circulation is autoregulated, allowing blood supply to be adjusted to metabolic demand. As 
sympathetic nerve terminals are localized in the smooth muscle cells of the choroidal vessels, retinal 
vessels do not receive autonomic innervation465 466. 
1.8.5. Venous drainage 
The venous system consists of many orbital veins, of which the superior ophthalmic vein is the 
largest in diameter467. It is generally regarded as the main source of drainage within the orbit. It 
originates from two roots at the medial orbital rim. The superior root being the supraorbital vein, 
and the inferior route from the terminal part of the angular vein. The roots form posterior to the 
trochlea and travel posteriorly in the direction of the ophthalmic artery before leaving the orbit 
through the superior orbital fissure and draining into the cavernous sinus468. Venous drainage from 
the choroid is mainly by 4 vorticose veins representing the different quadrants of the eye which also 
drain corresponding quadrants of the Ciliary body and iris469. The inferior orbital venous system 
comprises of the inferior orbital venous plexus which is responsible for the drainage of the inferior 
lateral and medial vorticose veins. The superior medial and lateral vorticose veins ultimately join the 
superior ophthalmic vein and drain directly into the cavernous sinus467 469. The central retinal vein is 
responsible for venous drainage within the retina. It receives its de-oxygenated blood from its four 
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quadrants within the retinal branches. The central retinal vein courses centrally within the optic 
nerve but exits the nerve 1-2mm behind the entry point of CRA and then runs posteriorly below it. It 
can drain directly into the cavernous sinus but also drains into the superior ophthalmic vein or other 
intra orbital venous branches470.   
 
FIG 1.8. Illustration of the human eye. The outer protective layer of the eyeball, the sclera, extends anteriorly to form the 
cornea through which light rays enter the eye. Underneath the sclera is the choroid, a layer that is heavily vascularized and 
responsible for nourishment of the structures in the eye. Underneath the choroid is the retina, the neural tissue containing 
the photoreceptor cells which is responsible for transmitting the information to higher orders of the brain336. In front of the 
lens (not shown) is the pigmented and opaque iris, the colored portion of the eye. The iris contains circular muscle fibers 
that constrict and radial fibers that dilate the pupil. The space between the lens and the retina is filled primarily with a 
clear gelatinous material called the vitreous humor. Aqueous humor, a clear liquid that nourishes the cornea and lens, is 
produced in the ciliary body by diffusion and active transport from plasma. Illustration sketched by author based on 
Netter’s medical illustrations350.  
1.9. Physiology of ocular blood flow 
Blood flowing through the body is determined by the cardiac output, which depends on heart rate 
and stroke volume. An adequate supply is a basic requirement for all tissue beds and organs to 
remain healthy. The distribution of cardiac output between vascular beds varies according to the 
haemodynamic situation that arises, and can be influenced by systemic hormones and the 
autonomic nervous system464. Despite variations in systemic blood pressure, arteries can preserve 
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constant flow through tissues due to the existence of vascular tone mediated by smooth muscles 
cells and other contractile elements within the vessels wall380, allowing blood supply to be adjusted 
to metabolic demand, this is autoregulation. Within each vascular bed, local factors regulate and 
supply the required blood. At the ocular level, this has been identified as a complex, multi-factorial 
process471, dependant on both ocular perfusion pressure and vascular resistance.  
Blood flow, inside a vessel is proportional to its perfusion pressure, and inversely proportional to 
vascular resistance392. This relationship is given by Q=∆P/R, where Q is blood flow, ∆P is the 
difference in pressure between 2 ends of a vessel, and R which is due to the friction of blood moving 
through the vascular endothelium. The principles of blood flow in intraocular tissues are similar in 
that blood flow is dependent on arterial pressure, local venous pressure, and resistance to flow.  
Based on the drop in blood pressure between the heart and OA, retinal arterial pressure can be 
estimated as 2/3 of the mean arterial pressure, (MAP=2/3DBP+1/3SBP) and venous pressure can be 
taken approximately equal to the level of IOP464 472, except in instances where the IOP is very low465. 
1.9.1. Ocular perfusion pressure (OPP) 
The IOP is determined as the force per unit area exerted on the ocular tissues within the anterior 
chamber by the fluids that contain them473, mainly through the combination of aqueous humor 
production by the ciliary body and drainage through the trabecular meshwork and canal of schlemm. 
The normal range of IOP is defined as being between 10-21mmHg474. There is considerably a large 
amount of variability between people but it exists in a constant state and is known to slightly 
increase with age and can also measure slightly higher in the morning than later on in the day. It can 
vary with cardiac and respiratory cycles and can be influenced by external factors such as exercise, 
diet and posture475. OPP is influenced by pulsatile variations in IOP, these pulsatile variations are 
thought to be delivered during systole contraction while diastolic flow accounts for 2/3 of ocular 
flow476. Put in another way, the ocular circulation pressure gradient begins with the arterial pressure 
being supplied by the CRA and ends with the pressure exiting the CRV. Within the eye the 
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vasculature is exposed to a significant compressing force, the intraocular pressure; the pressure 
within the small arteries and arterioles are the primary site of resistance within the ocular circulation 
and the drop in pressure from the systemic circulation to the capillary level can indicate the force of 
blood392. Ocular perfusion pressure is the force blood flow through the intra ocular vessels and is the 
difference between venous and arterial pressure, this affective venous pressure is also known as the 
IOP. This force can’t actually be measured directly in the retinal circulation and thus it can only be 
estimated using the following equation. OPP= 2/3MABP-IOP. The relationship between ocular 
perfusion pressure and blood flow is complex but a rise in systemic arterial pressure or a drop in 
intraocular pressure can potentially reduce OPP.   
1.9.2. Autoregulation and local control mechanisms 
Autoregulation represents the ability of organs and tissues to modify vascular resistance in order to 
allow constant and uninterrupted blood supply and its maintenance despite variations in perfusion 
pressure477. Autoregulation ensures tissues and organs receive adequate blood supply despite 
varying haemodynamic conditions and has been demonstrated within the retinal and optic nerve 
head circulation478-480. There are methods of evaluating the autoregulatory responses within the 
vasculature and they usually include a provocation method such as inducing hypoxia or hypercapnia, 
postural changes, exercise, hand grip testing, and stimulation of flickering light. These methods put 
the vascular system under stress and should evoke an autoregulatory response. A failure to respond 
results in dysregulation and is possibly indicative of altered regulatory capacity. The exact 
mechanisms which are involved in autoregulation are not quite clear as it is more probable to be a 
combination of factors that work to harmonize the relationship between responses in the systemic 
and ocular circulation. These local control mechanisms include, myogenic, metabolic, neurogenic, 
humoral as well as endothelial derived vasoactive agents481. In the absence of autonomic 
innervation, myogenic and metabolic stimuli are more involved within the retinal circulation.  These 
adjustments of vascular tone are described in detail below. 
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a. Myogenic control  
The myogenic mechanism responds to stretch and vascular wall tension which is characterised by a 
decrease in vessel diameter followed by an increase in transmural pressure482, ultimately referring to 
the maintenance of constant blood flow despite variations in systemic blood pressure477.  Myogenic 
autoregulation is thought to be independent from the endothelium and intrinsic to vascular smooth 
muscle cells. Whereby, stretching of the vessel wall is thought to lead to depolarization of the 
vascular smooth muscle cells membrane with an influx of calcium ion (CA++) into the cytosol and 
inducing vascular constriction483. At the level of the systemic vasculature, myogenic autoregulation 
mainly facilitates capillary fluid exchange, but its role in the eye484 485 is not clear. Although its auto 
regulatory capacity has been demonstrated within the retina and optic nerve head485, it  remains 
unclear whether this mechanism is involved within the choroidal blood flow484. 
b. Metabolic control  
Metabolic control refers to the metabolites that regulate blood flow to maintain adequate nutrient 
delivery. A tight coupling mechanism between tissue metabolism and perfusion is thought to exist477 
with alterations in the concentrations of metabolites including oxygen, carbon dioxide486 487, 
potassium, hydrogen380, and adenosine488. Since the majority of tissues use aerobic metabolism, 
oxygen delivery to the tissue is of utmost importance and when there is a demand of oxygen, this 
mechanism releases a vasodilatory signal that increases blood flow and capillary perfusion. Oxygen is 
the most regulated variable. Partial oxygen pressure has been identified as one of the main factors 
that act upon metabolic autoregulation489 490. Within the ocular circulation under conditions of 
hyperoxia or hypoxia, the auto regulatory mechanism maintains the delivery of oxygen consistently 
to the retina and optic nerve head.  Hyperoxic conditions reduce retinal blood flow and partial 
oxygen pressure, through causing the retinal arterioles to constrict486 491. While hypoxic conditions 
trigger retina arteriolar vasodilations, normalising partial oxygen pressure through increased retinal 
blood flow492. Other metabolic factors are also in play within the retinal circulation and include 
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endothelial cells, glial cells, and neurons that affect vascular tone, specifically NO, ET-1, prostacyclin, 
cyclooxygenase, and angiotensin 2. 
c. Neurogenic control  
The autonomic nervous system has a large network of vasomotor nerve fibres that are directed 
towards the uvea, posterior ciliary arteries, and the extraocular portion of the central retinal 
artery462 493. Vessels in the retina and pre-laminar portion of the optic nerve head, however, have no 
neural innervation494. Neuronal regulatory mechanisms play a key role within the regulation of 
choroidal blood flow but have little effect on retinal and optic nerve head blood flow495, despite 
alpha and beta adrenergic receptors having been identified within the retinal vasculature496. 
Numerous agents have been implicated as mediators in neuronal regulation such as acetylcholine497, 
vasoactive intestinal polypeptide498, substance P499 and NO500. However the exact role of these 
agents are still unknown. More recently, it was shown that even high levels of noradrenaline have 
little impact on retinal vascular tone501. It has been suggested however, that stimulation of the 
sympathetic nervous system regulates blood flow towards the eye, by regulating and preventing 
over perfusion during an increase in systemic arterial blood pressure, thereby assisting myogenic 
autoregulatory mechanisms502. 
 
d. Neurovascular coupling mechanism 
Neurovascular coupling, also known as functional hyperaemia, refers to the relationship between 
neural activity and its subsequent effects in regulating blood flow in the cerebral vasculature and 
was first identified in the late 1800’s503. The normal response at the cerebral level is characterized by 
an increase in dilation of arterioles and capillaries in a local brain region in response to amplified 
neural activity504. This results in rapid expansion increasing cerebral blood flow so the oxygen and 
glucose demands of the brain are met504. This is important because the brain, unlike the rest of the 
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body doesn’t possess the ability to reserve energy and oxygen. Although the exact mechanism which 
drives the neurovascular response is still up for debate, it is more likely a complex combination of 
intercellular communications between neurones, astrocytes and microvessels, endothelial cells, 
pericytes and vascular smooth muscle cells504 505, with NO having been identified as a key 
vasodilating contributor of the response506 507 but not necessarily as the primary mediator. The key 
components of the neurovascular coupling response, are astrocytes, neurons, microvascular 
endothelium and the extracellular matrix, collectively are known as the “neurovascular unit”. They 
are not only involved in the regulation of blood flow but are indispensable in preserving the health 
and function of the central nervous system508. The neurovascular unit is also responsible for 
maintaining homeostasis within the cerebral microenvironment through controlling blood brain 
barrier (BBB) metabolite exchange and contributing to immune surveillance509. The neurovascular 
coupling mechanism has also been detected at the retinal and optic nerve head circulations, where 
escalation in the retinal neuron activity increases blood flow to the excited regions510 511. This occurs 
through alterations in retinal vessel diameters, either through dilation or constriction of the retinal 
arterioles and capillaries512 513. 
 
1.10 Assessment of systemic vascular and endothelial function 
The capability to detect and evaluate endothelial dysfunction (ED) is important with regard to the 
identification, understanding and treatment of overweight and obese patients at risk of developing 
CVD. The techniques for identifying endothelial function can be broadly separated into three 
categories.  The first works by measuring soluble circulating endothelial markers such as NO, ET-1 
and von Willibrand factor (vWF).  The production of these markers is known to be increased in the 
presence of ED514 515.  The second category of measurement is determination of functional 
endothelial dependent vascular tone at focal sites of circulation516. This gives information on how 
the calibre of the vessel in correlates with its function.  The third category of technique used is the 
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identification of structural characteristics of the vascular wall353 517 that can be altered in the 
presence of ED. A summary of these investigations are given in table 1.10.    
The initial methods for assessing endothelial function were quite invasive and included such 
techniques as strain gauge plethysmography of the forearm518, and quantitative coronary 
angiography using intracoronary infusion of acetylcholine (Ach)519. During both techniques, infusion 
of Ach would cause the vessel of choice to dilate. If there was a disrupted or dysfunctional 
endothelium then vessels would constrict due to direct activation of the muscarinic receptors on the 
vascular smooth muscle cells516 519. These tests however are only suited when clinically indicated and 
are not ideal for the assessment of the asymptomatic patient.  The introduction of non-invasive 
techniques such as FMD have now superseded the aforementioned investigations. Currently 
systemic endothelial function as measured by FMD is the gold standard but can only be performed in 
highly specialized environments limiting its use within research settings. Indeed, it has previously 
been shown its application is technically challenging and requires extensive training520-522. Because of 
this, reproducibility has been hampered with inter-and intra-observer variations caused by a lack of 
a standardized protocol523 524. Although circulatory abnormalities have been known to occur in 
micro-vessels before they occur in larger vessels, there is a possibility that vascular changes in the 
retinal micro-circulation may represent an ocular manifestation of a generalized systemic disorder. A 
number of systemic endothelial assessments were therefore selected for the present study to 
provide a comprehensive view of an individual’s vascular status. Namely, assessments of systemic 
endothelial function and arterial stiffness were achieved by way of digital thermal monitor (DTM), 
and PWA respectively.  
 
DTM has been recently introduced as an alternative to FMD because of its similarity to FMD; 
occluding the forearm results in a temperature drop, when released reactive hyperaemia (RH) 
causes an increase in temperature rebound which is proportional to the RH response525. The 
advantage of DTM is its independence from the operator’s skills and experience making its 
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repeatability enhanced, so that is has become a preferred method in research526.  DTM was 
therefore the technique of choice for present study. Its principles are discussed in more detail in 
Section 3.3.2.  
 
1.11. Assessment of retinal vessels 
1.11.1 Static vessel analysis 
The first published image of the retina by Von Tright in 1853 was the result of many years of 
research and improvements in the technique by Von Helmholtz 1851. The concept of fundus 
photography dates back to the days of the early 1900’s when Gullstrand invented the fundus camera 
and won a Nobel prize for his achievement527.  The photographic technique has not changed 
significantly per se but the availability of technological advancements in digital imaging has allowed 
the clinician to make adjustments and refine the images as necessary as well as allowing the 
operator to view the fundus as the image is being captured.  
Since then fundus photography has facilitated the development of methods to quantify retinal vessel 
calibre and to yield specifications with regards to vascular characterization and risk stratification. It 
has been shown over time that the retinal vasculature can provide information regarding the future 
risk of systemic pathology528-533  
Retinal vessel assessments can aid in the interpretation of pathology and risk factor exposure over 
the course of life. It has been used as a research tool in exploring cardiovascular risk; assessing 
microvascular changes associated with systemic pathology, and treatment of vascular therapies. 
There are numerous parameters used in quantifying fundus photographs. Among them, the use of 
retinal vessel diameters has been most often used for the assessment of disease. The vessel 
diameter measurements correlate well with systemic diseases such as obesity and metabolic 
syndrome299 534 535, hypertension536-538, diabetes539-541, coronary heart disease542 543, and endothelial 
dysfunction543 544. These alterations could suggest specific vascular signs that correlate with the 
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systemic abnormality. For example, venular widening could represent obesity and metabolic 
abnormalities while arteriolar narrowing could represent hypertensive profiles.  
Even with the amount of information to date and the associations with retinal vessel calibre 
measurements it still only provides a snap shot of an individual’s circulatory state and conveys more 
information on established structural abnormalities rather than developing functional abnormalities. 
Nevertheless, the retinal microcirculation provides a useful marker for the evaluation of 
physiological or pathophysiological deviations from the systemic circulation and can represent a 
microvascular phenotype of endothelial dysfunction. 
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Table 1.10 Summary of techniques used to assess endothelial function 
Technique Advantages Disadvantages 
Circulating markers  
Nitric oxide - urine 
cGMP 
Elevated urine levels are in early 
indicator of endothelial dysfunction 
Heavily affected by diet 
Endothelin-1 (ET-1) 
Can be detected through increased 
bioavailability or receptor blockade 
Can only be determined in 
pathological states and not in controls 
von Willibrand factor 
(vWF) 
Production is known to be increased 
in the presence of damaged 
endothelial cells  
Can be difficult to distinguish with an 
acute infection or injury 
asymmetric 
dimethylarginine 
(ADMA) 
Elevated levels are present in 
patients with atherosclerosis- 
precursor to ED 
Can be affected by high salt and fat 
concentrations  
Plasminogen 
activator inhibitor-1 
(PAI-1) 
increased levels correlate with the 
severity of atherosclerosis 
Difficult to distinct between PAI-1 and 
the antigen PAI-A which is responsible 
for reduced fibrinolysis 
Vascular cell adhesion 
molecules. E-selectin 
and P selectin 
levels are increased with 
atherosclerosis and positively 
correlated with circulatory levels of 
inflammation 
Can be difficult to distinguish between 
an acute infection or injury with 
atherosclerosis 
Structural tests  
Pulse wave analysis 
Easily detect arterial stiffness and is 
non- invasive 
An indirect measure of endothelial 
function to be used in conjunction 
with other tests 
Pulse contour analysis 
Simple set-up and repeatable test 
for arterial stiffness 
In patients with stiff vasculature SBP 
and DBP cannot be distinguished 
readily 
Carotid wall 
distensibility co-
eficient 
Measures arterial wall ability to 
expand and contract with cardiac 
work. Useful index in late 
atherosclerosis 
Only useful in adults. Uses 
ultrasonography but it's relationship 
with endothelial function is yet to be 
determined  
Intima media 
thickness 
Reliable non-invasive and 
reproducible measurement of 
arterial stiffness 
Indirect measure of endothelial 
dysfunction and cannot be used for 
short term efficacy of therapy. 
Functional tests  
Coronary angiograpy 
Sensitive indicator of endothelial 
dysfunction 
Invasive procedure and can only be 
used when indicated clinically 
Coronary positron 
emission tomography 
Non-invasive can also provide 
information on inflammatory cells 
within the vessel wall- is going to 
supersede coronary angiography  
Relatively new technique but lacks 
specificity when used on its own to 
detect atherosclerosis. Can be used in 
combination with CT and MRI 
Forearm venous 
occlusion 
plethysmography 
Sensitive indicator of endothelial 
dysfunction 
Invasive. Requires specialised training 
and insertion of a catheter 
Brachial artery- Flow 
mediated dilation 
(FMD) 
Non-invasive. Sensitive indicator of 
endothelial dysfunction 
Requires specialised training to ensure 
repeatability and low variability. 
Protocols vary amongst studies 
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1.11.2 Retinal vascular function: Dynamic Vessel Analysis 
Quantification of retinal vessel diameter was first derived from studies that observed the increase 
and decrease of oxygen on the retinal circulation545, where by providing the individual with 100% 
oxygen caused a decrease in vessel diameter (vasoconstriction), and providing 10% oxygen resulted 
in vasodilation. This later resulted in dyes being imaged through the retinal circulation to look for 
microvascular abnormalities. Recent years have seen the advent of newer instruments that measure 
the haemodynamic parameters of the retina, such as, the laser Doppler flowmetry and the scanning 
laser ophthalmoscope546. Currently, the retinal vessel analyser (RVA) system (IMEDOS, GmbH, Jena, 
Germany) is the most widely used for assessing retinal microvascular reactivity in health and disease, 
and is considered to be a sensitive indicator of retinal microvascular function547 548. The dynamic 
nature of the instrument allows the retinal vessels to be assessed through a continuous online 
measurement of retinal vessel diameter changes in response to provocation549 550. This has led to the 
device being increasingly recognized as an alternate tool for the assessment of retinal vascular 
tone551, and functional microvascular assessment of endothelial function at the retinal level552.  
Studies have examined the link between functional microvascular abnormalities and the risk of 
developing cardiovascular disease. On the other hand, there have been numerous studies that have 
shown functional deficits of microvascular function in persons with established disease553 or as a 
consequence of ageing554. However, no study to date has looked at the effect on ocular health; 
specifically, retinal microvascular function responses during weight loss interventions. In order to 
enable a better appreciation of the vascular insufficiency and whether this can improve through 
advancements in weight reductions requires a review on the principles of blood vessels, and blood 
flow regulation within the systemic and retinal vasculature. (Refer to section 1.8 for further details). 
Table 1.11 shows the studies that have been used to describe the impact of obesity and higher BMI 
ranges on the microvasculature. 
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1.12. Assessment of the peripheral vascular function 
The initial methods of assessing endothelial function was quantitative coronary angiography and was 
superseded by FMD due to the investigation being much less invasive. With this technique, currently 
regarded as the gold standard, the dilation response following temporary cuff occlusion of the 
forearm (ischaemia) or oral administration of nitroglycerin (potent NO vasodilating agent) is the 
amount of reactive hyperaemia observed and the amount of dilation measured. There have been 
different protocols among researchers especially since the technique is highly dependent on 
operator experience and expertise520 555. In most cases two operators are required for reliability and 
repeatability but the result itself can be variable since to date the normal reference range for a FMD 
response has yet to be characterized516 556. Other techniques have been used to study endothelial 
function through temperature changes within the microvasculature and cutaneous circulation.  
The skin is affected in terms of structural and functional changes. Indeed, increased resistance due 
to microvascular dysfunction in hypertensive individuals is an important component on the 
maintenance of high blood pressure364. More specifically, spectral analysis of laser Doppler 
flowmetry (LDF) signals suggests that essential hypertension results in altered neurogenic and nitric 
NO synthase-dependent control of skin vasomotion557.  Cutaneous vasodilation of vasoconstriction 
can be elicited through post-occlusive reactive hyperaemia558. When vascular function is 
compromised, the dilatation following ischaemia (hyperaemia) is markedly reduced. This reduction is 
attributed to endothelial dysfunction, a globalized systemic disease process consisting of attenuated 
endothelium-dependant vasodilatation, augmented vasoconstriction and microvessel structural 
remodelling559. A blunted post-ischemic increase in skin endothelial dependent vasomotion was 
observed in patients with chronic kidney disease (CKD)560. In addition, blunted skin endothelial-
dependent vasomotion resulted from ACh iontophoresis in hypercholesterolemic patients without 
clinically manifest arterial disease372 561 and a decreased skin endothelial- and sympathetic 
dependent vasomotion was observed in obese women under basal conditions562. All of these are 
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suggestive and consistent with microvascular endothelial dysfunction. It was also shown that 
peripheral endothelial function measured with peripheral arterial tonometry at the fingertip is 
correlated with coronary microvascular function in patients with early atherosclerosis 563. Similarly, 
PORH assessed with LDF was found significantly reduced in untreated hypertensive subjects564.  
LDF is chosen as the standard to characterize microvascular function because 80% of blood in fingers 
is stored in the skin565 and strongly affects skin temperature variation. Newer modalities that test 
skin reactive hyperaemia have been introduced. Digital thermal monitoring (DTM) works on the 
premise that the hyperaemic response following arterial occlusion can be characterized by recording 
and analysing temperature alterations at the fingertips. Reductions in the hyperaemic response, a 
hallmark feature of impaired vascular function, are observed as reductions in thermal monitoring. 
Previous studies have already indicated a high correlation between heat flux at the skin surface, skin 
temperature and blood perfusion566 567. Indeed, it was found that the fingertip temperature, as 
measured with DTM, follows the same response as that of perfusion or heat flux361. Recent studies 
have demonstrated the ability of the DTM test to discriminate individuals with established CVD or 
high risk of future CVD in normal and low-risk individuals568-572. 
More recently insights into the mechanism of cutaneous post-occlusive hyperaemia have shown that 
the inhibition of cyclooxygenase (COX) and NO do not alter skin PORH but that endothelial derived 
hyperpolarizing factor (EDHF) has been suggested as the major endothelial contributor to PORH573. 
Nevertheless, the cutaneous circulation is an accessible and representative vascular bed for the 
assessment of endothelial function and for mechanisms of underlying vascular disease. Table 1.12. 
shows the current studies which have used the DTM to assess peripheral microvascular function and 
their relationships with novel CVD risk markers. To provide a basis for the studies described in this 
thesis, it is important for an understanding of the current aetiological thinking for the development 
of anterior eye pathologies. An understanding of the anatomy and physiology of anterior ocular 
health and their regulatory mechanisms is required. A summary of these is presented below. 
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Table 1.11 Summary of studies on obesity and its effects on the microvasculature. 
Author Year Participants Purpose/summary Main findings Disadvantages 
Leiden574 2002 
626 
participants 
To study potential risk factors for 
retinopathy in diabetic and non-diabetic 
subjects 
The prevalence of retinopathy was positively associated with elevated 
cholesterol, blood pressure and BMI. Elevated blood pressure and total 
cholesterol showed an association with retinal hard exudates 
The level of retinopathy was graded subjectively and it was not 
known how many graders there were or how many photographs 
they each graded.  
Wang575 2006 
3654 (1460 
M) 
To investigate the associations among 
retinal vessel diameters, and BMI in an 
older population 
Participants were 2x more likely to have wider venular calibres if they were 
obese even after adjusting for confounding variables.   
There was a proportion of participants who did not attend the 5 year 
follow up which could have possibly led to a selection bias.  
Wang576  2007 
7494 
participants  
To examine whether smaller retinal 
arterioles or larger venules predicted 
coronary heart disease and stroke 
mortality 
Participants that had smaller retinal arterioles and wider venular calibres 
were more likely to be older, have higher BMI and hypertension. This was 
significant in predicting higher risk of CHD mortality but was not significant 
in persons over age 70 
Blood pressure values were relied upon patients self-reporting the 
diagnosis without any validation checks or measurements. They also 
did not account for the medications which some of the participants 
were taking. 
Mitchell577 2007 
768 school 
children 
To examine the association of BMI and 
weight with retinal vascular calibre in 
children 
After adjusting for covariates BMI was associated with wider venular 
calibre in healthy children. For each 3.1kg increase in BMI was associated 
with 2.55microns increase in venular diameter.  
Photographs were only analysed from a subset of the original cohort 
and in this subset only half the participants underwent blood 
pressure measurements.  
Kotliar578 2011 
92 (46 
controls) 
obese 
participants 
To assess whether dynamic reaction to 
flicker stimulation is altered in obese 
subjects 
Mean maximal diameter in response to flicker was reduced in the obese 
group and the reaction time to maximal dilation was also prolonged. 
Maximal venular dilation was reduced in obese subjects. There was a 
significant correlation between waist circumference and retinal arterioles 
after flicker provocation 
They did not measure intra ocular pressure in obese subjects and this 
is not known whether it may affect retinal vessel response to flicker 
even though it is part of a normal protocol to measure IOP before 
mydriasis. The authors could have analysed at least 4 other 
parameters during DVA.  
Hanssen579 2011 
46 
participants 
(14 obese, 15 
lean, 17 elite) 
To assess the effects of regular exercise 
training on AVR and to investigate 
changes in obesity impairment of the 
retinal microcirculation.  
Results indicated at baseline that AVR ratio was significantly reduced 
compared to controls and that individual fitness levels positively 
correlated with AVR. The training program improved AVR improved in all 
groups and increased retinal arteriolar diameters in the obese subjects.  
There were 14 dropouts due to musco-skeletal injuries and 
respiratory tract infections probably due to the intense exercise 
regimen which in turn decreased the sample of participants in each 
group. There was no mention of diet and how the groups differed in 
terms of that. 
Hanssen535 2012 
578 school 
children 
To analyse the prevalence of obesity and 
the association between physical 
inactivity, metabolic risk factors and 
retinal vessel diameter 
Overweight and obese children had significantly lower AVR compared 
controls. Wider venular diameter was independently associated with 
higher BMI, WC, and CRP. BP was associated with retinal vessel 
constriction.  
Although there are associations between risk variables and vessel 
diameter, long term follow up still need to be carried out to prove 
the association.  
Lammert324 2012 
127 (87 W) 
obese 
participants 
To assess cardiovascular risk factors and 
retinal vascular parameters in morbid 
obesity 
WC was inversely proportional to AVR ratio. Impaired flicker reaction to 
retinal vessels was detected in 62% of the cohort, significantly reduced 
AVR in 56% and increased intima-media thickening in 26%.  
There was no control group and the authors compared their results 
with already published normative data. The authors generalized their 
findings for the participants that underwent flicker analysis even 
though there were a lot of dropouts. 
Boillot534 2013 
44000 
participants, 
meta-analysis 
To determine the association between 
BMI and retinal vessel calibre 
Obese participants had narrower arteriolar and wider venular calibres 
when compared controls independent of conventional cardiovascular risk 
factors. A 1kg increase in BMI was associated with a 0.07 micron decrease 
in arteriolar calibre and 0.22 micron increase in venular calibre.  
There was a potential measurement bias due to different protocols, 
photographic procedures and the software being used to analyse the 
retinal vessel calibres resulting in either overestimation or 
underestimation of the true association between BMI and vessel 
calibres  
Yau580  2014 
90 obese (51 
controls)  
To assess retinal arteriolar diameter and 
retinal structure in obese adolescents 
with metabolic syndrome with changes 
in cerebral white matter microstructure 
Obese adolescents with METs had significant reductions in arteriolar 
diameters. Waist circumference was the strongest component related to 
reduction in arteriolar diameter. White matter changes showed decreased 
microstructural integrity associated with narrower arteriolar calibre. 
Out of the control participants 35% had insulin resistance and 29% 
were obese.  
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Table 1.12 Summary of studies utilizing digital thermal monitoring (DTM) 
Author Year Participants Purpose/Summary Main Findings Disadvantages 
Dhindsa58
1 
2008 
40 healthy 
subjects 
To assess the interrelationships between 
different non-invasive measures of macro- and 
microvascular reactivity. 
No significant relationships were found due to the 
difference of physiological factors influencing the 
vascular bed being tested. 
Did not examine any participants with or suspected 
subclinical atherosclerosis. A case control study with the 
different techniques could have shown a better 
correlation between micro and macrovascular function. 
Ahmadi568 2008 
233 
asymptomati
c 
To assess the correlation between peripheral 
vascular dysfunction with the Framingham Risk 
Score (FRS) and extent of subclinical 
atherosclerosis measured by CAC. 
DTM showed a negative correlation with FRS 
independent of cardiac risk factors was and superior to 
the FRS in predicting significant CAC 
Study did not include controls or subjects with definitive 
diagnosis of atherosclerosis, rather asymptomatic 
patients were only included if they underwent CAC or 
increased FRS 
McQuilke
n525 
2009 N/A 
To assess the relationship between two 
measures of peripheral vascular reactivity. 
DTM & LDF 
Outcome measurements of peripheral vascular 
reactivity are strongly correlated. DTM sensors 
resemble the same frequency signals calculated by 
Doppler methods 
The study did not mention how many subjects were 
used to derive their correlation or the statistical test 
used to come to their conclusions 
Ahmadi570 2009 129 
To determine the correlation between DTM 
and coronary artery disease (CAD) in 
symptomatic patients 
The study indicated a strong correlation between low 
fingertip TR and the presence and extent of CAD 
measured by computed tomography.  
The tests were conducted in accordance with a protocol 
that was not excluding subjects taking caffeine, alcohol 
or tobacco. Also,  antihypertensive medication was 
allowed for certain subjects >65bpm 
Gul571 2009 
133 (19 with 
CAD) 
To assess the clinical utility of using the DTM 
system on patients diagnosed with CHD  
DTM of vascular dysfunction is associated with an 
increased FRS and CHD. Fingertip temperature rebound 
was lower in patients with CHD than without. 
Protocol was different with regards to other studies that 
use a 5 min cuff-occlusion. Current study only used 2 
minutes. 
Ahmadi569 2009 
233 
(127MS/DM) 
To assess peripheral vascular dysfunction in 
patients diagnosed with diabetes mellitus and 
metabolic syndrome (MS) 
Temperature rebound was significantly lower in 
diabetes and metabolic syndrome compared to 
controls. Potential to detect asymptomatic patients 
with increased subclinical atherosclerosis 
No mention was made on the extent and duration of DM 
or MS within these subjects and whether a relationship 
exists due to measurements of different vascular beds.  
Akhtar582 2010 
mechanical 
model 
To assess the sensitivity of DTM parameters to 
reactive hyperaemia. 
Temperature rebound was shown to correlate well with 
RH and had good sensitivity at the range of flow rates 
studied. 
The results were only from a mechanical model which 
do not truly represent a clinical population with varying 
degrees physical parameters. 
Ahmadi526 2011 
18 healthy 
subjects 
To evaluate the variability and reproducibility 
of DTM measurements. 
DTM measures correlated well with Doppler ultrasound. 
In a controlled environment, DTM was reliable and 
reproducible from day to day clinical use. 
This study had used a protocol consisting of a 2 minute 
cuff occlusive state, while previous studies have used a 5 
min cuff-occlusive state. 
Schier583 2013 60 Subjects 
To evaluate the clinical utility of DTM as a 
surrogate for evaluating vascular function 
postoperatively after major thoracic surgery. 
A significant difference was found for measurements 
taken between 24h and72h but not in between.  
Participants which were obese or had abdominal 
obesity displayed a higher TR after surgery. 
Participants presented with multiple comorbidities 
during thoracic surgery and they had only one week 
follow up. A protocol of only 2 min cuff-occlusion was 
used. 
Schier584 2013 30 subjects 
To evaluate the increase in RH after acute 
exercise and whether a lack of RH increase 
would correlate with preoperative 
cardiovascular risk factors. 
A single episode of anaerobic exercise enhanced RH. TR 
parameters increased significantly and all patients with 
preoperative cardiac risk factors had their values fall 
within the lower two thirds of the study population.  
This study suggested that the increase in RH 
preoperatively may serve as a diagnostic tool for better 
surgical outcomes but no follow up was done on the 
patients to check whether the increase in RH would 
correlate with a better surgical outcome. 
Zeb 
2013585 
2013 
210 (105 
controls) 
To evaluate the association of vascular 
dysfunction and Coronary Artery Calcium (CAC) 
score in patients with chronic kidney disease. 
Vascular reactivity is incrementally worse across CAC 
scores in patients with chronic kidney disease. 
Vascular reactivity was reported with the area under the 
curve as being significant difference but no mention was 
made with regards to TR and other parameters 
measured by the DTM. 
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1.13. Anterior eye anatomy and physiology 
The anterior portion of the eye consists of the eyelids, cornea, tear film, and the transparent 
conjunctiva that stretches from the superior and inferior fornix to the corneal limbus. The eye 
contains complex optical properties which allow for clear vision. In order to maintain clear vision at 
all times, the cornea, tear film, and the eyelids must act synergistically to maintain optical clarity and 
provide a smooth surface for light to travel through. It has antimicrobial properties within the tear 
film to protect itself against any foreign pathogens or objects and can also regenerate and washout 
debris simply by blinking. An overview with relevance to this thesis is presented below.  
The part of the orbicularis oculi muscle within the eyelid brings about blinking and eyelid closure and 
is supplied by the facial nerve. The tarsal plate is internal to the orbicularis which provides rigidity to 
the eye lid and also contains the meibomian glands586. The meibomian gland openings are located at 
the eyelid margin between the palpebral conjunctiva and skin. There are about 35 meibomian glands 
in the upper lid and 25 in the lower lid, which extend to the full height of the tarsal plate586. The 
inner layer of the eyelid is covered by the palpebral conjunctiva. The eye lashes leave the distal part 
of the eyelid skin and curve away from the globe586. 
The conjunctiva is a very thin and translucent mucus membrane that lines the anterior portion of the 
sclera and covers the globe (bulbar conjunctiva) and inside the eye lids (tarsal conjunctiva). It reflects 
back in the conjunctival fornices and covers the globe as far as the corneal limbus586  
 
1.13.1 The Cornea 
              The cornea is a transparent avascular connective tissue that acts as the primary infectious and 
structural barrier of the eye587. In conjunction with the tear film it provides the necessary conditions 
for light to refract and focus on the retina. The cornea relies on tiny blood vessels at the corneal 
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limbus, the tear film and aqueous humor for nutrients and oxygen. The shape of the cornea is flatter 
in the periphery and steeper centrally587. It is also well innervated with nerves which are derived 
from the nasociliary branch of the trigeminal nerve. The nerves enter the stroma radially in thick 
trunks which perforate Bowmans layer to provide a rich plexus beneath the epithelium588. The 
cornea is recognized as having 5 distinct layers which combine to give an overall thickness of 0.5mm 
centrally and increased towards the periphery. The distinct layers of the cornea from anterior to 
posterior are the Epithelium-Bowmans layer-Stroma- Descemets membrane- Endothelium. More 
recently, a 6th layer known as Dua’s layer has been discovered anterior to Descemets membrane.  
The epithelium is the outer most layer and is covered with the tear film. It is stratified with a non-
keratinizing squamous layer587. It regenerates itself every 7 to 10 days589. The epithelium is attached 
to the underlying Bowmans layer by a basement membrane with a hemidesmosomal system. This is 
the sight of the strongest attachment to the underlying corneal layers. Bowmans’ layer lies just 
anterior to the stroma and is actually a condensed part of the stroma but is also the junction at 
which the nerves enter the cornea. This has implications in diabetic patients due to the fact that they 
have reduced sensation to pain and are more susceptible to infections than non-diabetics. 
Bowmans’ layer is also responsible for maintaining corneal integrity and shape. If damaged unlike, 
the epithelium, it cannot regenerate and scar tissue will form. The corneal stroma lies just anterior 
to the Descemets membrane and is the thickest of all the layers. It is comprised of collagen fibres 
which are arranged in parallel bundles. These collagen fibres are known to change direction as they 
approach the limbus590. This network of collagen fibres allows the reduction of forward light scatter 
by maintaining tight junctions which ultimately contribute to the mechanical strength and 
transparency of the cornea. Dua’s layer lies posterior to the corneal stroma and anterior to 
Descemets membrane. It is acellular and contains only a few keratocytes. It is impervious to air591. 
Descemets membrane lies anterior to the corneal endothelium and is secreted by the endothelium. 
It has an amorphous structure and can increase in thickness with ageing. It is at this site along with 
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the stroma where lipid deposits can be seen on clinical examination and is known as corneal arcus. 
Lipid deposits are more densely compact towards the periphery of the cornea than centrally and is a 
sign of high CHOL592.   The corneal endothelium is the most posterior portion of the cornea and is a 
mono-layer. The surface of the endothelium has many hemidesmosomes that promote adhesion to 
the Descemets membrane. Endothelial cells are constantly changing throughout life and decreasing 
in density as we age. The state of corneal deturgescence is mediated by a pump-leak process as fluid 
egresses from the stroma down the osmotic gradient from a relatively hypo-osmotic stroma towards 
a relatively hypertonic aqueous humor587. This process is facilitated by the transporting of ions to 
generate the osmotic gradient. The barrier portion of the endothelium is unique in that it is 
permeable to some degree, permitting the ion flux necessary to establish the osmotic gradient593. 
Transport of these important ions involves membrane bound Na+ and K+-ATPase sites and the 
intracellular carbonic anhydrase pathway587. The endothelium is unable to regenerate itself, and is 
susceptible to age, trauma and inflammation which result in polymegathism and pleomorphism. 
1.13.2 Tear film function 
The tear film has a unique tri-laminar composition that enables it to perform a number of functions. 
The normal corneal tear film is responsible for providing an optically smooth surface that allows 
clear vision. It protects the eyes from infections and environmental hazards, provides nourishment 
to the cornea, washes out cellular debris and foreign bodies and sustains comfort by ensuring a 
smooth movement of the eyelids over the globe with a healthy corneal epithelium594. Tears are 
contained within the conjunctival sac when the eyes are closed, and redistribution of these tears 
across the conjunctival and corneal surface happens when the eyes re-open595. The classic 
description by Wolff recognized the tear film as a three layer layered structure comprising of an 
outer lipid layer (approx. 0.1micron thick), intermediate aqueous layer (approx. 7 microns thick), and 
inner mucous layer (approx. 0.05 microns thick)596. This model is generally accepted though there is 
uncertainty about its true thickness. Other researchers have suggested that the actual thickness is 
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closer to 40 microns597. More recently, it has been proposed that the thickness is roughly 3 microns 
thick598. Although, the thickness is still being debated, it is generally accepted that the three layers 
work together to maintain integrity of the tear film and health of the cornea.  
1.13.3 Lipid layer 
This oily layer is produced by the Meibomian glands, which are modified sebaceous glands located in 
the lower and upper tarsal plates599. The lipid layers’ main function is to reduce the evaporation of 
tears, provide a smooth optical surface, and to prevent contamination of the tear film debris599. 
Rapid and forceful blinking has also been shown to increase the thickness of the lipid layer600. The 
secretion of these glands are known as meibum. Meibum has a lower melting point then sebum, 
which allows it to remain a fluid when in the tear film599. It consists of both polar and non-polar 
lipids. The polar fraction of the Meibomian layer, acting like a surfactant, is comprised mostly of 
phospholipids and spreads over the aqueous layer of the tear film while the nonpolar fraction of the 
lipid layer lies more superficial601 602, at the air-lipid interface602. The removal of the lipid layer results 
in increased hyper-osmolality, through the reduction of goblet cell density, and glycogen levels thus 
leading to inflammation603.   
1.13.4 Aqueous layer 
The intermediate layer of the tear film is the aqueous layer and is responsible for lubrication, 
flushing away of desquamated epithelial cells and protection of the ocular surface. It washes away 
foreign materials introduced to the conjunctiva or cornea and contains antibacterial factors including 
immunoglobins595. Nutrients provided to the avascular cornea by the aqueous layer include glucose, 
oxygen, and protein604. The aqueous layer has antibacterial properties such as the effects of 
lysosome against gram +ve bacteria605, effects of lactoferrin against –ve bacteria606, as well as having 
anti-inflammatory properties607. It is produced mainly by the lacrimal and accessory lacrimal glands 
of Krause and Wolfring under the influence of autonomic innervation and various hormones608. The 
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aqueous layer also contains soluble mucin that decreases the surface tension, enhances the spread 
and coherence of the aqueous layer, and contributes the viscosity of the tear film609.  
1.13.5 Mucous layer 
Ocular mucous is composed of mucin, immunoglobins, glucose, urea, salts, enzymes, leukocytes and 
cellular debris610. The mucous layer lubricates and protects the cornea, anchors the aqueous tear 
film to the epithelium protecting it from bacterial contamination, shear forces, and desiccation611. 
The mucus is responsible for creating a hydrophilic layer, which facilitates the spread of the aqueous 
layer on top of the hydrophobic corneal epithelium. The mucus layer is not tightly adhered to the 
epithelial layer, but rather attaches to the glycocalyx and undergoes free movement across the 
cornea612. This allows the mucus to spread evenly across the cells and prevents damage to the 
epithelium during blinking613. The majority of the mucus layer is secreted by conjunctival goblet cells 
which can be stimulated to secrete mucin by shear force, blinking or by histamines614.   
1.13.6 Tear film production  
Tear production is a multifactorial process mediated by interconnected nervous, endocrine, vascular, 
muscular, and immune systems615. Tear secretion is a reflex response initiated by stimulation of the 
ocular surface or nasal mucosa616 617. Normal production of tears requires a healthy and normal 
functioning lacrimal unit. This functional unit is a subset of the ocular surface system618, and consists 
of the eyelids, lacrimal glands, cornea, meibomian glands, and their interconnected nervous system. 
This unit is responsible for the tear secretion and blink reflex. The blink reflex is critical for tear 
function as it stimulates the release of lipids from the Meibomian glands and replenishes the tear 
film with tears from the inferior tear meniscus600 619. The lacrimal gland is an exocrine gland that lies 
within the lacrimal fossa of the bony orbit620, and its secretory cells are the pyramidal acinar cells. 
The accessory lacrimal glands of Krause located in the stroma of the palpebral conjunctiva of the 
upper and lower fornix and Wolfring located in the superior tarsal plate, are thought to be similar to 
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the main lacrimal gland in both form and function. Previously it was though that the main accessory 
gland was responsible for reflex tearing, and the accessory lacrimal glands were responsible for basal 
tear secretion; however, it is now thought they contribute in unison, due to similarities in 
innervation, to both basal and reflex tear secretion621. The sensory nerve fibres in the cornea are 
primarily responsible for initiating tear secretion. These afferent sensory fibres relay signals to the 
spinal trigeminal nucleus where the information is relayed to the superior salivary nucleus of the 
pontine tegmentum622 623. Preganglionic parasympathetic neurons originating from the superior 
salivary nucleus project to the pterygopalatine ganglion624 625. Postganglionic parasympathetic 
neurons then project onto lacrimal glands, and also to the goblet cells and Meibomian glands615, 
where they release neurotransmitters such as acetylcholine and vasoactive intestinal peptide that 
stimulate tear secretion626-628.   
1.14. Assessment of Anterior eye 
Dry eye disease is an impairment of the ocular surface and tear ducts. It is multifactorial in nature 
and results in ocular discomfort and tear film instability328. Evaluation of anterior segment disorders 
has mainly relied on techniques such as the slit lamp bio-microscope. Traditionally tear break up 
time (TBUT) has been assessed with fluorescein, tear meniscus height has been measured with an 
attachment and Meibomian Gland Dysfunction has been judged on the blocked or atrophied 
meibomian glands on the lid margin. Bulbar and limbal redness are assessed by the naked eye or 
under the bio-microscope. It is important to note that all of these assessments are subjectively 
graded by the practitioner and that these measurements can thus vary amongst different examiners 
regardless of the addition of an anterior eye grading scale.  
Computerized software can aid the clinician by allowing standardized measurements with higher 
repeatability.  Indeed, The keratograph 5M (K5M, Oculus, Weltzar, Germany ) has the capability of 
measuring these parameters  within a single setting and does not require the use of staining agents, 
which alter tear volume and composition, for the determination of anterior segment disease. 
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Previous studies have reported that the K5M is a reliable method for scoring Bulbar redness (BR). Its 
reproducibility was the highest when compared to subjective examiner grading with 3 different 
scales629. The K5M also measures TBUT non-invasively as the first break up and as the average break 
up. A recent study compared these measurements in controls and in patients with DED. They 
showed the K5M was highly repeatable and reproducible and was comparable to the Schirmer test 
and fluorescein BUT630.  In addition, the correlation of the meiboscore with functional dry eye 
parameters suggest that in patients with detectable meibomian gland atrophy as assessed with 
infrared meibography, there is also an impaired meibomian gland function631. However, the authors 
have stated that this assessment alone is not sufficient to diagnose MGD but should be used in 
conjunction with other measurements of DED for the overall picture. Therefore, the K5M was the 
technique of choice for the present study on anterior eye assessment. Its principles are discussed in 
more detail in section 3.3.5. 
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2.0 Research Rationale 
Obesity is known to be a major risk factor for the development of several chronic diseases and the 
secondary implications associated with these risk factors have a direct impact on the quality of life 
and well-being for that individual. Together with an ever changing lifestyle directed towards longer 
working hours which leads to less time for an individual to revel in in extra-curricular activities has an 
important psychological affect; leading to laziness and an attitude that does not see the benefits of 
getting regular exercise and making healthier choices in grocery stores rather than eating the 
quickest meal possible that is loaded in saturated fats and refined sugars and salts.  
Obesity has been associated with multiple chronic diseases that could lead to fatal events. One 
underlying common denominator is that endothelial dysfunction through atherosclerosis and 
constant inflammation is one of the main transgressors that leads to future vascular complications. 
Obese individuals, at least 50 % of the time, have elevated blood pressure, diabetes, and high 
cholesterol or a combination of these diseases. This in conjunction with the patient’s age and 
whether they smoke, through a Framingham risk score calculation, can determine the risk that an 
individual can likely suffer from myocardial infarction or stroke. One of the main stays of treatment 
is through pharmacotherapy and studies have shown an increase in brachial artery function after 
treatment for hypertension and hypercholesterolemia. However, this considers macrovessel 
treatment and not the microvessels, and it is yet to be determined whether participants have 
improved in microvascular function alongside macrovascular function. It is understandable that, 
because of the nature of measuring different vascular beds, local control of vascular tone can be 
influential in revealing a possible relationship from vascular beds of different sizes and location 
throughout the body.  
Another consideration is whether endothelial dysfunction can alter after weight-loss interventions. 
Obesity through inflammation and atherosclerosis can have a compounding effect on vascular 
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function through the body, specifically targeting the vascular endothelium. Once the endothelium 
has been damaged, the beginning stages of vascular complications usually follow and are unique to 
each individual. There has been some progress with weight management strategies Dieting has 
resulted in decreased blood pressure and bariatric surgery, which certain type 2 diabetic patients 
completed, has resulted in a 180 degree reversal. However, the relationship between weight-loss 
management and endothelial function have yet to be fully understood in terms of their role in 
returning microvascular function to normative values. Measurement of ocular circulation could 
significantly aid the assessment and diagnosis of vascular alterations in obesity and enhance our 
understanding and management of the disease.  
Obesity can cause anterior eye pathologies but lacks concrete evidence. Neither have there been 
any studies on the impact of weight management strategies on anterior ocular health. Taking all of 
this into consideration, the principle purpose of this research was to investigate the presence of 
anterior eye pathologies and vascular alterations, at both the ocular and systemic level, in 
overweight and obese patients and to evaluate the potential impact of weight management 
strategies. In line with this, the overall aims of this research are as outlined in the following section.  
 
2.1 Aims 
 
• To investigate the relationship between retinal and peripheral microvascular function in 
healthy individuals 
• To investigate the presence and impact of 16 weeks of physical exercise training in 
overweight individuals on retinal and systemic microvascular function. 
• To investigate the impact of fasting during the month of Ramadan on retinal and systemic 
microvascular function. 
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• To investigate the impact of  bariatric surgery on retinal and systemic micro and 
macrovascular function 
• To compare anterior eye health in obese individuals 1 year before and after bariatric 
surgery. 
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3.0 Subjects and methods 
This chapter outlines the recruitment procedure, inclusion and exclusion criteria for the obese, 
overweight and control participants involved in this research. It then goes on to outline the study 
protocol and investigative techniques used throughout this thesis for the assessment of anterior eye 
health, ocular and systemic vascular function. 
3.1 Ethical approval   
Prior to the study ethical approval was received from Coventry & Warwickshire West Midlands 
research ethics committee, Heart of England Foundations trust (HEFT) NHS Research Ethics 
Committees, Heartlands Hospital Research and Development (MIDRU) as well as the Aston 
University Life and Health Sciences Ethics Committee. Written informed consent was received from 
all subjects before entry into the study and all procedures were designed and conducted in 
accordance with the tenets of the Declaration of Helsinki. 
3.2 Patient recruitment 
3.2.2 Recruitment of obese participants 
Successive diagnosed obese patients with BMI >40kg/m2 were recruited from the Birmingham 
Heartlands, Heart of England Foundations Trust (HEFT, UK) weight management clinics by a specialist 
consultant. All obese participants recruited have never received weight reduction treatment. This 
ensured any vascular alterations identified were less likely to have occurred due to previous 
pharmacotherapy treatment and could be more reliably attributed to the weight loss itself.  
3.2.2.1 Inclusion criteria 
Only those patients diagnosed as obese and listed for surgery were considered for this study. Of 
these patients only those classified as having morbid obesity were included in the final study as per 
the WHO guidelines on obesity and based on their BMI value of greater than 40 kg/m².  
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3.2.3 Recruitment of overweight participants 
Successive, participants that felt they were overweight with no previous health complications were 
recruited on campus from the Aston University’s Sports Centre  
3.2.3.1 Overweight participants’ inclusion criteria 
Only those patients that had a BMI greater than 25 kg/m² were enrolled in this study. They had to be 
relatively healthy with no known medical history or on any medications. Before inclusion, patients 
had agreed to involve themselves at least 4 times a week in programme of exercise over a period of 
16 weeks. 
3.2.4 Recruitment of fasting participants 
Successive, patients that were willing to fast during the month of Ramadan were recruited for this 
study. Participants were recruited on campus at Aston University.  
3.2.4.1 Fasting participants’ inclusion criteria 
Only those participants that were willing to fast for the whole month of Ramadan, from sunrise to 
sunset, were recruited. They had to be healthy with no medical history or taking any medications. 
Participants were recruited from volunteers at Aston University’s Eye Clinic.  
3.2.5 Recruitment of other healthy participants 
Healthy participants not included in either of the above studies and of normal weight, were also 
recruited by inviting the participation of patients’ spouses, same-generation relatives and friends, as 
well as through promotion of the study at the Aston University Health Clinics. 
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3.2.5.1 Healthy participants inclusion criteria 
All healthy participants were screened for ocular disease with slit lamp biomicroscopy and volk 
assessment. Normal weight status was measured using a BMI calculation less than 25 kg/m² before 
inclusion in the study. 
3.2.6 Exclusion criteria for all groups 
Patients with closed iridocorneal angles, a history of intraocular surgery or any form of retinal or 
neuro-ophthalmological disease that could result in visual field defects were excluded from the 
study. Overweight and healthy participants were excluded if they had a positive diagnosis of cardio- 
or cerebro-vascular disease, (coronary artery disease - CAD, heart failure, arrhythmia, stroke, 
transient ischaemic attacks),  peripheral vascular disease, severe dyslipidaemia (defined as plasma 
triglycerides>6.00mmol/L or cholesterol levels>7.00mmol/L), diabetes, and other metabolic 
disorders or chronic diseases that required treatment. Obese individuals were only excluded if they 
had a positive diagnosis of cardio- or cerebro-vascular disease and renal disease. Participants were 
screened for ocular disease and were excluded from the study if they had IOP>24 mmHg 
consistently, moderate to high cataracts or any other media opacity which did not allow proper 
fundus examination, a history of intraocular surgery or any form of retinal or neuro-ophthalmic 
disease affecting the ocular vascular system. Well-controlled systemic hypertension was neither an 
inclusion nor exclusion criteria; however any individuals taking medications which could potentially 
influence vascular function were excluded. 
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3.3 Methods 
The investigative techniques used throughout this thesis were carefully selected to ensure the most 
accurate and reliable assessment of vascular function at both the ocular and systemic level that 
could be obtained. A summary of these techniques is given below in Table 3.3 
 
Abbreviations: DVA, dynamic vessel analysis; DTM, digital thermal monitoring; PWA, pulse wave analysis; GLUC, fasting 
glucose; CHOL, total cholesterol, TG, triglycerides. 
 
 
3.3.1 Experimental protocol 
All measurements were performed between 8 am and 11 am following a 12 hour overnight fast, 
which included no alcohol or caffeine, water being the exception. All procedures were conducted in 
a consistent order outlined below and detailed in the following sections: 
 
Table 3.3 Summary of investigational parameters
Technique Purpose
DVA Assessment of ocular vascular function
Fundus photography Asssessment of ocular vascular structure
Keratography Assessment of anterior ocular structure/function
DTM Systemic endothelial function
PWA Systemic arterial stiffness
Tanita body comp Composition of total body fat and water
GlUC, CHOL, TG Cardiovascular risk
Ocular level
Systemic level
Blood analysis
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•Approached and provided with the patient information 
leaflet
participant identified
•Procedures and risks explained, questions invited, 
concerns addressed
Explanation of study
•Form read, understood, completed and signed by 
participant
Consent
•Demographic questionaire
•Lifestyle questionarire
•Ocular assessment- slit lamp bio-microscopy/Indirect 
ophthalmoscopy
•Height and weight measurement
Preliminary assessments
•Assessment of anterior ocular structures (Keratography, 
obese participants only)
Anterior eye
•O.4% Oxybuprocaine hydrochloride inserted in both 
eyes
•Assessment of IOP with Perkins applanation tonometry
IOP assessment
•1% Tropicamide inserted into randomly selected eye Dilation
•Assessment of systemic endothelial function 
(Endothelix, all participants)
Endothelial function
•Assessment of systemic arterial stiffness (PWA, obese 
participants only)
Arterial stiffness 
•Assessment of body composition (Body Comp, exercise 
and healthy controls only)
Body composition
•Assessment of retinal endothelial function (DVA 
,exercise, fasting, controls)
Retinal vessel function
•Final measurement ocular vascular structure (fundus 
photography, obese only)
Fundus photography
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3.3.2 Assessment of systemic parameters  
3.3.2.1 Pulse wave analysis (PWA) 
The method for assessing arterial stiffness in this thesis was pulse wave analysis (PWA) which was 
implemented using the SphygmoCor device (Atcor Medical, /PWV Medical Pty Ltd, Australia) in 
agreement with a well-established protocol353 632 633. This non invasive device has simple set up, and 
can be utilized for the assessment of arterial stiffness with high repeatability353 634. PWA represents 
an assessment of the arterial pulse contour and the relative degree of vessel stiffness alongside 
mathematical algorithms which can characterize the arterial pulse pressure waveform and generate 
indices of vascular interactions through identification of periods during systole and diastole632. Once 
the signal from the sphygmocor device is obtained, the algorithm converts the pulse pressure wave 
form into a central aortic pressure waveform which yields arterial stiffness parameters such as, the 
Augmentation index (Alx). The sphygomocor device also has quality control indices to ensure 
reliability of measurements. In this thesis, readings obtained with a reliability index of greater than 
80 were used in the analysis.  
 
3.3.2.1.1 Procedure 
The procedure involves placement of the high fidelity pressure sensor (sphygmocor transducer) on 
the wrist underneath the thumb where the radial artery is located. The pressure sensor is then 
relatively flattened over the skin to generate a signal which represents the intravascular pulse of the 
radial artery. The profile generated by the system can provide important information of the stiffness 
of the systemic vasculature. This aortic pressure waveform is derived from two separate 
components; a forward pressure wave created by ventricular contraction (representing systole), and 
a reflected pressure wave created by the reflection of the incident wave back from bifurcations and 
peripheral vascular beds (representing diastole)635.  
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In elastic vessels the reflected wave returns to the aortic root in diastole, supplementing coronary 
perfusion and creating the waveform profile (Figure 3.3.2). The speed at which the outgoing and 
reflected waveforms travel is dependent on the stiffness of the artery. This return of the waveform 
at a much quicker rate during systole, represents an augmentation of systolic pressure and decrease 
of diastolic pressure, along with decreased coronary perfusion.  
The Augmentation index (Alx) value generated by the sphygmocor device is a widely used research 
parameter and is considered a sensitive value for assessing arterial stiffness633. In this thesis, Alx was 
the main parameter of interest. The Alx value is a percentage corrected for a heart rate of 75 bpm 
which indicates the amount the aortic pressure increase by the peripheral reflection of blood flow636. 
Influences of age, gender and ethnicity are known to exist, being greater in females and older 
persons637 638 as well as being greater in Africans and Hispanics. A summary of the normal reference 
ranges matched with age are presented in table 3.3.2 
 
 
PWA is a non invasive technique and poses no risk to the patient. One of the main weaknesses in the 
technique is that the estimation of the central pressure waveform may be inadequate to enumerate 
the magnitude of the pressure waveform reflections and therefore the true precision and reliability 
of any results through PWA may be limited639.  However, studies have demonstrated that the 
technique is accurate with good reproducibility and repeatability with low inter-observer variation 
and is among the most widely used to assess arterial stiffness640 641. 
Age Mean Lower 5% CI Upper 5% CI
20 -4.67 -23.27 16.87
30 3.03 -15.57 24.57
40 10.73 -7.87 32.37
50 18.43 -0.17 39.97
60 26.13 7.53 47.67
70 33.83 15.23 55.37
80 41.53 22.93 63.07
Table 3.3.2 Normal reference values according to age for Alx (augmentation index)
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FIG 3.3.2. Representative example between normal and abnormal arterial stiffness 
 
 
3.3.2.2 Digital thermal monitoring (DTM) 
Peripheral microvascular reactivity at the level of the fingertips was assessed by way of DTM using 
VENDYS 5000BC Digital Thermal Monitoring (DTM) system (Endothelix, Inc., Houston, TX, USA). This 
FDA approved device consists of a computer-based thermometry system (0.006°C thermal 
resolution), with two special thermocouple fingertip probes designed to minimize the area of skin-
probe contact and fingertip pressure. A standard sphygmomanometer cuff and a compressor unit to 
control cuff inflation and deflation is included to facilitate the occlusion-hyperaemia protocol584.  
3.3.2.2.1 Measurement Protocol 
The test is conducted with the patient at rest for 30 minutes in the supine position, in a quiet, 
dimmed room with ambient temperature of 22°C to 26°C. VENDYS DTM probes are affixed to the 
index finger of each hand and after a period of stabilization of basal skin temperature (defined as 
stabilization within a 0.05°C threshold) the temperature is measured in the index fingers of both 
hands (of which the right arm only is subjected to occlusion-hyperaemia) with an automated, 
operator-independent protocol. The right upper arm cuff is rapidly inflated to ≥50 mmHg above 
systolic pressure for 5 minutes and then rapidly deflated to invoke reactive hyperaemia distally. 
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Thermal tracings are measured continuously and digitized automatically using a computer-based 
thermometry system with 0.006°C thermal resolution. Dual channel temperature data is 
simultaneously acquired at a 1 Hz sample rate.  
 (Figure 3.3.2.2) shows a representative example of a temperature-time trace and the primary DTM-
derived measures, related to thermal debt and recovery, that were recorded and calculated. 
Measurements include (1) Temperature rebound (TR): maximum temperature- start temperature 
(just before cuff inflation), (2) adjusted temperature rebound (aTR): temperature rebound/ start 
temperature, (3) area under the curve temperature rebound (AUCTR): area under the curve between 
maximum temperature and minimum temperature.  The post-occlusive adjusted temperature 
rebound aTR determined by the software algorithm is directly associated with the extent of the 
subjects vascular reactivity582. An aTR below 1 is considered to show poor cardiovascular reactivity, 
whereas an aTR of between 1 and 2 is considered intermediate, and an aTR of more than 2 is 
considered healthy.  
 
Figure 3.3.2.2:  Graphical representation of the Digital Thermal Monitor software analysis; T MAX, maximum temperature; 
TMIN, minimum temperature; AUCTR, Area under the curve temperature rebound. 
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3.3.3 Assessment of ocular vascular structure 
3.3.3.1 Quantification of retinal vessel calibre 
Retinal vascular parameters can be extracted from the retinal image obtained from a specialized 
adapted camera. Currently, through advancements in technological capabilities, there are a wide 
variety of cameras that can take the necessary retinal images and software that can provide the user 
with the quantification of retinal images or provide the user with the basic data for manual 
calculations. These post processing techniques are used to aid the clinician in managing disease or 
progression. The quantitative values expressed and calculated are described below. 
 
3.3.3.2 Central retinal artery equivalent 
The central retinal artery equivalent is a measurement that incorporated all the retinal arterioles to 
give a single value that would represent the average width of a vessel within the retina. This method 
provides a quantifiable value that is far superior then objective grading of the vessel. In 1974, Parr 
and Spears642 643 had developed a calculation to quantify retinal arteriole widths. First, retinal 
photographs were taken of the optic nerve head and arterioles were calculated out to 30 degrees. 
The rationale behind this measurement zone, according to Parr643, was that pathological conditions 
affect the vessels as they branch out since the vessels are arterioles and venules respectively and 
they no longer have a continuous muscle layer and are void of an internal elastic lamina644. The 
following calculation incorporated the parent trunk vessel with its branches and is measured in 
micrometers.  
𝐴𝑟𝑡𝑒𝑟𝑦 ?̈? = √(0.87𝑊1
2 + 1.01𝑊2
2 − 0.22𝑊1𝑊2 − 10.76) 
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Where W₁ (narrower), and W₂ (wider) are the paired retinal arteriole branches. ?̈? Being the parent 
trunk arteriole diameter. All the arterioles were taken into account within the peripheral retina 
which yielded a single value known as the central retinal artery equivalent (CRAE). 
3.3.3.3 Central retinal vein equivalent  
Hubbard645 expanded and devised a similar mathematical formula which is based on the above 
formula and experimental data that could be used to analyse the retinal veins. As the previous 
model Parr and Spears 1974 only takes into consideration the arterioles;   
 
𝑉𝑒𝑖𝑛 ?̈? = √(0.72𝑊1
2 + 0.91𝑊2
2 + 450.05) 
Where W₁ (narrower), and W₂ (wider) are the paired retinal venular branches. ?̈? Being the parent 
trunk venular diameter. This calculation similar to the arterioles gives a single value which yields the 
central retinal vein equivalent (CRVE). Which can lead to the AVR ratio being calculated. 
AVR =
𝐶𝑅𝐴𝐸
𝐶𝑅𝑉𝐸
 
3.3.3.4 Artery Venous Ratio 
The AVR has an advantage over generalised width measurements as the calculation does not require 
any modifications regarding refractive errors. Though absolute vessel diameters are important when 
correcting for refractive errors, this can be cancelled out when using equivalent measurements646 647. 
The resultant AVR can provide the clinician with a baseline value but changes in vascular morphology 
can result in simultaneous reductions or increases in the CRAE and CRVE possibly leading to the 
same AVR value as before. One must take into consideration the overall value of the equivalent 
diameter widths as well when contemplating disease progression or regression. Knudtson in 2003648 
revised the formula due to constant values within the PARR- HUBBARD equation which led to 
variability within the measurement calculation. The advantage of this being the revised formula does 
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not contain constant values and can be solved for different measuring units and is independent of 
image scale.  
𝐴𝑟𝑡𝑒𝑟𝑖𝑜𝑙𝑒𝑠 ?̈? = 0.88 ∗ √(𝑊1
2 + 𝑊2
2) 
𝑉𝑒𝑛𝑢𝑙𝑒𝑠 ?̈? = 0.95 ∗ √(𝑊1
2 + 𝑊2
2) 
Where W₁ (narrower) and W₂ (wider) are the paired retinal vessel diameters. ?̈? Being the parent 
trunk vessel.  The branching co-efficient for the arterioles 0.88 and venules 0.95 were estimated 
based on the approximation of Hubbards experiment and as follows the equation. 
𝐵𝑟𝑎𝑛𝑐ℎ𝑖𝑛𝑔 𝐶𝑜 − 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 =
(𝑊1
2 + 𝑊2
2)
𝑊²
  
Where W₁, and W₂ are the widths of the narrower and wider branch and W is the parent trunk. After 
all the arterioles and venules are selected the six biggest of each group then go on to form the CRAE 
and CRVE which then can be used to quantify the AVR with the revised formula. The pairing process 
requires the biggest vessel to be matched with the smallest vessel and the next biggest with the next 
smallest, until all vessels are paired. The revised formula can begin with each iteration considered 
separately; in the case of an odd number vessel, this can be moved forward to the next iteration648.   
3.3.3.5 Measurement protocol 
Mydriasis with 1% tropicamide (Chauvin pharmaceuticals, UK) was instilled 30 mins prior to fundus 
images being taken. The photograph taken 30o centered on the optic nerve head. The ARIA649 
software was used. This is a Matlab (Matlab, Mathworks, VR2013a) plug in for the analysis of retinal 
images. The software protocol has been described elsewhere649. The measurement area is defined 
as a concentric ring centred on the optic nerve head at 1/2 to 1 disc diameter from the edge of the 
optic disc margin (Figure 3.3.3). Fundus photos are uploaded and the arteries and veins are chosen 
separately. Once all specified vessels are acquired they can be manually entered into the chosen 
formula, which in this thesis refers for Knudtson’s 2003 revised formula.  
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Figure 3.3.3. Aria measurement zone equivalent to 0.5 to 1DD from optic disc margin 
 
 
3.3.4 Assessment of ocular vascular function 
3.3.4.1 Dynamic retinal vessel analysis 
This is a technique used to assess retinal microvascular function i.e. the behaviour of retinal arteries 
and veins in response to provocation. The RVA system (IMEDOS, GmbH, Jena ,Germany) enables the 
continuous recording of diameters of the retinal microvessels in real time. These diameter 
fluctuations occur physiologically owing to the pulsatile nature of blood flow and additionally can be 
altered through external provocation. Recordings can be stored on a video tape which is coupled to 
the CCD camera and can then be reviewed offline for further processing. Flicker light provocation 
was the method of choice in this thesis.  
The RVA system (IMEDOS, GmbH, Jena ,Germany) consists of a fundus camera, (FF450, Zeiss Jena, 
Germany), a charged coupling device (CCD) camera, a high resolution video recorder, a real time 
monitor and a personal computer with analysis software. 
In order to obtain a good quality illuminated fundus image with good contrast requires the use of 
dilating drops, usually 1% tropicamide (Chauvin, pharmaceuticals, UK). The camera itself is set at a 
300 viewing angle to provide a proper field of view for examination with a temporal resolution of 
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40ms. This allows a sampling rate of 25 HZ, such that 25 video frames are captured per second. The 
investigator will then choose a region of interest that incorporates appropriate vessel segments 
greater than 90 microns. These vessel segments are used in continuous diameter recordings over a 
specified time period. It encompasses a selection of an arteriole and venule between 0.5mm to 1mm 
in length, roughly 1 to 2 disc diameters away from the optic nerve head (figure 3.3.4). 
 
Figure 3.3.4. DVA analysis in real time 
 
 
3.3.4.2 Measurement principle 
The ability of the DVA to measure the diameter of vessels in real time depends on the brightness 
profile of the retinal vessels which is based on the absorption properties of erythrocytes. During 
retinal vessel analysis, maximum absorption of light occurs at 400-620nm, and by comparing the 
brightness profile of the red blood cell column within the vessel and the surrounding tissue, a 
continuous assessment can be made. Therefore, the DVA actually measures the width of the red 
blood cell column549 650. This is achieved as illumination from the fundus camera enters through a 
dilated pupil and is reflected by the different layers of the retina and is then delivered via the 
observation pathway to the CCD camera.   
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To ensure optimal patient alignment the operator can observe the fundus image on the display 
before the examination begins. A green filter is inserted into the fundus camera to ensure optimal 
contrast for visualizing the chosen segment. Furthermore, a series of adaptive algorithms 
compensate for any disruption to the brightness profile by shadowing structures from the 
background or reflections from the vessel surface. The software also has the capability to correct for 
slight eye movements and can continuously monitor image quality according to image contrast, and 
remove any inadequate measurements from the analysis549 651.  
However, it is important to note that the method for assessing retinal microvascular function does 
have its limitations which are summarized below along with its advantages in Table 3.3.4. 
 
In order to assess microvascular reactivity of the retinal vessels, the vessels need to be provoked. 
This can be done through a variety of provocation methods and have been used in other studies. 
Namely, through the use of suction cup IOP enhancement652 653, pure oxygen breathing654-656, 
inhalation of CO2657, isometric exercise658-661, infusion of vasoactive substances662 663, and flicker light 
stimulation664 665.  
 
 
 
Advantages Disadvantages
non-invasive measurement
Image quality is strongly dependant on an optically clear 
media
Vessel segments and different retinal vessels can 
be examined simultaneously  
The patient requires good fixation for approximately 350 
seconds
High reproducibility 
Assumes the eye has no refractive error. Difficulty with high 
myopia or hypermetropia
Low variability 
Dilation with the use of tropicamide 1% only (to avoid 
adverse vascular effects)
Potential to monitor drug effectiveness Can not be performed on patients with epilepsy
Table 3.3.4 Summary of DVA advantages and disadvantages 
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3.3.4.3 Flicker stimulation 
The normal vascular response to flickering light has been widely studied666 667. Under normal 
circumstances the stimulation of flickering light should lead to an increase in vessel diameter, retinal 
blood flow and optic nerve head blood flow668. Flickering light can be considered the most natural 
provocation method for assessing the behaviour of the retinal vessels and has the advantage of only 
stimulating the retina and not another vascular bed. Throughout this thesis the DVA was equipped 
to generate flickering light at a sampling rate of 12.5HZ via an optoelectronic shutter placed in the 
optical path of the camera illumination system. The shutter generated flicker by interrupting the 
illumination to provide a bright to dark contrast ratio of at least 25:1.  A sampling rate of 12.5 Hz lies 
within the optimum flicker frequency range and has been shown to provide appropriate retinal 
stimulation667 669. Flickering light increases the neural demand of the retina. An increase in the 
metabolic rate of the photoreceptors is thought to trigger the release of nitric oxide from the retinal 
endothelial cells causing an increase in vessel diameter followed by an increase in blood supply to 
meet the increased demand670. An altered vascular response could be indicative of impaired 
autoregulatory mechanisms or endothelial dysfunction in the form of increased levels of endothelin-
1 or reduced bioavailability of nitric oxide. After the removal of the flicker stimulus, the vessel 
diameter normally resides to baseline values and is most accurate for the venous response; 
however, the artery has been shown to constrict below baseline immediately following stimulus 
cessation which is thought to be a regulatory mechanism of the retinal vascular endothelium as a 
result of an imbalance in nitric oxide and Endothelin-1413.  
3.3.4.4 Measurement Protocol 
The measurement protocol in this thesis is in accordance with that introduced by Nagel et al671. The 
fundus camera is positioned to obtain a uniform illuminated fundus image through a dilated pupil. 
Adjustments of brightness and contrast to ensure a good quality image. The patient is directed to 
fixate on a needle so that the area of interest lies within the centre of the display. The user then 
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selects a rectangular area for the assessment. Within this region of the inferior temporal retina, an 
artery and vein is selected approximately 1 to 2 disc diameters from the optic nerve head for 
analysis. The measurement begins automatically and vessel diameters are continuously recorded 
over a period of 350 seconds. The baseline measurement consists of 50 seconds under still 
illumination (25 Hz), followed by 20 seconds of flicker stimulation (optoelectronically generated at 
12.5Hz) and finally a recovery period of 80 seconds. This represents a single flicker cycle and under 
the examination it is repeated three times (figure 3.3.4.4). 
 
Figure 3.3.4.4. Example of DVA time course, showing 3 cycles of flicker provocation 
 
Traditionally the inbuilt software of the DVA can provide an analysis of the retinal vascular response 
to flickering light. However, this has been identified to have a number of shortfalls and the need to 
evaluate the retinal response times in more detail has been increasingly recognised651 672. The 
algorithm used by the software calculates the maximum diameter response by averaging all three 
flicker cycles and then calculating the flicker response +/-3 seconds after clicker cessation673 674.  This 
will actually cause an underestimation of arterial dilation times for those individuals that reach 
maximum dilation before 17 seconds or after 23 seconds. To overcome these shortfalls of the inbuilt 
software analysis, Heitmar et al672 introduced the sequential and diameter response analysis SDRA. 
The SDRA has the advantage of utilizing the raw data generated by the DVA and allows each flicker 
cycle to be considered separately, enabling a more accurate assessment of the vessel response with 
additional parameters on top of the standard dilation and constriction response parameters. These 
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additional parameters include the baseline diameter fluctuation (BDF), baseline flicker response 
(BFR), dilation amplitude (DA), and the time taken for the vessel to reach maximum dilation or 
minimum constriction for the artery and vein for each individual flicker cycle. It is important to note 
that, analysis of individual flicker cycles relies on a full data set. If this cannot be obtained because of 
excessive patient movements, blinking or loss of concentration, then the average response times 
using SDRA are considered more reliable.  The SDRA has been shown to be a sensitive measure of 
the vascular response to flicker light with good co-efficients of variation672.  
The principles of SDRA have been used in this thesis with the inclusion of additional parameters to 
evaluate the entire dynamic response profile. A statistical polynomial regression algorithm can be 
applied to the raw response data from the RVA software which can be implemented using the 
“polyfit” and “polyval” functions in Matlab (Mathworks, Inc., R2013a, USA) to create a visualization 
plot675. The statistical algorithm used for data visualization in this thesis was constructed and 
implemented in consultation with an experienced statistician at Aston University (Dr Aniko Ekart). 
These now follow. 
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The polyval function was used to calculate the fitted polynomials which provided curves that 
represent the dynamic vascular response. The degree of the polynomial, n, is an adjustable 
parameter. In this case, n = 20 was applied for consistency as this provided the closest fit 
polynomials on the data points. As well as the original parameters of the SDRA method the 
polynomial fitted curves allowed the nature of the dynamic response profile and the slope of the 
dilation and constriction responses to be calculated separately for the artery and vein.  An example 
of the visualization plot (Figure 3.3.4.5) and a summary of the main parameters used in this thesis is 
provided below in table (3.3.4.6).    
 
FIG 3.3.4.5. Representation of the SDRA response parameters 
Abbreviations: BDF, baseline diameter fluctuation; MD,maximum diameter; MD%, percent dilation relative to 
average baseline diameter; MC, minimum constriction diameter; MC%, percent constriction relative to average 
baseline diameter. 
 
 
 
107 
 
 
 
3.3.5 Assessment of anterior ocular structure and function 
3.3.5.1Keratography  
The Keratograph (K5M, Optikgerate GmbH, Wetzlar, Germany), combines keratometry measuring 
processes with topographic mapping. It is an illumination system which has a special reflector 
illuminating a placido bowl which contains a series of 22 white concentric rings, and thus images 
obtained are reflected from this placido bowl from the patients’ eye. Besides being an advanced 
corneal topographer it also contains additional imaging modalities to measure the anterior ocular 
surface. These include infra-red measurements of the meibomian glands at 840nm, evaluation of the 
tear break up time non-invasively, measuring the amount of bulbar and limbal hyperaemia, tear 
meniscus height, and a dynamic evaluation of the lipid layer. It also has a built in video recorder and 
software to analyse the data, and can be used for future reference when evaluating the ocular 
surface after treatment or post-surgical interventions.  
 
 
 
Parameter Calculation
BD- Baseline diameter Average diameter during baseline
BDF- Baseline diameter fluctuction Maximal range of diameter measurements during baseline
MD- maximum dilation Maximum diameter following flicker
% Dilation- expressed from baseline ((MD-BD)/BD)*100
MC- Maximum constriction Minimum diameter after clicker cessation
% Constriction- expressed from baseline ((MC-BD)/BD)*100
RT- Reaction time Time in seconds to reach MD
CT- Constriction time Time in seconds to reach MC
DA- Dilation Amplitude MD-MC
BCFR- Baseline corrected flicker resposne (DA-BDF)
Slope D- Dilation slope (MD-BD)RT
Slope C- Constriction slope (MC-BD)/CT
Table 3.3.4.6 Summary of DVA parameters used for calculation of artery and venous profiles
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3.3.5.2 Procedure 
The test is conducted in a dim room to eliminate reflections from the surface of the keratograph. 
The patient is in a seated position with their chin placed on the chin rest and the outer canthus is 
aligned with the chin-forehead reference bar. The patient must focus on the red light located 
directly in the centre of the concentric rings. All subsequent measurements are taken from this 
reference point. The following procedures described below are in the order of the protocol used in 
this thesis.  
3.3.5.3 Tear meniscus height 
Images obtained of the tear meniscus height (TMH ) from the keratograph are taken from the lower 
lid. The tear meniscus can be evaluated with different options to magnify the view. The height of the 
tear meniscus can give an indication of the tear volume i.e. quantity of tear reserve. TMH should be 
directly measured under the pupil centre at the lower lid. The classification of normal tear reserve is 
as follows: good >0.2mm; normal = 0.2mm; poor < 0.2mm676. The software allows the user to 
quantify the height of the tear meniscus with an integrated ruler. An example of the assessment is 
presented below in Figure 3.3.5.3. 
 
FIG 3.3.5.3. Example of TMH measurement 
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3.3.5.4 Non-invasive keratograph break up time NIKBUT 
The non invasive break up time is evaluated and displayed in a color coded map of the cornea Figure 
3.3.5.4. Once the patient is aligned, the clinician requires the patient to blink twice consecutively. 
This second blink triggers the program to initiate the recording. The recording of break up time 
ceases when one of two events occur; the patient blinks or there is a significant amount of distortion 
from the reflected image of the placido rings. The information is then encoded by the software and 
displayed to the clinician. The time it takes for the tears to break up can give an indication of the 
quality of the tear film. Normal tear break up time is > 10 seconds. Areas highlighted in red indicate 
an unstable tear film, and areas in green indicate a stable tear film. 
  
FIG 3.3.5.4. Example of NIKBUT measurement 
 
3.3.5.5 Dynamic evaluation of the lipid layer 
The evaluation of the lipid layer is performed with the patient looking directly at the centre of the 
placido disc Figure 3.3.5.5. Once aligned, the measurement commences and the clinician should 
advise the patient to blink normally to reveal the spread and formation of the lipid layer across the 
corneal surface. This measurement is usually recorded to assess the dynamic behaviour of the tear 
film, as well as giving an indication of the thickness of the lipid layer. If the interference pattern 
displays colours and structures it is regarded as normal; however, if no colours or structures are 
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visible it could be an indication of early tear film evaporation. Recordings can last from 5 to 10 
seconds or longer if the clinician deems so. There is also the ability to capture images within the 
video recording for analysing images later on.  
 
FIG 3.3.5.5 Example measurement of dynamic evaluation of lipid layer 
 
3.3.5.6 Redness 
The Keratograph is also able to evaluate the amount of limbal and bulbar hyperaemia. This feature 
can record and grade redness automatically and objectively with the inbuilt software that compares 
the amount of redness and analyses it according to the Efron grading scale. The area analysed is 
based on the area percentage between the vessels and the rest of the analysed area represented in 
figure 3.3.5.6.  
  
FIG 3.3.5.6. Measurement example of bulbar redness 
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3.3.5.7 Meibography 
Meibomian gland structure can be imaged with infra-red light. The superior lid as well as the lower 
lid must be everted before capturing the image. The morphological changes in the glandular tissue 
can be made visible using a 3D meibo scan represented in figure 3.3.5.7. Once the image is captured 
the software makes a contrast enhanced image alongside a normal image which can be viewed by 
the clinician and is usually subjectively graded. 
 
FIG 3.3.5.7. Example of infrared superior and inferior meibography 
 
3.3.5.8 Data analysis 
The in inbuilt software is capable of automated analysis. These analysed images are limited to the 
amount of hyperaemia, graded according to the EFRON grading scale, and the NIKBUT with the use 
of the placido discs.  The algorithm shows good agreement with previous techniques and is highly 
repeatable and reproducible629 630.   
The quantification of tear meniscus height is made on the actual image with the use of an inbuilt 
ruler which measures to 1/10th of a mm and can be graded accordingly. The classification of lipid 
layer thickness can be made subjectively on the interference pattern observed during the video 
recording. An open/closed meshwork correlates to a thickness of 13-50nm, wave or flow pattern is 
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between 50-70nm, an amourphous pattern is between 80-90nm, colour fringes represent a 
thickness between from 90-180nm, and finally a globular network represents a thickness of >200nm.  
The meibomian glands can be analysed according to a number of different protocols. Originally a 4 
point scale was used to assess the level of meibomian gland drop out or a change in its 
morphology677 678. More recently a new scale was introduced by Pult et al679 which incorporated a 5 
point scale based on the level of Meibomian gland dropout. The infrared image is captured and then 
analysed with the imajeJ software V1.49 (Wayne Rasband, NIH, USA). The software allows the user 
to trace the whole area under analysis and then to trace the area where gland drop out occurs 
(figure 3.3.5.8). The percentage of gland drop is equal to (area of dropout/whole area)*100. In a 
further study, Pult et al680 analysed the repeatability of objective grading and subjective grading 
using the meibomian gland loss ratio and found that intra-observer and inter-observer agreement 
was better in computerized grading than the subjective 5 point scale and 4 point scale 
conventionally used to diagnose meibomian gland dropout. 
 
FIG 3.3.5.8.  Measurement example with Image J representing Area of loss of the superior tarsus. 
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3.3.6 Assessment of cardiovascular risk 
Determination of cardiovascular risk is often made based on health and lifestyle questionnaires 
which aim to determine the presence of obesity, smoking status, diabetes, hypercholesterolemia, 
and hypertension. A more accurate way of determining the risk specified for an individual is by 
calculating the Framingham risk score (FRS). The FRS provides an estimate of the 10 year absolute 
risk for developing coronary heart disease681 682. It is sex specific, taking into account age, total 
cholesterol, HDL cholesterol, smoking status, blood pressure, and diabetes and has been shown to 
be validated across different ethnic groups681. It has been shown that deviations in these risk 
variables normally account for the majority of cases that go on to develop cardiovascular disease683. 
In the present studies the FRS was calculated using the current version of the Framingham risk 
score684. The scoring algorithm is based on gender-specific points assigned for each risk factor 
variable that can be determined using FRS tables i.e. point scores by age group; age group and total 
CHOL; age group and smoking status; HDL-c level; SBP and treatment status. Ten-year risk 
percentage is then calculated by total points (1 point, 6%; 2 points, 8%; 3 points, 10%; 4 points, 12%; 
5 points, 16%; 6 points, 20%; 7 points, 25%; 10 points or more, > 30%). Absolute CVD risk percentage 
over 10 years was classified as low risk (< 10%), intermediate risk (10-20%), and high risk (> 20%)685.  
Furthermore, fasting blood samples were obtained from the antecubital fossa vein of the 
participants and tested immediately for fasting triglycerides (TGs), glucose levels and total and HDL 
cholesterol, using a Reflotron Desktop Analyser (Roche Diagnostics, UK). 
Recently our understanding of the pathogenesis of cardiovascular disease has progressed on a 
molecular level, being able to identify mechanisms that affect the vascular endothelium. Currently it 
is quite common to use quantitative values measuring blood pressure, cholesterol levels, glucose 
levels and more recently inflammatory markers. An alternative approach could be envisioned so that 
blood vessel health, loss of arterial elasticity, endothelial dysfunction, and or reduced reactive 
hyperaemia can provide additional prognostic value to better identify individuals with overt disease 
or those who are more at risk. 
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4.0 The relationship between retinal and peripheral vascular function in healthy individuals with 
low cardiovascular risk  
4.1 Abstract 
Purpose: To assess the relationship between retinal and systemic microvascular function in 
individuals with low cardiovascular risk.  
Methods: Anthropometric measurements were collected on 136 healthy participants. Microvascular 
reactivity was measured using the dynamic vessel analyser (DVA, IMEDOS GmbH, Jena, Germany) 
and peripheral vascular reactivity was measured using the digital thermal monitor (DTM) VENDYS® 
system (Endothelix, Inc., Houston, TX). Additionally, blood analysis was assessed for the calculation 
of the Framingham risk score (FRS). Participants were categorised based on the value of their 
peripheral vascular reactivity indices. 
Results: Participants with higher peripheral vascular reactivity indices showed a significant 
difference in arterial reaction time across groups (p < 0.001), dilation amplitude (p=0.006), and 
slopeAC (p=0.019). Digital thermal monitoring correlated positively with retinal arterial DA (r = 
0.576, p = 0.002), BDF (r = 0.434, p =0.039) and negatively with mDRT (r = -0.643, p < 0.001) and 
slopeAC (r = -0.463, p = 0.027). 
Conclusions: The findings of this study showed significant positive and negative associations 
between retinal and peripheral vascular measurements. As retinal microvascular reactivity reflected 
systemic reactivity then retinal measurements may serve as early warning of future CVD.  
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4.2 Introduction 
In the primary prevention of cardiovascular disease, the use of predictive models such as the 
Framingham Risk Score681 686 687(FRS), the Prospective Cardio- vascular Mὒnster (PROCAM) score and 
the European Society of Cardiology Systematic Coronary Risk Evaluation (SCORE)688-691 are useful 
preliminary steps for assessing each individuals’ risk. However, such methods rely on measurements 
that are useful in predicting long-term risk assessment in populations and not in individuals with 
specific genetic and environmental influences570 692-694. As a direct result, such risk calculators either 
over- or underestimate risks in more than 50% of individuals554 695-697. It is now increasingly 
recognised that predictive, preventive and personalised approaches could better contribute to 
establishing integrative management tailored to the individual patient. Indeed, while there are 
various biomarkers offering a disease-specific individual biological profile, none of these techniques 
enable non-invasive assessments in primary care settings while being sufficiently sensitive to enable 
early detection and prevention.  
The assessment of vascular and endothelial dysfunction (VED) is one very important marker for early 
CVD risk. It is well recognized that VED plays a role in the occurrence of hypertension, coronary heart 
disease (CHD), dyslipidemia, obesity, and types 1 and 2 diabetes247 698-700. Therefore, its quantification 
is very important when trying to establish an early risk and successfully implement preventive 
measures. The vascular function is usually assessed by employing techniques such as ultrasound flow-
mediated dilation (FMD), pulse wave analysis (PWA), plethysmography and iontophoresis701. These 
tests can, however, be complex and time-consuming, and are performed only in highly specialized 
services. Among the more user-friendly methods developed to measure microvascular function, 
dynamic retinal vessel analysis (DVA) represents a non-invasive method that allows for continuous 
recordings of retinal arterial and venous diameter changes in response to flicker-light stimulation. The 
main advantage of the DVA assessment is that it provides integrated and dynamic data analysis that 
is specific to each individual. In addition, its output has proven to be modified not only by overt disease 
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but also in the presence of more subtle risk factors for CVD578 702 703 including ageing554, ethnicity 665 
and  impaired glucose tolerance 704. Therefore, it is possible to use the assessment of retinal 
microvascular function as an early marker for VED.   
Another method, called Digital Thermal Monitoring (DTM), has been developed to measures both 
cutaneous microvascular and vascular reactivity using reactive hyperaemia after increasing the blood 
pressure (BP)  to suprasystolic values. This method was also found to detect increased risk of CVD and 
VED568-570 584. To date DTM has shown a strong relationship with FMD581 , coronary calcium score, 
myocardial perfusion defects, and coronary angiographic findings568-571 585 705-707 and has excellent 
reproducibility and low variability when used in controlled environments526.     
So there are at least a couple of candidates for non-invasive assessments of CVD risk in primary care 
settings. Nevertheless, the vascular beds assessed by the two machines have regional and 
physiological differences525 708. Moreover, the differences extend to the provocation stimulus used by 
each of the instruments to induce vascular dilation and constriction569 581 671 708. It would be useful to 
know, however, that regardless of the provocation stimulus and microvascular bed assessed, the 
existing methods are equally sensitive to signs of early CVD risk. Therefore, the aim of the present 
study was to investigate the relationship between retinal microvascular function as assessed by the 
DVA and peripheral vascular reactivity measured using the DTM in apparently healthy, normotensive 
individuals with no known history of cardiovascular disease.  
4.3 Subjects and methods 
Study participants were recruited through advertisements within Aston university (Birmingham, UK) 
campus, specifically the health clinics and the vascular research laboratory. The inclusion and 
exclusion criteria for the participants was detailed in section 3.2.5. Briefly, participants were healthy 
individuals that were currently not taking any medications and were willing to participate. The 
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investigative procedures performed in this study are outlined below and were conducted in 
accordance with the protocols set out in section 3.3.1.  
 1. Anthropometrics 
 2. IOP measurements 
 3. Blood pressure 
 4. Assessment of systemic vascular reactivity (DTM) 
 5. Assessment of retinal vascular reactivity (DVA) 
 6. Assessment of fasting blood samples (CVD risk) 
 
4.4 Statistical analysis 
All analyses were performed using Statistica® software (StatSoft Inc., Version 13, USA). Distributions 
of continuous variables were determined by the Shapiro-Wilks test. Group differences in clinical 
characteristics were assessed by one-way ANOVA. Univariate associations were determined using 
Pearson’s (normally distributed) or Spearman’s method (non-normally distributed), and multivariate 
analyses were performed to test the influence of clinical parameters, and circulating markers on the 
measured vascular reactivity variables. Differences between groups in retinal and peripheral vascular 
reactivity measures were computed by ANOVA or analysis of covariance (ANCOVA), where 
applicable, followed by a post hoc Bonferroni test. Statistical significance was defined at p < 0.05. 
 
4.5 Power calculations 
The sample size was calculated using the software G power709 (University of Kiel, version 3.1.6, 
Germany) Based on previous studies, normal expected retinal arterial responses to flicker-light 
stimulation have been around 6.9 ± 2.8% which is a clinically significant amount of vessel diameter 
changes710. As the study design was multi-factorial in nature, it was anticipated that an analysis of 
variance ANOVA or covariance ANCOVA would be required in this study, therefore to provide a 
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statistical power of 80% and medium effect size of 0.5 with an alpha level of 0.05 it was estimated 
that a sample size of n= 138 participants was required.  
 
4.6 Results 
4.6.1 Clinical characteristics 
A total of 150 participants were initially screened for study inclusion of which 14 individuals were 
excluded based on having a moderate to high FRS (>10%). The remaining 136 participants with low 
FRS (<10%) were included in the final analysis and classified into one of three groups based on the 
aTR vascular reactivity index cut-off represented in table 4.6.1.2: group 1 (high risk): aTR >0; group 2 
(intermediate risk): aTR >1<2, and group 3 (low risk): aTR >=2. The number of participants in each 
group was: group 1: 45 (males=22, females=23); group 2: 46 (males=25, females=21); Group 3: 45 
(males=22, females=23). There was no significant difference between the number of males and 
females in each of the study group (chi-square test p=0.715). The aTR values for each group are 
presented in table 4.6.1.1. 
Table 4.6.1.1 Digital Thermal monitoring parameters 
  Mean (SD) 
Parameter High risk Intermediate risk Low risk 
TR -0.17 (0.60) 0.03 (0.54) 0.84 (1.26) 
aTR 0.73 (0.35) 1.73(0.19) 2.62(0.78) 
AUCTR 121 (68.52) 267 (72.64) 420 (144.90) 
Abbreviations: TR, temperature rebound; aTR, adjusted temperature rebound; AUCTR, Area under the curve temperature 
rebound  
 
Table 4.6.1.2 below provides a summary of the anthropometric and clinical data for the study groups. 
There were no significant differences in any of the measured clinical variables (ANOVA, all p > 0.05).  
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Table 4.6.1.2 Summary of clinical data    
               Mean (SD)   
Variable High risk  Intermediate risk Low risk P value 
N 45 46 45   
Age (years) 34 (11.51) 29 (9.56) 32 (10.57) 0.098 
BMI (kg/m2) 25(4.36) 24(4.50) 24(4.69) 0.428 
SBP (mmHg) 122(11.98) 126(12.77) 122(11.22) 0.233 
DBP (mmHg) 72(7.86) 73(9.01) 71(8.40) 0.462 
HR (bpm) 64(11.45) 65(11.20) 67(9.60) 0.395 
MAP 89(8.43) 91(9.19) 88(8.68) 0.306 
IOP (mmHg) 14(2.25) 14(2.76) 13(2.85) 0.234 
OPP 45(5.78) 46(7.03) 45(6.05) 0.740 
CHOL (mmol/L) 4.38(0.82) 4.20(0.94) 4.76(1.09) 0.479 
HDL-C (mmol/L) 1.48(0.56) 1.55(0.43) 1.67(0.59) 0.749 
LDL-C (mmol/L) 2.48(0.90) 2.06(1.03) 2.46(1.07 0.673 
CVD risk % 3.73(3.65) 2.17(1.82) 2.71(2.01) 0.593 
 Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; MAP, mean 
arterial pressure; IOP, intraocular pressure; OPP, ocular perfusion pressure; CHOL, total cholesterol; HDL-C, high-density 
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CVD risk%, cardiovascular disease risk percentage. * 
Significant p-values are indicated in bold where, ANOVA, p < 0.05 was considered significant. 
 
4.6.2 Retinal vascular function measurements 
The results of retinal vascular function assessments are displayed in Table 4.6.2 below. After 
controlling for all influential covariates identified in multivariate regression analysis, there was a 
clinically significant difference in the arterial mDRT between the 3 study groups. There was also a 
statistically significant difference in the DA & slopeAC between group 3 and groups 1&2 Figure (4.6.2.) 
There were no other significant differences at the retinal microvascular level in either the measured 
arteries or veins (all p>0.05). 
4.6.3 Correlations between retinal and peripheral vascular function measures 
Retinal arterial DA, BDF correlated positively (r = 0.576, p = 0.002, r = 0.434, p =0.039); mDRT and 
slopeAC negatively (r = -0.643, p < 0.001, r = -0.463, p = 0.027) with fingertip aTR which are represented 
in figure 4.6.3. No significant correlations between aTR and any of the other measured retinal arterial 
and venous reactivity parameters were identified (all p>0.05) 
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Table 4.6.2. Summary of retinal vascular function parameters 
    Mean (SD)     
Parameter High risk Intermediate risk Low risk P value Significance 
Arteries: 
Baseline 100(0.02) 100(0.03) 99.96(0.25) 0.398 - 
BDF 5.43(2.42) 6.35(3.57) 6.24(2.66) 0.269 - 
BCFR 3.02(2.52) 3.33(2.78) 2.86(2.63) 0.695 - 
MD 105.05(2.75) 105.50(2.47) 104.95(1.96) 0.537 - 
mDRT 25.27(7.79) 21.48(5.44) 17.28(4.17) <0.001* 1>2>3 
Dilation % 5.05(2.74) 5.50(2.73) 4.98(1.96) 0.57 - 
MC 96.59(1.80) 95.81(3.01) 95.83(2.39) 0.234 - 
mCRT 29.07(9.09) 25.67(6.23) 26.42(6.57) 0.871 - 
Constriction % -3.41(1.78) -4.20(2.98) -4.13(2.43) 0.247 - 
DA 23.80(10.76) 24.97(7.54) 29.54(7.80) 0.006* 3>2,1 
SlopeAD 0.31(0.23) 0.33(0.22) 0.38(0.23) 0.415 - 
SlopeAC -0.34(0.18) -0.50(0.29) -0.59(0.63) 0.019* 3>2,1  
Veins: 
Baseline 100(0.03) 99(0.03) 99(0.16) 0.254 - 
BDF 4.69(2.82) 4.93(2.43) 5.27(2.74) 0.587 - 
BCFR 3.12(2.13) 3.11(2.58) 3.35(3.28) 0.889 - 
MD 106(3.51) 105(2.25) 106(3.43) 0.453 - 
mDRT 21.42(4.87) 22.23(5.70) 22.19(6.44) 0.751 - 
Dilation % 6.11(3.49) 5.81(2.25) 6.65(3.42) 0.427 - 
MC 98.31(1.70) 97.75(2.03 98.01(1.55) 0.422 - 
mCRT 33.78(6.41) 33.42(6.88) 33.25(7.92) 0.906 - 
Constriction % -1.83(1.93) -2.26(1.99) -1.98(1.55) 0.611 - 
DA 31.50(7.08) 31.18(8.62) 31.05(8.71) 0.964 - 
SlopeVD 0.31(0.16) 0.29(0.14) 0.37(0.21) 0.101 - 
SlopeVC -0.28(0.16) -0.28(0.16) -0.34(-0.24) 0.301 - 
 Abbreviations: Baseline diameter; BDF, baseline diameter fluctuation; BCFR, Baseline corrected flicker response; mDRT, 
reaction time to MD; MD (%), percent dilation; mCRT, reaction time to MC; MC (%), percent constriction;  DA, dilation 
amplitude (difference between MD and MC during flicker) SlopeAD, slope of arterial/venous dilation; SlopeAC, slope of 
arterial/venous constriction. * Significant p-values are indicated in bold where p < 0.05 was considered significant.  ANOVA, 
analysis of variance; ANCOVA, analysis of covariance. Multivariate regression analysis revealed that SBP, DBP, PR, CHOL were 
influential factors on some of the identified retinal measurements, which were then analysed using ANCOVA between 
groups. If there were no influential factors then analysis was carried out with ANOVA.   
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Figure 4.6.2: Comparison of retinal arterial response profile across groups based on the temperature rebound parameters. 
AU, arbitrary units; MD, maximum diameter during flicker; MC, maximum constriction post flicker; mDRT, reaction time in 
seconds to MD;  DA, MD-MC; SlopeAC, ,calculated as (MC-MD)/(mCRT). 
  
 
 
Figure 4.6.3: Correlations between retinal and peripheral vascular function measures, graphs A,B,C,D 
BDF, Baseline diameter fluctuation; mDRT, reaction time in seconds; DA, Dilation Amplitude; Slope ac, Arterial constriction 
slope; aTR, adjusted temperature rebound. 
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4.7 Discussion  
The results presented in this study show that otherwise healthy individuals with impaired peripheral 
microvascular reactivity (as detected by the DTM technique) also exhibit signs of impaired retinal 
vascular function demonstrated by an abnormal arterial mRDT, slopeac, and DA responses. This 
behaviour was not demonstrated in individuals without peripheral microvascular function  
abnormalities. Moreover, the dysfunction measured at the retinal microvascular level correlated with 
similar changes at the peripheral circulation, as measured by DTM. 
Conventionally, endothelial dysfunction is assessed at the macro-circulatory level, using techniques 
such as brachial artery flow mediated dilation (FMD)382 711 712 or venous occlusion forearm 
plethysmography713.  Nevertheless, such techniques are challenging in more than one aspect, 
including availability, care setting and level of complexity.  As endothelial dysfunction is known to have 
a profound and much earlier effect on the microvasculature701 714, efforts were made to develop 
methods that test vascular function at the microcirculatory level. Among these instruments, DVA was 
proven to be an invaluable asset for assessing risk for disease or for proving disease progression664 665 
704. The reactive temperature rebound after sheer stress assessed by the DTM machine, also 
represents a candidate for microvascular function assessments in risk and disease progression 
demonstrations.  Nevertheless, as the two tests investigate different vascular beds, with different 
structure and physiology, it would be important to show that there is an agreement between such 
methods and risk can be picked on regardless of the availability, choice or vascular bed assessed.The 
mechanism behind the retinal vascular response to flickering light includes nitric oxide (NO) release in 
response to increased metabolic demands. It also includes, however, neurovascular coupling driven 
response 708.  For the DTM, the mechanism involves a combined endothelial 
NO synthase (eNOS) and cyclooxygenase (COX) inhibition which attenuates the acetylcholine (Ach)-
induced, endothelium- dependent, cutaneous vasodilatation715 but also a non-NO, non-prostanoid-
dependent pathway, potentially attributable to endothelium-derived hyperpolarizing factor519 (EDHF). 
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There are many conflicting views upon literature review in regards to endothelial function affecting 
vascular beds quite differently522. However, researchers are demonstrating correlations between 
retinal circulation and systemic circulation716.  The retina provides a non-invasive assessment of an 
arterial bed that makes it possible to assess the structure and integrity of the vasculature and its 
function. The presence of retinal vasculature abnormalities such as arterio-venous nicking, focal and 
generalised narrowing, altered arterio-venous ratio, and micro-infarcts and haemorrhages can be 
indicative of a more widespread systemic dysfunction with blood supply532 717-719.  A study by chapman 
et al718 demonstrated the relationship between peripheral vascular disease and retinal arteriolar 
abnormalities that are also represented in the atherosclerosis risk in communities study (ARIC). The 
ARIC study further demonstrated that abnormalities in retinal arterioles (i.e. Hollenhorst plaque), are 
related to the presence of carotid artery plaque aggregation, serum markers of inflammation and 
endothelial dysfunction717.  Park et al720 also demonstrated that a significant correlation exists 
between endothelial function in the brachial artery as measured by FMD and in the subcutaneous 
small arteries where abnormally measured dilatory responses during FMD can predict the presence 
of endothelial dysfunction in resistance arteries.  
Nguyen and colleagues in 2010 showed that increased venule calibres as an independent 
cardiovascular risk factor also had a reduced FMD response but showed no association with arteriorlar 
calibre721. The authors of the aforementioned study did not analyse the arterio-venous ratio in relation 
to FMD response. However, also in 2010, Katsi observed the relationship between alterations within 
the retina and arterial stiffness in untreated hypertensive patients722. Artery resistance plays a key 
role in the control of blood pressure due to the drop in hydrostatic pressure that occurs at these 
arteries723 724.  To date, a great body of research data indicates that hypertensive patients show a 
greater tunica media thickness in resistance arteries, a reduced internal and external diameter with 
increased tunica media to lumen ratio723. Katsi et al722, concluded that there was a progressive 
stiffening of the aorta that can be paralleled with signs of hypertensive retinopathy suggesting that a 
similar pathophysiological process of endothelial impairment or lumen wall remodelling occur in both 
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small and large blood vessels.  Significant correlations between coronary flow reserve and 
subcutaneous small resistance artery remodelling was detectable in hypertension patients, which the 
study suggested that structural alterations in small resistance vessels may be simultaneously present 
in different vascular beds and that changes in morphology of the subcutaneous vasculature may even 
reflect alterations in the coronary vessels375 723.  
In addition to physiological factors responsible for vascular reactivity, measurement site and location 
of tissue used at which vascular reactivity was obtained is possibly responsible for the varying 
responses581. It was previously reported that measurements of endothelium dependant vasodilation 
that included FMD and intra-brachial artery infusion with AcH did not correlate with each other725. 
Gori et al,726 also supported the finding of Eskurra et al725. This is likely due to the microvascular and 
macrovascular properties affecting each technique. FMD assess large conduit artery endothelial 
function in response to sheer stress and the latter from AcH infusion assess resistance vessel 
endothelium dependant vasodilation581. In the same study, where they measured microvascular 
reactivity by DTM and reactive hyperaemia index (RHI) with the ENDOPAT the authors found a 
surprising association with FMD as this is a measured of macrovascular reactivity,  however, they note 
that further tests would be needed to confirm this finding.  
It is of note to mention that all the current studies have made analysis of retinal vasculature with the 
use of static retinal vessel analysis that only provides a snap shot of the circulatory bed. Nevertheless, 
by being able to demonstrate that otherwise healthy individuals showing impaired peripheral 
microvascular reactivity also exhibit signs of impaired retinal vascular function, we indicate that 
endothelial dysfunction, when present, is a general process and is detectable with accuracy regardless 
of the method used or location of the vascular bed. As molecular and imaging biomarkers drive the 
shift towards personalized medicine, both retinal and peripheral  vessel reactivity can be used for 
profiling individualized vascular risk by providing an integrated and dynamic analysis of vascular 
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function as a variable specific for each individual and, therefore, to be used in prediction, prevention 
and personalised intervention. 
4.8 Conclusion 
The findings of this study showed associations between retinal and peripheral vascular 
measurements. The identification of differences in vascular function in accessible peripheral arteries 
provides a means for the early detection in pre-symptomatic groups. The clinical information gathered 
with retinal and peripheral vascular function is essential given that they can provide prognostic 
information to previously un-identified ‘at-risk’ individuals. 
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5.0 The effects of physical training on the retinal microvascular function in healthy individuals. 
5.1 Abstract 
Purpose: To assess the effect of regular physical exercise on retinal and systemic microvascular 
function in overweight individuals. 
Methods: Retinal vascular function was assessed in 20 healthy overweight volunteers by way of DVA 
and systemic vascular function with the DTM. General anthropometric measurements were also 
collected. Participants who were enrolled did a minimum of 45 mins exercise which included 30mins 
of weight lifting 4 times per week for 16 weeks. Nutritional intake was on ad libitum basis. They 
were followed up in 16 weeks for a repeat of their measurements.   
Results: In comparison to baseline measurements, subjects had an increased arterial reaction time 
to dilation (MDRT) for the first flicker cycle (p=0.001) and through 3 cycles (p=0.024) as well as 
increased reaction time to constriction (MCRT) for the second cycle (p=0.046) and through 3 cycles 
(p=0.044). Although arterial minimum constriction MC was decreased (p=0.002), overall arterial % 
constriction from baseline was increased (p=0.002) following flicker. On the venous side, MCRT and 
DA were decreased at follow up (p=0.010, and p=0.029, respectively).    
Conclusions: Retinal microvascular function was positively influenced by regular physical exercise.  
5.2 Introduction 
More individuals now have an increased propensity of being classified as overweight mainly due to 
poor dietary habits and sedentary lifestyles. Excess adipose tissue induces several metabolic 
changes, including dyslipidaemia, elevated blood pressure (BP), oxidative stress, and increased 
inflammation. In so doing these contribute towards atherosclerosis, increased arterial stiffness, and  
macro- and micro-vascular endothelial dysfunctions727-729. These changes in obesity are associated 
with higher levels of adiposity and indicate increased risk of CVD compared to controls by 60%730. It 
has been demonstrated that sedentary lifestyles consisting of very low energy expenditure, such as 
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watching TV or the use of computers, is a risk factor for increased weight gain290 731 732. More 
recently, researchers were able to predict midlife endothelial dysfunction based on factors such as, 
BMI, total cholesterol and fitness level in children, noting that these predisposing factors in 
childhood lead to adult obesity and in turn risk factors for CVD733. In addition, overweight individuals 
exhibit signs of microvascular dysfunction compared to their leaner counterparts727. A normal 
functional endothelium is critical to maintaining a normal vascular tone. When endothelial cells lose 
their ability to release NO, the amount of the constricting factors, such as ET-1, are increased and 
endothelial dysfunction ensues138. This latter step, is actually the initial step in a cascade of events 
that leads to atherosclerosis. It is known that endothelial dysfunction affects the microcirculation 
before the macrocirculation734 in the course of disease development.   With an increase in mortality 
rates due to being overweight or obese, it is proposed that those who maintain a healthy lifestyle 
with physical activity are at less risk of developing CVD. Physical exercise has been recognized as an 
important modifiable lifestyle intervention, mainly due to its effects on energy expenditure, 
reduction of adiposity579 735 736, and increasing NO bioavailability737. Indeed, studies that utilized the 
FMD technique have reported increases in endothelial function738-740 with physical exercise. Physical 
exercise also improved in the elderly. However this was only during intense bouts741 and not with 
moderate exercise. More recently, it was shown in obese women that a single session of weight 
lifting can actually decrease vasodilator function742. Hanssen et al579 measured static retinal 
photographs to determine arterio-venous ratios (AVR) after an exercise program. The results 
indicated an increase in AVR that is associated with dilatation of the arterioles, which indicates that 
individuals who exercise are at less risk of microvascular events.  
 
However, despite all this information pertaining to structural retinal assessments and the risk of 
future CVD events, there have only been measures made via static retinal photography which only 
provide a snapshot of an individual’s circulatory state. Limitations in these earlier studies can be 
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overcome by use of the dynamic retinal vessel analyser (DVA) that measures retinal diameter 
changes in real time in response to flickering light. Therefore the aim of the study was to determine 
the effects of physical training on systemic vascular function as measured by cuff-occlusive reactive 
hyperaemia (DTM) retinal microvascular function by way of DVA. 
5.3 Subjects and methods. 
Study participants were recruited through advertisements within Aston University (Birmingham, UK) 
campus, specifically the Health Clinics and Sports Centre. The inclusion and exclusion criteria for the 
participants was detailed in section 3.2.3.1. Briefly, participants that enrolled had to work out at-
least 4 times a week for 45 mins. Feeding was on an ad libitum basis. Follow up appointments were 
conducted 16 weeks after baseline measurements were performed. The investigative procedures 
performed in this study are outlined below and were conducted in accordance with the protocols set 
out in section 3.3.1.  
 1. Anthropometrics 
 2. IOP measurements 
 3. Blood pressure 
 4. Assessment of systemic vascular reactivity (DTM) 
 5. Assessment of retinal vascular reactivity (DVA) 
5.4 Statistical analysis 
All analyses were performed using Statistica® software (StatSoft Inc., Version 13, USA). Distributions 
of continuous variables were determined by the Shapiro-Wilks test. Baseline and follow up 
differences in clinical characteristics were assessed by a paired t-test. Multivariate analyses were 
performed to test the influence of clinical parameters such as age, SBP, BMI, HR on the measured 
vascular reactivity variables. Differences between baseline and follow up in retinal and systemic 
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vascular reactivity measures were computed by t-test or analysis of covariance (ANCOVA) where 
applicable, follow by a post hoc Bonferroni test. Statistical significance was defined at p < 0.05. 
5.5 Power calculations 
The sample size was calculated using the software G power709 (University of Kiel, version 3.1.6, 
Germany), Based on previous studies, normal expected retinal arterial responses to flicker-light 
stimulation have been around 6.9 ± 2.8% which is a clinically significant amount of vessel diameter 
changes651 667 710. It was anticipated that a paired t-test or ANCOVA would be required in this study 
for the baseline and follow up measurements. Therefore to provide a statistical power of 80% and 
medium effect size of 0.5 with an alpha level of 0.05, it was estimated that a sample size of n=19 
paired observations was required.  
5.6 Results 
5.6.1 Clinical characteristics 
A total of 26 participants were initially screened for study inclusion of which 6 individuals were lost to 
follow up. The remaining 20 healthy participants were included in the final analysis and repeated 
measurements were performed 16 weeks from baseline. The clinical characteristics of the study 
groups are presented in table 5.6.1. During the follow up measurements. Participants presented with 
lower SBP (p=0.006), MAP (p=0.024), and IOP (p<0.001). There were no significant differences in any 
of the other measured clinical variables. Systemic vascular assessments did not reveal any differences 
between baseline and follow up all p>0.05. 
5.6.2 Retinal vascular function measurements 
The results of the retinal vascular function parameters are presented in table 5.6.2 and 5.6.2.1. All 
values reported are based on each individual flicker cycle and averaged cycles with the artery and 
vein considered separately using traditional SDRA analysis. The dynamic retinal response profiles 
were generated using the polynomial computational analysis (Matlab; Mathworks inc, Vr2013a, 
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MA).  After controlling for all influential covariates identified in multiple regression analysis, the 
follow up parameters showed a clinically significant arterial MDRT for the first flicker cycle and when 
averaged (p=0.001, p=0.024), MC had also reduced for the first cycle and when averaged (p=0.030, 
p=0.002), % constriction from baseline had increased for the first flicker cycle and when averaged 
(p=0.027, p=0.002), Finally MCRT had also reduced for the second flicker cycle and when averaged 
(p=0.046, p=0.044 respectively) (Figure 5.6.2a). On the venous side, MCRT had reduced for the third 
flicker cycle (p=0.010), and DA had reduced for the third flicker cycle and when averaged (p=0.013, 
0.029) (figure 5.6.2b). 
 
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart 
rate; MAP, mean arterial pressure; IOP, intra ocular pressure; OPP, ocular perfusion pressure. * Significant p-
values are indicated in bold were p< 0.05 was considered significant.  
variable Baseline Follow up P value Significance
BMI (kg/m2) 27.385 (4.75) 27.355 (4.50) 0.916 -
SBP (mmHg) 133.600 (12.75) 127.550 (10.12) 0.006* 1>2
DBP (mmHg) 74.900 (7.79) 72.450 (6.22) 0.144 -
HR (bpm) 66.750 (13.04) 65.550 (11.75) 0.555 -
MAP (mmHg) 94.467 (8.20) 90.816 (6.53) 0.024* 1>2
IOP (mmHg) 14.925 (2.54) 12.25 (2.15) <0.001* 1>2
OPP 48.052 (5.85) 48.289 (3.74) 0.826 -
Mean (SD)
Table 5.6.1 Summary of clinical data
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Abbreviations: BDF, baseline diameter fluctuation; BCFR, baseline corrected flicker response;MD, maximum diameter; RTMD, reaction time to MD; % Dilation, percent 
dilation during flicker; MC, minimum constriction; % constriction, percent constriction post flicker; RTMC, reaction to MC; DA, dilation amplitude; SLopeAD, slope of arterial 
dilation; SLopeAC, slope of arterial constriction. *significant p-values are indicated in bold where p<0.05 was considered significant. 
Arteries
Baseline Baseline (1) Follow up (2) P value Significance MC Baseline (1) Follow up (2) P value Significance
F1 99.98 (0.01) 100.01 (0.01) 0.15 - F1 96.61 (0.71) 94.71 (0.60) 0.030* 1>2
F2 100.00 (0.01) 100.00 (0.01) 0.24 - F2 95.78 (0.62) 95.38 (0.54) 0.61 -
F3 100.00 (0.01) 100.02 (0.01) 0.38 - F3 96.65 (0.92) 95.42 (0.60) 0.17 -
AVG 99.99 (0.008) 100.02 (0.009) 0.07 - AVG 96.35 (0.46) 95.17 (0.40) 0.002* 1>2
BDF % constriction
F1 5.83 (0.74) 6.40 (0.59) 0.55 - F1 -3.36 (0.71) -5.30 (0.60) 0.027* 1<2
F2 6.53 (0.79) 6.01 (0.50) 0.53 - F2 -4.21 (0.62) -4.63 (0.54) 0.59 -
F3 6.17 (1.04) 4.85 (0.56) 0.13 - F3 -3.35 (0.93) -4.60 (0.60) 0.16 -
AVG 6.36 (0.78) 5.75 (0.46) 0.48 - AVG -3.64 (0.46) -4.84 (0.40) 0.002* 1<2
BCFR RTMC
F1 4.69 (0.89) 4.27 (0.64) 0.69 - F1 28.95 (2.91) 24.6 (3.08) 0.32 -
F2 2.92 (0.93) 3.52 (0.67) 0.61 - F2 29.40 (3.45) 22.65 (2.58) 0.046* 1>2
F3 2.29 (1.27) 5.13 (0.99) 0.09 - F3 27.30 (3.03) 24.15 (2.96) 0.34 -
AVG 3.30 (0.61) 4.31 (0.51) 0.17 - AVG 28.55 (2.49) 23.80 (1.97) 0.044* 1>2
MD DA
F1 107.15 (0.94) 105.39 (0.59) 0.14 - F1 25.5 (2.94) 30.55 (3.12) 0.24 -
F2 105.24 (0.56) 104.92 (0.78) 0.67 - F2 26.55 (3.69) 22.1 (3.56) 0.27 -
F3 105.65 (0.68) 105.40 (1.02) 0.83 - F3 28.1 (2.32) 27.2 (3.10) 0.68 -
AVG 106.01 (0.51) 105.24 (0.63) 0.30 - AVG 26.71 (2.47) 26.7 (1.92) 0.98 -
RTMD Slope AD
F1 23.45 (2.35) 14.05 (1.37) 0.001* 1>2 F1 0.34 (0.04) 0.48 (0.08) 0.08 -
F2 22.85 (2.83) 20.55 (1.74) 0.45 - F2 0.25 (0.02) 0.29 (0.07) 0.63 -
F3 19.20 (2.70) 16.45 (2.02) 0.34 - F3 0.37 (0.06) 0.54 (0.14) 0.14 -
AVG 21.83 (1.94) 17.01 (0.86 0.024* 1>2 AVG 0.32 (0.03) 0.44 (0.07) 0.07 -
% Dilation Slope AC
F1 7.17(0.93) 5.37 (0.58) 0.13 - F1 -0.43 (0.04) -0.61 (0.11) 0.15 -
F2 5.24 (0.55) 4.89 (0.76) 0.64 - F2 -0.43 (0.09) -0.49 (0.05) 0.92 -
F3 5.64(0.68) 5.38 (1.02) 0.81 - F3 -0.43 (0.06) -0.50 (0.05) 0.27 -
AVG 6.02 (0.50 5.21 (0.62) 0.29 - AVG -0.45 (0.05) -0.53 (0.04) 0.16 -
(SD)(SD)
Table 5.6.2 Summary of retinal vascular function parameters (arteries)
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Abbreviations: BDF, baseline diameter fluctuation; BCFR, baseline corrected flicker response;MD, maximum diameter; RTMD, reaction time to MD; % Dilation, percent 
dilation during flicker; MC, minimum constriction; % constriction, percent constriction post flicker; RTMC, reaction to MC; DA, dilation amplitude; SLopeAD, slope of arterial 
dilation; SLopeAC, slope of arterial constriction. *significant p-values are indicated in bold where p<0.05 was considered significant. 
Veins
Baseline Baseline Follow up P value Significance MC Baseline Follow up P value Significance
F1 100.00 (0.01) 99.98 (0.01) 0.181 - F1 97.84 (0.72) 97.02 (0.83) 0.516 -
F2 99.99 (0.01) 100.03 (0.01) 0.21 - F2 97.12 (0.76) 97.51 (0.53) 0.666 -
F3 100.00 (0.01) 99.99 (0.01) 0.598 - F3 98.45 (0.57) 98.63 (0.56) 0.806 -
AVG 100.00 (0.008) 100.00 (0.007) 0.976 - AVG 97.80 (0.45) 97.72 (0.55) 0.905 -
BDF % constriction
F1 4.17 (0.44) 4.02 (0.57) 0.728 - F1 -2.16 (0.73) -2.96 (0.83) 0.525 -
F2 5.10 (0.76) 4.32 (0.67) 0.42 - F2 -2.87 (0.76) -2.51 (0.54) 0.693 -
F3 4.85 (0.79) 4.09 (0.54) 0.438 - F3 -1.55 (0.56) -1.35 (0.56) 0.787 -
AVG 4.70 (0.58) 4.14 (0.49) 0.35 - AVG -2.19 (0.46) -2.28 (0.55) 0.906 -
BCFR RTMC
F1 4.50 (1.03) 3.88 (0.81) 0.59 - F1 35.10 (2.99) 30.65 (2.84) 0.244 -
F2 3.31 (0.74) 3.79 90.63) 0.547 - F2 29.65 (2.78) 31.35 (2.25) 0.396 -
F3 3.54 (1.06) 2.84 (0.92) 0.658 - F3 32.40 (2.76) 23.6 (2.89) 0.010* 1>2
AVG 3.78 (0.53) 3.50 (0.59) 0.746 - AVG 32.38 (2.01) 28.53 (1.82) 0.142 -
MD DA
F1 106.51 (0.88) 104.93 (0.56) 0.109 - F1 33.60 (3.52) 20.05 (2.70) 0.412 -
F2 105.53 (0.49) 105.63 (0.67) 0.859 - F2 28.9 (2.90) 29.65 (2.97) 0.775 -
F3 106.85 (1.56) 105.57 (0.95) 0.538 - F3 33.65 (2.61) 22.70 (3.34) 0.013* 1>2
AVG 106.30 (0.77) 105.38 (0.56) 0.32 - AVG 32.05 (1.86) 27.46 (1.69) 0.029* 1>2
RTMD Slope VD
F1 21.50 (2.17) 20.60 (1.64) 0.789 - F1 0.35 (0.05) 0.25 (0.02) 0.068 -
F2 20.75 (1.77) 21.70 (2.07) 0.735 - F2 0.41 (0.14) 0.34 90.08) 0.607 -
F3 18.75 (1.03) 20.9 (2.29) 0.402 - F3 0.33 (0.06) 0.47 (0.15) 0.459 -
AVG 20.33 (1.01) 21.06 (1.25) 0.695 - AVG 0.37 (0.06) 0.35 (0.06) 0.9 -
% Dilation Slope VC
F1 6.50 (0.88) 4.94 90.560 0.112 - F1 -0.30 (0.04) -0.33 (0.06) 0.727 -
F2 5.53 (0.49) 5.60 (0.65) 0.907 - F2 -0.35 (0.04) -0.34 (0.09) 0.951 -
F3 6.84 (1.54) 5.58 (0.94) 0.54 - F3 -0.34 (0.08) -0.86 (0.51) 0.311 -
AVG 6.29 (0.77) 5.37 (0.56) 0.316 - AVG -0.33 (0.04) -0.51 (0.17) 0.34 -
Table 5.6.2.1 Summary of retinal vascular function parameters (veins)
(SD) (SD)
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Figure 5.6.2. Retinal arterial and venous response profiles. 
(A) Arterial response, (B) Venous response. 
Abbreviations: BDF, baseline diameter fluctuation; MD, maximum diameter; MDRT, maximum diameter reaction time; MC, minimum diameter; MCRT, minimum 
constriction reaction time; MC%, percent constriction; DA, dilation amplitude, difference between MD&MC.   
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5.7 Discussion 
The present study demonstrated, for the first time, that participants engaged in physical exercise 
had a lower arterial RTMD for the first flicker provocation and overall average throughout the three 
flicker cycles compared to baseline. It was noted that the MC was lower on the first flicker cycle and 
on average while MC% was markedly increased for the first flicker cycle and on average. RTMC was 
also reduced which results in a shorter period of time required for the vasculature to return to 
baseline values. Our results show that physical exercise has positively modified  retinal 
microcirculation’s function and moreover, for the first time, we were able to show that the retinal 
microvascular reactivity can be augmented through exercise.  
Physical inactivity has been associated with reduced endothelial function which is a notable  early 
marker of atherosclerosis propensity and in turn, CVD743 744. Thus, the need for understanding how 
exercise and microvasculature function was researched.  Adipose tissue is a metabolically active 
endocrine organ and also a major source of pro-inflammatory molecules and cytokines. Current 
findings suggest that excess adipose tissue, especially in the visceral region, propagates an 
inflammatory response characterized by leukocyte infiltration745 and increased secretion of adipose 
tissue- derived pro-inflammatory adipokines (i.e. leptin and resistin)746 and well-established 
inflammatory mediators (i.e. tumor necrosis factor-alpha and interleukin-6)747 In addition, 
production of anti-inflammatory adipokines and cytokines (i.e. adiponectin and interleukin-10) is 
reduced in the presence of excess adipose tissue which exacerbates the inflammatory response748. 
The pro-inflammatory environment associated with excess adipose tissue can directly impact 
vascular endothelial function745 749. During obesity, inflammatory cytokines such as TNF-α and IL-6, 
act on leukocytes and vascular endothelial cells producing Reactive oxygen species. Excess 
production of ROS can, in turn, induce oxidative stress and endothelial dysfunction750.  
Leptin is an adipokine that is increased during obesity751 and contributes to ROS mediated 
endothelial dysfunction in human endothelial cells during weight gain752. Previous studies have 
demonstrated that circulating leptin is reduced in adults performing resistance training and 
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associated with improved conduit artery endothelial function during weight loss753 754. Impaired 
endothelial function represents a pathophysiologic mechanism linking sedentary lifestyle to CVD 
risk.  Vascular endothelial dysfunction due to increased BMI represents an early marker of 
atherosclerosis and755 and can affect the microcirculation much earlier than the macrocirculation734 
which can precede the clinical manifestations of CVD. In patients with a higher than average BMI, 
normal or mildly diseased coronary arteries was independently associated with reduced coronary 
dilation to intra-arterial infusions of ACh compared to normal patients with normal BMIs756. In 
addition, from early in life, increases in BMI have been associated with low levels of NO757 and 
elevated adult BMI has also been associated with increased carotid intima media thickness727 and 
lower retinal microvascular dilation727 as well as narrower retinal arteries and wider venular 
calibres534. Physical activity has been shown to provide a protective effect against health risks 
associated with increased BMI, conferring health benefits independent of changes in body weight or 
composition758 759 which suggests that overweight and obese individuals can obtain the same 
benefits of physical activity as normal weight individuals. 
 
Regular exercise training has been recommended as a non-pharmacologic therapeutic strategy for 
the prevention and treatment of increased adipose leading to hypertension and CVD760. It is well 
recognized that aerobic training has BP lowering effects  consistent with our findings. It was shown 
that 3 months of moderate intensity exercise training reduced systolic BP and diastolic BP in 
normotensive and previously sedentary older adults761.  An important finding of the present study 
was the detection of an improvement in retinal vessel function in response to flickering stimulus (a 
decreased RTMD and decreased RTMC and an increased % constriction) in the follow up group. It 
has previosuly been reported that decreases in BMI have been associated with increases in retinal 
vessel calibre324 579 and that exercise training has been associated with increases in microvascular 
reactivity as measured with laser doppler flowmetry762 763. Dietary factors (such as quantity and 
quality of food) have not been assessed as well as circulating markers of endothelial function in the 
136 
 
present study and this could therefore be perceived as a limitation. Other possible limitations of the 
study was that participants were relied upon actually attending and performing the exercises them 
selves without any proper supervision, nor was there a control group. It can be invisaged that not all 
participants were able to attend the gym four times a week and also possible some could have 
suffered injuries and made up the time at a later date.  
Nevertheless, this is the first report showing functional retinal vascular changes in participants 
undergoing physical exercise, opening a new opportunity for early detection and prevention of  
future cardiovascular complications. This study did not show any signs of macrovascular changes. 
This is possibly due to the macrovessels being of larger diameters and less susceptible to slight 
changes that can effect their reactivity.     
 
5.8 Conclusions 
The results indicate that exercise training is an important non-pharmocologic intervention that can 
improve microvascuar endothelial function in asymptomatic overweight individuals. It is important 
for maintaining physical fitness and is widely accepted that regular exercise provides enormous 
health benefits that can promote and sustain physiological welfare. 
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6.0 The long-lasting effects of fasting during the month of Ramadan on retinal and peripheral 
vascular function. 
6.1 Abstract 
Purpose: To assess the effect of fasting during the month of Ramadan on retinal and peripheral 
microvascular function. 
Methods: Retinal vascular function was assessed in 18 healthy, normal weight 
(BMI>18kg/m2<25kg/m2) volunteers by way of DVA and systemic vascular function by DTM. General 
anthropometric measurements were also collected. Parameters were recorded during the 3rd week 
of fasting.  Non-fasting values were established by measures performed 7-8 weeks after Ramadan.  
Results: Compared to the non-fasting status, during fasting subjects had an increase in arterial MD 
for the first flicker cycle (p= 0.043) and on average when flicker cycles were combined (p= 0.022). 
Additionally, there was also an increase in % dilation for the first flicker cycle (p=0.046) and when 
averaged through 3 cycles (p=0.022). On the venous side, Baseline diameter was increased on the 
second flicker cycle (p=0.048) but decreased when taking into account the baseline corrected flicker 
response (BCFR) for the first, third and averaged flicker cycles (p=0.041, p=0.012, p=0.007 
respectively).  
Conclusions: These findings suggest that fasting alone is an effective way of increasing the elasticity 
of retinal arterial diameters to provocation and ameliorating the venous baseline response possibly 
through an increase in endothelial function.  
6.2 Introduction 
Fasting during the month of Ramadan is one of the five fundamental pillars of Islam during which 
capable adults must fast from sunrise to sunset764 765. This type of fasting is defined as periodic food 
and water deprivation during daylight hours or the duration of the month765. Fasting itself causes a 
reduced caloric intake in which people usually resort to two meals a day rather than the typical 3 
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meals along with snacks. This reduced caloric intake has been measured to approximately 1200 
calories a day and those who partake can lose up to 2-4kg in body weight766. Studies have also 
demonstrated that individuals can experience decreases in body mass index (BMI) and waist 
circumference (WC) in both males and females766 767. More recently, studies have shown to be in 
agreement with these previous findings and have confirmed that BMI and WC do decrease768 769. In 
contrast there have also been studies which have shown no significant differences770 771. 
It has been indicated that participants who are under 36 years of age will benefit greatly during the 
period of abstinence with reductions in BMI and WC compared to older participants. A reduction in 
blood pressure also occurs310 768.  Sayeeda et al768 also demonstrated that high density lipoprotein 
(HDL-c) increased while low density lipoprotein (LDL-c) decreased despite unchanged total 
cholesterol (CHOL). A similar increase in HDL-cholesterol occurs in participants on reduced calories 
diet and physical exercise for weight loss772. All the above findings would suggest that fasting during 
Ramadan should have a beneficial effect on cardiovascular risks, where these exist.  Therefore, 
measuring endothelial function could provide important information on the benefits of fasting and 
elucidate whether fasting can be used as an intervention for the improvement in vascular function.  
The assessment of vascular and endothelial dysfunction (VED) is one very important marker for early 
CVD risk. Yousefi et al773 examined endothelial function during Ramadan fasting but mainly using 
biochemical markers rather than clinical functional measurements. While there are various blood 
biomarkers offering a disease-specific individual biological profile, none of these techniques enable 
non-invasive assessments in primary care settings while being sufficiently sensitive to enable early 
detection of endothelial dysfunction.  The main advantage of the DVA assessment is that it provides 
integrated and dynamic data analysis that is specific to each individual. In addition, its output alters 
not only by overt disease but also in the presence of more subtle risk factors for CVD578 702 703 
including ageing554, ethnicity665 and  impaired glucose tolerance704. Therefore, it is possible to use the 
assessment of retinal microvascular function as an early marker for VED. There is one other study to 
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date that recorded retinal microvascular function by way of DVA in a single case report. The authors 
stated that retinal vessel reactivity was blunted during a single day 20hr fast compared to eating a 
meal right after774.  
In addition peripheral microvascular reactivity was measured by DTM. This method was found to 
detect increased risk of atherosclerotic cardiovascular disease568 569 571, as well as improvements in 
reactive hyperaemia during acute exercise584, & surgery583. This technique has the advantage of 
being operator independent without the use of expensive ultrasound equipment allowing for use in 
community clinical settings.  Thus, the aim of our study was to determine the long-lasting effects of 
fasting during the month of Ramadan on the retinal and peripheral vascular endothelial function. As 
we are studying the long term effect of fasting, the study was designed to analyse whether the 
observed “beneficial” changes in micro-macrovascular function can be sustained beyond the end of 
Ramadan.  
6.3 Subjects and methods. 
Study participants were recruited through advertisements within Aston University (Birmingham, UK). 
The inclusion and exclusion criteria for the participants was detailed in section 3.2.4. Briefly, Initial 
fasting measurements were performed mid-day during the 3rd and 4th week of Ramadan 2016, while 
the participants were within their fasting hours. The latter weeks in Ramadan were chosen because 
the body has had time to adapt to reduced calorie intake and energy demand. Non-fasting baseline 
measurements were conducted 7-8 weeks after the last day of fasting, at the same time of the day 
when the initial measurements were performed in each of the participants. Feeding was on an ad 
libitum basis when participants break their fast at sundown. The investigative procedures performed 
in this study are outlined below and were conducted in accordance with the protocols set out in 
section 3.3.1.  
 1. Anthropometrics 
 2. Body composition 
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 3. IOP measurements 
 4. Blood pressure 
 5. Assessment of systemic vascular reactivity (DTM) 
 6. Assessment of retinal vascular reactivity (DVA) 
 
 
6.4 Statistical analysis 
All analyses were performed using Statistica® software (StatSoft Inc., Version 13, USA). Distributions 
of continuous variables were determined by the Shapiro-Wilks test. Group differences in clinical 
characteristics were assessed by a paired t-test. Multivariate analyses were performed to test the 
influence of clinical parameters such as age, SBP, BMI, HR on the measured vascular reactivity 
variables. Differences between fasting and non-fasting measurements in retinal vascular reactivity 
measures and systemic microvascular function were computed by t-test or analysis of covariance 
(ANCOVA) where applicable, followed by a post hoc Bonferroni test. Statistical significance was 
defined at p < 0.05. 
6.5 Power calculations 
The sample size was calculated using the software G power709 (University of Kiel, version 3.1.6, 
Germany). Based on previous studies, normal expected retinal arterial responses to flicker-light 
stimulation have been around 6.9 ± 2.8% which is a clinically significant amount of vessel diameter 
changes667 710. It was anticipated that a paired t-test or ANCOVA would be required in this study, 
therefore to provide a statistical power of 80% and medium effect size 0f 0.5 with an alpha level of 
0.05 it was estimated that a sample size of n=19 paired observations were required.  
6.6 Results 
6.6.1 Clinical characteristics 
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A total of 23 participants were initially screened for study inclusion and had completed all the 
baseline measurements of which 5 participants were lost to follow up. The remaining 18 healthy 
participants were included in the final analysis and repeated measurements were performed 7-8 
weeks from fasting. The clinical characteristics of the study groups are presented in table 6.6.1. 
There were no significant differences in any of the measured clinical variables between the 2 periods 
(all p > 0.05). 
Table 6.6.1. Summary of clinical data 
  Mean (SD)   
Variable Baseline Follow up P value 
N 18 (5F) - - 
BMI (kg/m2) 24.8 (5.61) 25.3 (5.58) 0.774 
BF % 25.5(9.19) 25.09(8.56) 0.891 
MM Kg 51.31 (13.08) 52.7(13.25) 0.93 
BW % 53.94(6.72) 54.24(6.43) 0.892 
SBP (mmHg) 124.83(11.22) 125.77(13.05) 0.817 
DBP (mmHg) 74.44(6.95) 70.11 (9.02) 0.115 
HR (bpm) 65.44 (10.15) 71.6(11.70) 0.096 
MAP (mmHg) 75.00 (6.93) 70.71(8.99) 0.118 
IOP (mmHg) 12.74 (2.00) 14.07(3.06) 0.131 
OPP 48.08 (5.82) 45.03 (7.40) 0.178 
Abbreviations: : BMI, body mass index; BF%, body fat percentage; MM%, muscle mass percentage;  BW%, body water 
percentage; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; MAP, mean arterial pressure; IOP, 
intraocular pressure; OPP, ocular perfusion pressure. * Significant p-values are indicated in bold where p < 0.05 was 
considered  
significant. 
 
6.6.2 Systemic vascular function  
Table 6.6.2 provides a summary of the parameters using DTM that were assessed during fasting and 
non-fasting periods and follow up. There were no significant differences in any of the measured 
clinical variables (all p > 0.05). 
Table 6.6.2 Summary of DTM measurements 
  Mean (SD)   
Parameter Baseline Follow up P value 
TR 0.68(1.51) 0.08(0.64) 0.105 
aTR 2.30(1.18) 2.15(0.69) 0.63 
AUCtr 408(256.25) 329(151.38) 0.23 
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Abbreviations: TR, temperature rebound; aTR, adjusted temperature rebound; AUCtr, area under the curve temperature 
rebound. * Significant p-values are indicated in bold where p < 0.05 was considered significant. 
 
6.6.3 Retinal vascular function measurements 
The results of the retinal vascular function parameters are presented in table 6.6.3 and 6.6.3.1. All 
values reported are based on each individual flicker cycle and averaged cycles with the artery and vein 
considered separately using traditional SDRA analysis. The dynamic retinal response profiles were 
generated using the polynomial computational analysis (Matlab; Mathworks inc, Vr2013a, MA).  After 
controlling for influential covariates identified by multiple regression analysis, there were no 
significant differences between baseline and follow up measurements on each flicker cycle or their 
averages for the following parameters; baseline, BDF, MDRT, MC, % constriction, DA, BCFR, MCRT, 
Slope AD, and Slope AC (all ANCOVA P >0.05). Nevertheless, during baseline measurements there was 
a significant difference in MD for the first flicker cycle (p= 0.043) and on average when flicker cycles 
were combined (p= 0.022). Additionally, there was also a significant increase in % dilation for the first 
flicker cycle (p=0.046) and on average when the flicker cycles were combined (p=0.022) (figure 6.6.3). 
On the venous side, there was a significant difference in the baseline parameter for the second flicker 
cycle (p=0.048), BCFR for the first flicker cycle (p=0.041), third flicker cycle (p=0.012), and combined 
averages of flicker cycles (p=0.007) (figure 6.6.3). There were no significant differences between 
baseline and follow up measurements on each flicker cycle or there averages for the following 
parameters; BDF, MD, MDRT,% Dilation, MC, MCRT, % constriction, SlopeVD, and slopeVC (all ANCOVA 
P >0.05,).  
6.7 Discussion 
The present study demonstrated, for the first time that during the period of fasting individuals had a 
higher arterial MD for the first flicker provocation and overall average throughout the three flicker 
cycles comparing to their non-fasting status. Similar results were achieved in the amount of dilation 
%, which shows that retinal arteries on average were able to dilate from baseline to MD significantly 
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better during fasting than during non-fasting period. For the retinal veins it was noted that the BCFR 
was notably stable during the fasting period as compared to the follow up which showed great   
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Abbreviations: BDF, baseline diameter fluctuation; BCFR, Baseline corrected flicker response; MDRT, reaction time to MD; % dilation, percent dilation; MCRT, reaction time 
to MC; % constriction, percent constriction; DA, dilation amplitude; SlopeAD, slope of arterial dilation; SlopeAC, slope of arterial constriction. * Significant p-values are 
indicated in bold where p < 0.05 was considered significant 
Table 6.6.3 Summary of retinal vascular function parameters (arteries)
Arteries
Baseline Baseline Follow up P Value MC Baseline Follow up P value
F1 100.03 (0.09) 100.00 (0.09) 0.326 F1 94.46 (3.25) 92.87 (4.30) 0.172
F2 100.02 (0.54) 100.03 (0.58) 0.799 F2 94.88 (3.99) 95.92 (3.85) 0.899
F3 100.01 (0.08) 100.00 (0.74) 0.783 F3 95.66 (3.39) 94.05 (5.37) 0.288
AVG 100.02 (0.03) 100.01 (0.05) 0.529 AVG 95.01 (2.87) 94.28 (3.21) 0.463
BDF MCRT
F1 8.59 (4.71) 7.82 (3.81) 0.417 F1 29.66 (11.12) 29.44 (11.95) 0.961
F2 7.75 (3.96) 6.66 (3.03) 0.193 F2 23.61 (10.84) 25.88 (11.30) 0.547
F3 8.02 (4.06) 7.22 (4.46) 0.603 F3 24.83 (10.48) 23.16 (12.05) 0.614
AVG 8.14 (2.97) 7.23 (3.31) 0.271 AVG 26.03 (6.70) 26.16 (6.47) 0.953
BCFR % constriction
F1 4.51 (3.32) 4.67 (3.07) 0.894 F1 -5.56 (3.24) -7.12 (4.28) 0.174
F2 4.40 (4.80) 3.66 (4.44) 0.645 F2 -5.13 (4.00) -4.10 (3.84) 0.902
F3 4.00 (4.03) 4.67 (4.56) 0.641 F3 -4.35 (3.37) -5.95 (5.37) 0.292
AVG 4.30 (2.00) 4.33 (2.56) 0.97 AVG -5.01 (2.89) -5.73 (3.21) 0.467
MD DA
F1 107.58 (4.22) 105.37 (3.62) 0.043* F1 30.11 (9.59) 29.44 (16.57) 0.896
F2 107.04 (2.18) 106.25 (3.45) 0.252 F2 27.44 (11.53) 24.33 (11.50) 0.316
F3 107.74 (3.19) 105.95 (3.04) 0.156 F3 25.66 (10.89) 23.83 (12.93) 0.656
AVG 107.45 (2.17) 105.85 (2.54) 0.022* AVG 27.72 (6.09) 25.87 (8.66) 0.391
MDRT SlopeAD
F1 19.55 (7.14) 20.00 (9.18) 0.867 F1 0.422 (0.27) 0.302 (0.32) 0.231
F2 16.16 (6.75) 21.55 (13.77) 0.081 F2 0.539 (0.35) 0.488 (0.54) 0.743
F3 19.22 (9.47) 19.33 (6.68) 0.962 F3 0.527 (0.47) 0.452 (0.60) 0.701
AVG 18.31 (5.79) 20.29 (5.99) 0.128 AVG 0.496 (0.23) 0.414 (0.30) 0.344
% Dilation SLopeAC
F1 7.54 (4.15) 5.36 (3.58) 0.046* F1 -0.509 (0.32) -0.51 (0.29) 0.965
F2 7.02 (2.17) 6.22 (3.43) 0.145 F2 -0.686 (0.50) -0.471 (0.23) 0.121
F3 7.72 (3.15) 5.94 (3.00) 0.152 F3 -0.609 (0.41) -0.608 (0.32) 0.996
AVG 7.43 (2.16) 5.84 (2.52) 0.022* AVG -0.601 (0.32) -0.531 (0.19) 0.441
Mean (SD)Mean (SD)
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Abbreviations: BDF, baseline diameter fluctuation; BCFR, Baseline corrected flicker response; MDRT, reaction time to MD; % dilation, percent dilation; MCRT, reaction time 
to MC; % constriction, percent constriction;  DA, dilation amplitude; SlopeVD, slope of venous dilation; SlopeVC, slope of venous constriction. * Significant p-values are 
indicated in bold where p < 0.05 was considered significant. 
 
Veins
Baseline Baseline (1) Follow up (2) P Value MC baseline follow up P value
F1 99.98 (0.06) 99.98 (0.07) 0.937 F1 97.54 (3.87) 96.12 (3.92) 0.359
F2 100.04 (0.09) 99.99 (0.05) 0.048* F2 97.80 (1.70) 97.78 (7.02) 0.988
F3 100.02 (0.07) 100.01 (0.07) 0.616 F3 96.93 (2.96) 96.04 (4.97) 0.54
AVG 100.01 (0.05) 99.99 (0.04) 0.258 AVG 97.42 (2.11) 96.65 (2.10) 0.243
BDF MCRT
F1 6.13 (2.77) 5.34 (2.66) 0.377 F1 32.55 (13.59) 32.11 (8.53) 0.919
F2 6.91 (3.09) 6.07 (2.85) 0.416 F2 35.44 (13.15) 31.33 (9.13) 0.298
F3 6.92 (3.60) 5.64 (3.53) 0.321 F3 32.5 (12.00) 33.61 (11.96) 0.804
AVG 6.65 (2.28) 5.68 (2.26) 0.069 AVG 33.5 (8.26) 32.35 (5.21) 0.682
BCFR % constriction
F1 2.50 (4.70) 6.17 (5.31) 0.041* F1 -2.44 (3.87) -3.85 (3.90) 0.357
F2 2.33 (3.62) 3.85 (3.99) 0.362 F2 -2.23 (1.68) -2.20 (7.02) 0.988
F3 2.27 (3.32) 5.63 (4.31) 0.012* F3 -3.08 (2.94) -3.97 (4.93) 0.542
AVG 2.37 (2.05) 5.22 (2.96) 0.007* AVG -2.58 (2.09) -3.34 (2.11) 0.255
MD DA
F1 106.17 (4.08) 107.65 (5.06) 0.374 F1 30.27 (12.57) 28.38 (11.95) 0.685
F2 107.06 (4.08) 107.70 (7.83) 0.787 F2 33.00 (14.52) 25.50 (17.76) 0.145
F3 106.12 (3.31) 107.31 (3.86) 0.359 F3 34.77 (12.14) 32.11 (12.93) 0.601
AVG 106.45 (2.71) 107.55 (3.68) 0.381 AVG 32.68 (7.76) 28.66 (8.21) 0.153
MDRT Slope VD
F1 22.27 (8.54) 23.72 (9.34) 0.632 F1 0.33 (0.26) 0.37 (0.32) 0.66
F2 22.44 (10.60) 25.83 (14.30) 0.205 F2 0.36 (0.23) 0.49 (0.67) 0.399
F3 17.72 (8.28) 21.5 (8.94) 0.287 F3 0.53 (0.59) 0.42 (0.31) 0.559
AVG 20.81 (6.63) 23.68 (7.23) 0.143 AVG 0.40 (0.28) 043 (0.26) 0.811
% Dilation Slope VC
F1 6.18 (4.05) 7.66 (5.04) 0.369 F1 -0.44 (0.69) -0.39 (0.25) 0.768
F2 7.01 (4.05) 7.71(7.83) 0.771 F2 -0.33 (0.22) -0.33 (0.20) 0.917
F3 6.10 (3.25) 7.30 (3.84) 0.351 F3 -0.33 (0.23) -0.46 (0.50) 0.281
AVG 6.43 (2.67) 7.56 (3.70) 0.369 AVG -0.37 (0.24) -0.39 (0.24) 0.779
Mean (SD)Mean (SD)
Table 6.6.3.1 Summary of retinal vascular function (veins)
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Figure 6.6.3. Retinal arterial and venous response profiles. 
(A) Arterial response, (B) Venous response. 
Abbreviations: AU, arbitrary units; BDF, baseline diameter fluctuation; BCFR, baseline corrected flicker response,DA (MD-MC)-(BDF); MD, maximum diameter; & Dilation, 
percent dialtion; DA, dilation amplitude. 
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variations in assessment. The BCFR was first described by Nagel et al775 and is the difference between 
the peak of dilation and constriction of the vessels accounting for the fluctuation during baseline 
resting condition and has been successively reported in other studies when comparing parameters of 
healthy individuals to that of pathology675 704. It has also been shown in the presence of vascular 
disturbances to vary significantly in smokers and vasospastic subjects672 776 777. Accordingly, this study, 
findings would indicate that the increased BCFR of retinal micro vascular function after fasting is a 
result most likely related to increased vascular tone. These results are in contrast to a previous study 
which showed a blunted dilation response after fasting774. This is most probably due to our 
participants having already been adapted to the fasting cycle rather than a single case study.   
The participants of the present study did not show any differences in anthropometrics in contrast to 
other studies778. however one study compared fasting participants to controls and did not record any 
significant changes779. Reductions in IOP due to fasting are still debatable as some studies have shown 
a reduction in IOP780-782, while others have not783 784. The participants of the present study at follow up 
did have lower IOP readings but were not significant. It may be that any benefit in IOP reduction that 
is maintained during the fasting state is absent when individuals begin their normal feeding routine. 
This however, needs further confirmation.  
In the present study a specific computational model was used to evaluate the dynamic response 
profile of the retinal micro vessels before and after fasting. The results show that participants had 
differing dilatory and constricting responses to flickering stimulation in retinal arteries and veins. This 
was the first study of its kind to determine the profile of retinal veins and arteries during fasting. The 
retinal vascular response to flickering light occurs to an increase in retinal metabolic demand and is 
predominantly a neurovascular coupling driven response670 777. It could be hypothesized that the 
altered retinal vessel activity demonstrated could be a consequence of endothelial dysfunction or a 
reduced bioavailability of NO.  The endothelium plays an integral role in the regulation of vascular 
tone, platelet activity, inflammation, leukocyte adhesion and thrombosis and is ultimately involved in 
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the development of atherosclerosis714. It exerts its effects on the surrounding vascular smooth muscle 
cells by way of vasodilation, vasoconstriction and also has pro-inflammatory and anti-inflammatory 
properties785 to maintain vascular homeostasis786. Notably, the process of atherosclerosis begins early 
in life, and endothelial dysfunction contributes to atherogenesis and precedes the development of 
morphological vascular changes787 788. It is known that the microcirculation represents the first 
vascular area to be affected by pre-clinical signs of endothelial dysfunction734 789 and early vascular 
disturbances could be anticipated to occur before they can be detected in the macro vessels.  
There has been only one study that has shown that CVD risk is reduced during fasting by assessments 
of the Framingham risk score but it was noted that participants were physically active during the 
month although the amount of activity was not recorded790.  Another study by Yousefi et al773 looked 
at the amount of Nitric oxide bioavailability after fasting had increased compared to baseline values. 
There have been other studies that looked at individual biochemical markers such as triglycerides and 
cholesterol but have revealed conflicting results791-793. This is possibly due to the fact that it has been 
revealed that individuals that come from a well-established economic country gain weight after 
fasting794 795, while losing weight is associated from being in a deprived economic country796 797.  
No functional vascular changes identified were detected during systemic endothelial assessments. 
Similar to FMD, the DTM uses ischaemia-induced reactive hyperaemia as a stimulus to induce changes 
in vascular reactivity and increased blood flow584 (schier 2013). This technique has been shown to 
strongly correlate with the Framingham risk score and coronary artery calcium568. In the present study 
trends were observed that showed individuals on average had better vascular reactivity during fasting 
but that these measured parameters were not significant after our follow up measurements (all P > 
0.05).  
There have not been any studies to date that have examined systemic endothelial function during 
fasting. Studies that have examined endothelial function as a consequence of weight loss have mainly 
focused on the effects of exercise which have shown promising results798-800.  To date majority of the 
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studies have looked at individuals before fasting and during the last week of fasting. Most studies have 
noted a difference in biomarkers, clinical, and anthropometric measurements. What would be useful 
to know is whether these improvements can be sustained beyond the end of fasting and if there is 
truly a reduction of CVD risk? 
Limitations of the present study are now considered. The amount of calories consumed was not 
recorded. This could have differed greatly between individuals. Physical exercise was not recorded 
and some of the participants were in relatively good physical shape compared to others. It would have 
been useful to know if they were still exercising. The power calculation was for 19 participants but due 
to the loss of follow up for some participants the study was slightly underpowered. Further research 
in this field should include the constituents of the diet, physical activity and at least 3 measurements 
that should encompass before fast, during, and sometime after wards to determine if any value gained 
or lost is sustainable.  
6.8 Conclusion 
In conclusion, this study demonstrated a higher MD and % dilation for retinal arteries during the 
fasting period and a decreased BCFR for retinal veins during the follow up period.  This can be 
important for individuals during phases of long term fasting for weight loss and significant health 
benefits (not only to individuals but community health practices) would arise with early detection and 
appropriate preventative management.  Retinal vasculature function of this type is non-invasive and 
gives real time indications of function or dysfunctions so that either holistic or pharmaceutical 
interventions may be applied before individuals develop cardio-vascular diseases.  
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7.0 The effect of bariatric surgery on retinal vessels structure and systemic microvascular function 
7.1 Abstract 
Purpose: To assess the effect of bariatric surgery on cardiovascular risk, retinal vessel calibre and 
endothelial function. 
Methods: A total of 29 obese participants were measured at baseline and after one year from 
bariatric surgery. General anthropometric data was collected including waist/neck circumference as 
well as circulating markers for calculation of Framingham risk score. Retinal vessel calibre 
measurements were done on a randomly selected eye. Arterial stiffness was measured by pulse 
wave analysis (PWA), and microvascular reactivity by way of DTM.  
Results: General anthropometric data was significantly decreased as expected. Additionally intra 
ocular pressure (IOP) was also reduced (p<0.001). CVD risk was significantly diminished (p<0.001). 
Central retinal artery equivalent trunk (CRAET) (p=0.003) and central retinal vein equivalent CRVE 
(p=0.007) had increased in calibre although the artery/venous ratio for the branches had decreased 
(p=0.010). Arterial stiffness had declined and peripheral microvascular reactivity improved (p<0.001, 
p=0.008 respectively).  
Conclusions: These findings suggest that bariatric surgery alone is an effective way of reducing CVD 
risk through metabolic factors as well as improving retinal vessel diameters. Augmented vascular 
reserve through improvements in endothelial function are proposed for the enhancements in retinal 
vessel calibres, peripheral microvascular reactivity and arterial stiffness. 
 
7.2 Introduction 
Maintaining an appropriate weight and active lifestyle has been encouraged globally as these lead to 
many health benefits. Studies have demonstrated the positive correlations to individual health when 
individuals are within normative values pertaining to body weight. Obesity increases the risk of 
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cardiovascular disease and is targeted when treating patients who have progressed to a diseased 
state801.  Obesity has become an important health issue. The WHO has described it as a growing global 
epidemic and has characterised it as a medical condition in which excess amount of body fat has 
accumulated which can lead to increased health problems and reduced life expectancy13. The 
prevalence of individuals who are overweight or obese is increasing rapidly in the developed world. 
The percentage of overweight or obese adults in the United Kingdom has risen sharply, increasing the 
prevalence rates as much as three to four times since the 1980’s. There has also been an increase of 
500% in obesity from 1972 to 2002 for boys and girls aged 10 years old802, though there have been 
some signs of it slowing down. It has been projected that 60% of the United Kingdoms population 
could be obese by the year 2050 if these current trends continue803. These trends appear to be related 
to the typical Western diet high that is high in trans fats804-806 and decreased physical activity804.  
Although the prevalence of people who are overweight and obese has increased for both sexes in all 
age and racial/ethnic groups, certain disparities may exist. Obesity in childhood, which is dramatically 
increasing, is a strong predictor of obesity in adulthood and studies have demonstrated that being 
overweight in early adult years is associated with a substantial incidence of obesity by middle age807. 
The causes of obesity are complex though a global consensus is that people become obese due to a 
combination of predisposed, socio-economic factors and behavioural factors including inherited genes 
that confer susceptibility, a lifestyle consisting of low levels of physical activity and consumption of 
excess calories (especially of poor nutritional value)247. Cardiovascular disease is an important health 
epidemic growing in prevalence as a result of greater childhood obesity rates and currently, 
worldwide, 10% of all children are classed as being obese or overweight15 808.  
Due to the relation between abdominal obesity and cardiovascular disease, it is useful to determine 
the waist circumference in addition to BMI. For individuals with a BMI of 25.0 to 34.9, a waist 
circumference >40 inches for men and >35 inches for women is associated with an increased risk of 
obesity-related cardiovascular disease18. Obesity plays a key role in endothelial dysfunction and 
involves either an increase (or a decrease) in any of the endothelial-related chemical messengers 
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and/or by alteration in function. The most commonly accepted endothelial dysfunction alteration 
pertains to abnormalities in the regulation of the lumen of vessels where endothelial cells within the 
lining prevent adhesion to the vessel wall in order to maintain morphology and function. However, 
any damage to the vessel wall, subsequently decreases blood vessel function809. Some examples of 
endothelial dysfunction include an increased permeation of macromolecules810,  increased or 
decreased production of vasoactive factors producing abnormal vasoconstriction/vasodilation, and 
increased pro-thrombotic and pro-coagulant activity140.  A critical balance between endothelium-
derived relaxing and contracting factors maintains vascular homeostasis. When this balance is 
disrupted, it predisposes the vasculature to vasoconstriction, leukocyte adherence, platelet activation, 
mitogenesis, pro-oxidation, thrombosis, impaired coagulation, vascular inflammation, and 
atherosclerosis714.  Endothelial dysfunction has been described in many cardiovascular and metabolic 
disorders such as hypertension, coronary heart disease, dyslipidemia, and types 1 and 2 diabetes77 698 
699. Endothelial dysfunction appears to precede the clinical manifestations of many of these 
cardiovascular disorders, hypertension for example, and also atherosclerosis, where abnormal 
vasoconstriction can be observed at the future site of plaque development544.  
An indicator that has also been used for the evaluation of endothelial dysfunction is the assessment 
of the arteriole-to-venue ratio of retinal vessels. It has been shown that the narrowing of arterial 
vessels is a marker for elevated blood pressure324 575 811 812 and the increasing diameters of retinal veins 
have been linked to obesity, metabolic syndrome and, dyslipidemia542 813 814. Thus, endothelial 
dysfunction is one of the earliest hallmarks of vascular abnormality and is measurement of is proposed 
to help detect early stage increased risk for CVD. The AVR of retinal vessels is the most important static 
parameter of endothelial function associated with CVD and is independent of classic CVD risk factors815 
816.  
It is known that reversible changes can be made with the loss of weight and decreasing central 
abdominal obesity and BMI. Bariatric surgery is the most effective treatment that reduces obesity and 
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in turn reduces an individual’s risk of CVD324 817; and is a reliable pathway to sustained and substantial 
weight-loss in morbidly obese patients818 819. Although benefits of surgery have been associated with 
a reduction in abdominal obesity and certain macrovascular complications, few studies have assessed 
the effects of bariatric surgery on the peripheral microcirculation. Therefore, the purpose of this study 
was to determine the reduction in CVD risk as measured by the Framingham risk score (FRS) and to 
determine a relationship between the amount of weight-loss and the caliber of retinal vessels.  
7.3 Methods and subjects 
Successive diagnosed obese patients with a BMI > 40 kg/m2 and listed for surgery were recruited 
from the Birmingham Heartlands Hospital, Heart of England Foundations Trust (HEFT, UK) weight 
management clinics by a specialist consultant. The inclusion and exclusion criteria for the 
participants was detailed in section 3.2.2. Initial baseline measurements were performed 1 month 
prior to the participant undergoing surgery. Additional circulatory markers were also included for 
the calculation of the Framingham risk score (section 3.3.6). Follow-up measurements were 
conducted 12 months after, at the same time of day when the initial measurements were performed 
in each of the participants. The investigative procedures performed in this study are outlined below 
and were conducted in accordance with the protocols set out in section 3.3.1.  
 1. Anthropometrics 
 2. IOP measurement  
 3. Blood pressure  
 4. Assessment of systemic vascular reactivity (DTM) 
 5. Assessment peripheral arterial stiffness (PWA) 
 6. Assessment of retinal vessel calibre (DVA) 
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7.4 Statistical analysis 
All analyses were performed using Statistica® software (StatSoft Inc., Version 13, USA). Distributions 
of continuous variables were determined by the Shapiro-Wilks test. Group differences in clinical 
characteristics were assessed by a paired t-test. Multivariate analyses were performed to test the 
influence of clinical parameters such as age, SBP, BMI, HR and circulating markers such as CHOL, 
HDL, LDL, and HbA1c on the measured vascular reactivity variables. Differences between groups in 
retinal calibre and systemic vascular reactivity measures were computed by t-test or analysis of 
covariance (ANCOVA) where applicable. Statistical significance was defined at p < 0.05. 
7.5 Power calculations 
The sample size was calculated using the software G power709 (University of Kiel, version 3.1.6, 
Germany). Based on previous studies, retinal vessel calibres  in healthy individuals have a mean 
diameter of 202.3um that vary 10-15um but can change up to 30% with pathology324 820 821. Pulse wave 
analysis is also known to change by 4.8% for every 10bpm in heart rate353. Additionally, DTM 
measurements in healthy individuals have been known to change in temperature between 2.4 +/- 
1.60c361. It was anticipated that a paired t-test or ANCOVA would be required in this study, therefore 
to provide a statistical power of 95% and large effect size 0.7 with an alpha level of 0.05 it was 
estimated that a sample size of n=23 participants were required.  
7.6 Results 
7.6 1 Clinical characteristics 
A total of 40 participants were initially screened for study inclusion and had completed all the 
baseline measurements of which 11 participants were lost to follow up. The remaining 29 obese 
participants were included in the final analysis and repeated measurements were performed 12 
months from baseline. The clinical characteristics of the study groups are presented in table 7.6.1.  
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Bariatric surgery resulted in a significant mean reduction in BMI (10.82 kg/m2; ⸗22%; p<0.001), as 
well as, reductions in WC (25.13cm; ⸗18%; p<0.001), and NC (4.55cm; ⸗10%; p<0.001). Reductions in 
SBP (15.49mmHg; ⸗11%; p<0.001), DBP (5.62 mmHg; ⸗7%; p=0.039), HR (4.93bpm; ⸗7%; p=0.046), 
and interestingly IOP reduced (2.42 mmHG; ⸗16%; p<0.001) were also observed. 
Bariatric surgery also resulted in significant improvements in mean fasting glucose GLUC (0.38mol/L; 
⸗6%; p=0.004). Lipid profile also showed improvements with reduction in total cholesterol, CHOL 
(0.37 mmol/L; ⸗8%), LDL-C ( 0.48mmol/L; ⸗16%; p<0.001), TG (0.31mmol/L; ⸗21%; p=0.002), and 
increases in HDL-C (0.27mmol/L; ⸗21%; p<0.001).  
Amelioration of CVD risk as was observed with a 42% reduction in FRS (p<0.001).    
7.6.2 Systemic vascular function  
Table 7.6.2 provides a summary of the systemic investigations using DTM and PWA that were 
assessed at baseline and follow up. Bariatric surgery resulted in an amelioration of endothelial 
dysfunction through mean increases in DTM parameters, specifically aTR (0.68; ⸗39%; p=0.08), and 
AUCtr (96.45; ⸗36%; p=0.025). Additionally arterial stiffness, as measured with PWA, also decreased 
(5.69; ⸗22%; p<0.001 respectively).  
7.6.3 Retinal microcirculation 
Bariatric surgery resulted in an improvement in CRAE T (5.61µm; ⸗4%; p=0.003), and conversely a 
deterioration in CRVE (8.52µm; ⸗4%; p=0.007), and AVR B (2.58µm; ⸗4%; p=0.010 respectively). Table 
7.6.3 provides a summary of the retinal vessel calibres that were assessed at baseline and follow up. 
7.6.4 Correlations between retinal vessel calibres and systemic parameters. 
In the follow up group, decreases in SBP and DBP were associated with increases in CRAE T (r= -0.62, 
p<0.001, r= -0.70, p<0.001), whereas increases in HDL-C were associated with increases in CRAE T (r= 
156 
 
0.46, p=0.011 respectively) (figure 7.6.4). However, a similar trend was not observed in the baseline 
group. No other within group correlations were identified all (P >0.05). 
Abbreviations: : BMI, body mass index; WC, waist circumference; NC, neck circumference; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate;  IOP, intraocular pressure; OPP, ocular 
perfusion pressure; CHOL, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein 
cholesterol; TG, triglycerides; GLUC, glucose.  * Significant p-values are indicated in bold where p < 0.05 was considered 
significant 
 
 
Abbreviations: TR, temperature rebound; aTR, adjusted temperature rebound; AUCtr, area under the curve temperature 
rebound; Alx, augmentation index.  * Significant p-values are indicated in bold where p < 0.05 was considered significant. 
 
Variable Baseline Follow up P-value Significance
BMI (kg/m2) 49.2 (7.69) 38.38 (7.84) <0.001* 1>2
WC cm 137.17 (20.42) 112.04 (24.21) <0.001* 1>2
NC cm 42.58 (4.74) 38.03 (4.18) <0.001* 1>2
SBP (mmHg) 144.24 (14.35) 128.75 (13.23) <0.001* 1>2
DBP (mmHg) 78.96 (11.35) 73.34 (10.84) 0.039* 1>2
MAP (mmHg) 100.72 (10.58) 92.48 (10.94) <0.001* 1>2
HR (bpm) 74.10 (13.45) 69.17 (9.88) 0.046* 1>2
IOP (mmHg) 15 (2.40) 12.58 (1.95) <0.001* 1>2
OPP 52.14 (8.01) 49.06 (8.11) 0.026* 1>2
CHOL (mmol/L) 4.90 (1.21) 4.53 (0.97) 0.003* 1>2
HDL-C (mmol/L) 1.24 (0.35) 1.51 (0.40) <0.001* 1>2
LDL-C (mmol/L) 2.97 (1.01) 2.49 (0.81) <0.001* 1>2
TG (mmol/L) 1.44 (0.72) 1.13 (0.50) 0.002* 1>2
GLUC (mmol/L) 5.75 (0.75) 5.37 (0.42) 0.004* 1>2
FRS % 12.00 (7.73) 6.51 (5.17) <0.001* 1>2
Mean (SD)
Table 7.6.1. Summary of clinical data
Parameter Baseline Follow up P- Value Significance
TR 0.05 (1.05) 0.38 (1.42) 0.283 -
aTR 1.71 (1.02) 2.39 (1.04) 0.008* 2>1
AUCtr 264.51 (159.18) 360.96 (181.40) 0.025* 2>1
Alx 25.79 (8.85) 20.10 (10.45) <0.001* 1>2
Mean (SD)
Table 7.6.2. Summary of systemic vascular function
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Abbreviations: CRAE T, central retinal artery equivalent-Trunk; CRAE B, central retinal equivalent- Branch; CRVE, central 
retinal vein equivalent; AVR T, arteriolar to venular diameter ratio-Trunk; AVR B, arteriolar to venular diameter ratio- 
Branch. * Significant p-values are indicated in bold where p < 0.05 was considered significant. 
 
7.6.5 Results of differences between surgical procedures 
Although there was a significant difference in the amount of participants between the Bypass group 
compared to the Sleeve and the Band p=0.002, the surgical procedures as described in section 
(1.4.3) did not reveal much differentiation between the measured anthropometric, systemic and 
retinal measurements. However, participants that underwent the sleeve procedure had a more 
favourable outcome of reducing total CHOL p=0.028 and reducing LDL-C compared to the other 
groups. However, this latter finding was borderline and not significant Table (7.6.5). 
Parameter baseline follow up P -value Significance
CRAE T µm 143.70 (13.97) 149.31 (12.05) 0.003* 2>1
CRAE B µm 136.95 (15.67) 137.02 (13.42) 0.968 -
CRVE µm 204.72 (23.26) 213.24 (20.75) 0.007* 2>1
AVR T µm 70.60 (6.61) 70.33 (5.95) 0.802 -
AVR B µm 67.31 (7.62) 64.73 (7.89) 0.01* 1>2
Mean (SD)
table 7.6.3. Summary of retinal vessel calibres
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Abbreviations: BMI, body mass index; WC, waist circumference; NC, neck circumference; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate;  IOP, intraocular pressure; OPP, ocular perfusion 
pressure; CHOL, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; 
TG, triglycerides; GLUC, glucose; TR, temperature rebound; aTR, adjusted temperature rebound; AUCtr, area under the 
curve temperature rebound; Alx, augmentation index; CRAE T, central retinal artery equivalent-Trunk; CRAE B, central 
retinal equivalent- Branch; CRVE, central retinal vein equivalent; AVR T, arteriolar to venular diameter ratio-Trunk; AVR B, 
arteriolar to venular diameter ratio- Branch. * Significant p-values are indicated in bold where p < 0.05 was considered 
significant. Differences are calculated for baseline and follow up between the 3 different surgical procedures. 
Procedure Bypass Sleeve Band P value Significance
N 17 5 7 0.002 -
BMI (kg/m2) -11.57 (3.66) -7.79 (2.43) -10.28 (4.76) 0.162 -
WC cm -26.91 (23.22) -21.64 (16.10) -23.28 (9.72) 0.839 -
NC cm -4.88 (2.28) -3.00 (2.12) -4.64 (1.02) 0.207 -
SBP (mmHg) -14.11 (14.32) -21.00 (15.00) -14.85 (6.76) 0.587 -
DBP (mmHg) -5.88 (12.51) 1.4 (14.44) -5.87 (5.04) 0.454 -
MAP (mmHg) -8.62 (11.51) -6.06 (12.51) -8.85 (5.35) 0.880 -
HR (bpm) -9.00 (13.64) 5.40 (9.12) 2.42 (7.56)) 0.064 -
IOP (mmHg) -2.52 (2.06) -1.80 (2.68) -2.57 (2.93) 0.820 -
OPP -3.22 (7.66) -2.24 (8.21) -3.33 (5.34) 0.961 -
CHOL (mmol/L) -0.12 (0.49) -0.86 (0.76) -0.57 (0.50) 0.028* 2>1
HDL-C (mmol/L) 0.31 (0.25) 0.28 (0.34) 0.16 (0.14) 0.402 -
LDL-C (mmol/L) -0.27 (0.55) -1.02 (0.56) -0.58 (0.63) 0.050 -
TG (mmol/L) -0.37 (0.55) -0.28 (0.17) -0.15 (0.46) 0.609 -
GLUC (mmol/L) -0.24 (0.66) -0.58 (0.64) -0.55 (0.57) 0.419 -
FRS % -5.22 (4.05) -8.36 (3.16) -4.07 (2.08) 0.127 -
TR 0.56 (1.43) 0.85 (1.48) -0.66 (1.77) 0.158 -
aTR 0.87 (1.09) 1.05 (1.74) -0.05 (1.29) 0.220 -
AUCtr 114.64 (180.92) 195.60 (315.21) -18.57 (219.44) 0.224 -
Alx -6.64 (7.88) -4.80 (5.89) -4.00 (5.65) 0.683 -
CRAE T µm 6.45 (11.28) 0.82 (8.86) 6.98 (3.64) 0.482 -
CRAE B µm -2.53 (10.26) 0.40 (7.24) 6.17 (9.92) 0.159 -
CRVE µm 8.01 (17.99) 7.52 (12.88) 10.46 (13.92) 0.936 -
AVR T µm 0.53 (6.33) -2.51 (5.10) -0.58 (3.87) 0.572 -
AVR B µm -3.39 (5.94) -2.50 (3.28) -0.63 (3.41) 0.494 -
Table 7.6.5.  Summary of different surgical procedures
Mean (SD)
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Figure 7.6.4. Correlation between SBP, DBP, HDL-C and CRAE T in the follow up subjects. 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high  
Density lipoprotein cholesterol; CRAE T, central retinal artery equivalent-Trunk. 
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7.7 Discussion 
The results show that bariatric surgery has made improvements in the retinal microcirculation 
through an improvement in the CRAE T, which are consistent with other studies324 579. This confirms 
that there is a marked reduction in peripheral arterial stiffness as measured with PWA. Bariatric 
participants, as expected, also benefited from a significant reduction in anthropometrics and shown 
for the first time, that post occlusive reactive hyperaemia was improved with the novel DTM.  
 
Classically, increasing diameters of retinal venules have been linked to obesity, metabolic syndrome, 
systemic inflammatory markers, and dyslipidemia575 813 814. Large observational studies have 
established an association of arterio-venous ratio AVR with cardio-vascular disease (CVD), in part 
independent of classical cardiovascular risk factors815 816. A clinically assessable indicator of vascular 
disease is the AVR of retinal vessels. Narrowing of retinal arteries is a marker of chronic damage 
from elevated blood pressure811 822 823 as in the results also showed the positive relationship between 
SBP and CRAE T, and DBP and CRAE T. Interestingly, an increase in venular diameter (CRVE) was 
found after bariatric surgery while other studies have reported the decrease in diameter after 
interventions324 579. Additionally the overall ratio for the trunk arterioles did not change. This was 
due to the fact that our venular diameters had increased and consequently had also affected the 
ratio for the branches (AVR B) resulting in a decrease after bariatric surgery. Arterial stiffness, which 
is characterized by the loss of elasticity and increased rigidity owing to the formation of 
atherosclerotic lesions, was also suggested as a biomarker for primary and secondary CVD 
prevention824. AIx has been a recognized marker of CVD risk and an indicator of arterial stiffness825. 
Increased arterial stiffness was identified as a risk factor for all-cause mortality and cardiovascular 
disease in recently published papers referring to the different risk factor groups and examined 
populations such as like obese children826-828 and individuals with metabolic syndrome and its 
components829 830. Furthermore, the principal atherogenic lipoprotein in the blood is the LDL, and 
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has been implicated in obesity in many studies272 831 832. Increased levels of LDL promote cholesterol 
accumulation and an inflammatory response in the artery wall, which drives the process of 
atherosclerosis and in turn increases arterial stiffness by promoting the cellular outflow of 
cholesterol. Conversly, HDL opposes this process and reduces inflammation833 834. The results show 
that obese individuals benefited from decreases in arterial stiffness and LDL cholesterol with gains in 
HDL cholesterol.  
Clinical studies have shown that endothelial dysfunction is manifested by impaired vascular 
reactivity, which can be measured by assessing flow mediated dilation (FMD) using non-invasive 
techniques such as brachial artery reactivity testing835 836. While FMD is a non-invasive measurement 
of vascular reactivity and endothelial-dependent vasomotion382, this technique is dependent on 
technical expertise and expensive ultrasound equipment, thereby restricting it to a vascular research 
laboratory. Previous studies by Dhindsa et al581 found that DTM parameters were significantly 
associated with FMD suggesting that DTM may be used as an alternative approach to FMD. Indeed, 
DTM has previously been positively correlated with the FRS, CAD568 and, Doppler flow velocity525. 
DTM responds to both the macro- and microvascular reactivity. The macrovascular reactivity 
component is attributed to the dilation of the macrovessels induced by the vasodilatory response to 
increased shear stress levels caused by surge in flow rates (RH) postocclusion which is primarily NO 
mediated581 837. RH plays a pivotal role in delivering oxygen to the ischemic tissues in order to 
maintain the homeostatic balance of the vasculature838. The microvascular reactivity is induced by a 
macrovascular response to brachial occlusion and is primarily responsible for the amount of 
peripheral resistance582. 
The current study demonstrated that fingertip TR, as measured by DTM, increased after bariatric 
surgery, possibly though an increase in NO bioavailability. Indeed, reactive hyperaemia after a period 
of ischemia is a physiologic response of the vasculature and endothelial system that results in rapid 
increases in local blood flow and temperature352 571 839. This is strongly dependent on the degree of 
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endothelium-derived nitric oxide release following local ischemic stress571 837. However, an increase 
in AUCtr, which corresponds to faster temperature rebound response after induced ischemia, is a 
marker of improved endothelial function because blood traveling through more elastic vessels takes 
a longer time840.  
The increase in CRAE with the additional benefits of improved endothelial function and decreases in 
arterial stiffness as well as, reduction in the FRS point towards a favourable outcome for obese 
individuals, and this reduction in risk (⸗40%) was similar in other studies assessing CVD risk after 
bariatric surgery324 841. It should be noted that the participants during the follow up period were still 
registered as obese due to BMI not falling below 30kg/m2. Participants are at decreased risk 
compared to baseline values but are perhaps more at risk when compared to people of normal 
weight. This could also be perceived as a limitation to this study in that controls with less BMI were 
not measured. Other limitations that could have modified our results were exercise habits of the 
individuals and the precise calorie intake, both of which were not recorded. Additionally, there were 
unequal numbers of participants in the surgery groups, any findings would need to be confirmed in a 
larger study.  
7.8 Conclusion 
In conclusion, our study shows that bariatric surgery can significantly decrease morbid obesity and 
reduce CVD risk through improvements in retinal arteriolar calibre and systemic endothelial 
function.  Further enhancements to participants’ habitual diet and exercise as well as advice on the 
psychology of sedentary behaviour must be reinforced to the patient.
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8.0. Is there an improvement in anterior ocular health after bariatric surgery? 
8.1 Abstract 
Purpose: To assess the effect of bariatric surgery on the anterior ocular surface. 
Methods: A total of 29 obese participants were measured at baseline and followed up one year after 
bariatric surgery. General anthropometric data were collected including serum lipid markers of 
cholesterol. Anterior eye measurements were taken with the keratograph (K5M, Optikgerate GmbH, 
Wetzlar, Germany) instrument and included tear meniscus height (TMH), tear break up time (TBUT), 
bulbar/limbal redness and infrared meibography. Staining was evaluated using fluorescein and 
lissamine green. 
Results: There were no differences between any of the measured clinical variables measured at the 
5% significance level. There were tendancies for a reduced TMH and a decrease in Meibomian gland 
drop out after bariatric surgery, but these were insignificant (p>0.05). 
Conclusions: Weight reduction through bariatric surgery did not have an effect on ocular health. 
Further study is warranted to determine if Meibomian gland loss can be reduced.   
 
8.2 Introduction 
Obesity has been gaining much attention over the past few decades and it has been reaching 
epidemic proportions within the western world. Obesity is an established risk factor for the 
development of cardiovascular diseases such as hypertension, diabetes mellitus, coronary heart 
disease18. It is typically associated with the western diet which is low in nutritional value but 
excessively high in saturated fats. The World Health Organization (WHO) has defined obesity as BMI 
greater than 30 kg/M2 and the current international obesity task force has estimated that worldwide 
there are around 325 milliion people who meet this criterion18. The impact of obesity on health and 
its deleterious effects on the body are well known842. There have been studies which have tried to 
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establish associations between obesity and ocular pathologies such as glaucoma, through increased 
IOP843 844, cataracts, by way of increased BMI845 846, and diabetic retinopathy574 847. The associations 
found, however, have mainly been due to obesity related risks of systemic diseases that manifest 
themselves through retinopathy. For example, diabetes is a risk factor for the development of 
cataracts earlier on in life. Less, however, is known about the impact of obesity on the tear film and 
ocular surface health. Dry eye syndrome is a multifactorial disease of the ocular surface which 
results in symptoms of discomfort, visual disturbance and tear film instability328. It can be brought 
upon by certain medications, poor nutritional diets333, contact lens wear and also laser refractive 
surgery848. More recently, Floppy Eyelid Syndrome (FES) has been associated with ocular surface 
disease resulting in dry eyes and a number of studies have attributed this to the severity of disease 
progression849 850. This is important because the number one risk factor for the development of FES is 
obesity.  
 A study by Caffery et al330 looked at the diet within the western world and its influence on tear 
function. In this review more than 25 years ago, it was noted that the maintenance of a healthy tear 
film requires sufficient amount of protein and vitamin A. Within the western world protein intake is 
not the problem as there is an abundant supply. The real problem lies with the vitamins and 
minerals which are part of a balanced diet and this was hypothesized to be the problem of 
maintaining a healthy tear film. More recently, elevated amounts of serum lipids were associated 
with dry eyes in the Beaver Dam eye study331 and in the Taiwan nationwide population based 
survey332. However, there was no link with obesity or BMI. The link between higher serum lipid levels 
and ocular deposition is well established for manifestations such as corneal arcus and 
xanthelasma333 334.  However, the exact mechanism for the association between dry eye syndrome 
and obesity has yet to be elucidated. A study by Dao et al335 identified high serum lipid levels as a 
risk factor for the development of Meibomian gland dysfunction. However, this was identified as 
elevated HDL levels. Along this line, another study by Uchino et al338 found the prevalence of dry eye 
syndrome was higher in men with a low BMI than women. A further study by modulo et al340, 
165 
 
conducted on mice, found no association between serum cholesterol levels and dry eye syndrome 
but noticed that males who were fed a higher fat diet secreted less tears, though the tests that were 
involved were probably not sensitive enough to detect changes in serum cholesterol levels.  
The tear film plays a vital role in the maintenance of ocular health by keeping the cornea lubricated. 
The meibomain glands are responsible for the secretion of the lipid layer, which helps the aqueous 
from evaporating too quickly. The tear films stability can be assessed through different methods 
including tear break up time (TBUT), its volume through the schirmer test or measurement of the 
meniscus height. Staining is also a reliable indicator of an irregular tear film through drying of the 
corneal and conjunctival surface. A comprehensive review of these methods has already been 
published in the DEWS report 2007328.     
Among the various methods developed to measure dry eyes, the keratograph features as a non 
invasive method that allows for simultaneous evaluation of the corneal tear film, bulbar and 
palpebral conjunctival surfaces as well as an infrared sensor to measure meibography. It has in-built 
software that analyses hyperaemia, based on the Efron grading scale. It has been used within the 
last few years within specialist ophthalmic departments for the evaluation of corneal topography 
before and after surgery, specialist contact lens fitting and dry eye disease management. The main 
advantage of the keratograph is that it provides integrated and dynamic data analysis that is specific 
to each individual and can be used to show patients’ progress during any regiments or to help in the 
understanding of certain ocular conditions. Therefore, the aim of this study was to use the 
keratograph for ocular health assessment of obese individuals before and after bariatric surgery.   
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8.3 Methods and Subjects 
Successive diagnosed obese patients with a BMI > 40 kg/m2 and listed for surgery were recruited 
from the Birmingham Heartlands hospital, Heart of England Foundations Trust (HEFT, UK) weight 
management clinics by a specialist consultant. The inclusion and exclusion criteria for the 
participants was detailed in section 3.2.2. Briefly, initial baseline measurements were performed 1 
month prior to the participant undergoing surgery. Measurements of circulatory markers were also 
included to determine their relationship with anterior eye health. Follow-up measurements were 
conducted 12 months after, at the same time of day when the initial measurements were performed 
in each of the participants. The investigative procedures performed in this study are outlined below 
and were conducted in accordance with the protocols set out in section 3.3.1.  
 1. Anthropometrics 
 2. Assessment of anterior eye health (keratograph) 
8.4 Statistical analysis 
All analyses were performed using Statistica® software (StatSoft Inc., Version 13, USA). Distributions 
of continuous variables were determined by the Shapiro-Wilks test. Group differences in clinical 
characteristics were assessed by a paired t-test. Multivariate analyses were performed to test the 
influence of clinical parameters such as age, SBP, BMI, HR and circulating markers such as CHOL, 
HDL, and LDL on the anterior eye variables. Differences between groups in ocular health were 
computed by t-test or analysis of covariance (ANCOVA) where applicable. Statistical significance was 
defined at p < 0.05. 
8.5 Power calculations 
The sample size was calculated using the software G power709 (University of Kiel, version 3.1.6, 
Germany). As this is the first study of its kind, power calculations were based on similar studies that 
used the Keratograph system for the assessment for dry eye disease and infrared meiobography629 
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680 851 852. Nevertheless, It was anticipated that a paired t-test or ANCOVA would be required in this 
study, therefore to provide a statistical power of 80% and medium size of 0.5 with an alpha level of 
0.05 it was estimated that a sample size of n=27 participants were required. Therefore, the recruited 
participants from the previous study would suffice for the sample size.  
8.6 Results 
8.6.1 Clinical characteristics 
A total of 40 participants were initially screened for study inclusion and had completed all the 
baseline measurements of which 11 participants were lost to follow up. The remaining 29 obese 
participants were included in the final analysis and repeated measurements were performed 12 
months from baseline. The clinical characteristics of the study groups are presented in table 8.6.1 
and have previously been described in the previous chapter (section 7.6.1).  
8.6.2 Anterior ocular health 
Bariatric surgery did not improve any of the anterior ocular health measurements. However, there 
was a tendancies for TMH to be reduced at the follow up which would point towards a reduced 
TBUT but no changes in TBUT were recorded. Additionally, there was also a trend for the 
amelioration of meibomian gland drop out but this was also non-significant (table 8.6.2). 
No correlations were identified in within group analysis all p>0.05. 
8.7 Discussion 
This study was the first to look at anterior eye health changes in obese subjects undergoing bariatric 
surgery. No identifiable changes were measured at the ocular level at 1-year follow up post 
reduction in obesity.  
 
168 
 
 
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure;  
MAP, mean arterial pressure; HR, heart rate; CHOL, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, 
low density lipoprotein cholesterol; TG, triglycerides. * Significant p-values are indicated in bold where p < 0.05 was 
considered significant.  
 
 
Abbreviations: TMH, tear meniscus height; NIKBUT, non-invasive keratography break up time; MGD, Meibomian gland 
dyfunction; NAFL, sodium fluorescein. * Significant p-values are indicated in bold where p < 0.05 was considered 
 
The tear film is essential for maintaining the health of the ocular surface and is an important optical 
element which ensures a smooth refracting surface853. It forms a complex and stable hydration and 
nutrient delivery system for the ocular surface. As a result, the instability of a disrupted tear film 
may compromise ocular health and lead to dry eye syndrome630.  
variable Baseline Follow up P-value Significance
BMI (kg/m2) 49.2 (7.69) 38.38 (7.84) <0.001* 1>2
SBP (mmHg) 144.24 (14.35) 128.75 (13.23) <0.001* 1>2
DBP (mmHg) 78.96 (11.35) 73.34 (10.84) 0.039* 1>2
MAP (mmHg) 100.72 (10.58) 92.48 (10.94) <0.001* 1>2
HR (bpm) 74.10 (13.45) 69.17 (9.88) 0.046* 1>2
CHOL (mmol/L) 4.90 (1.21) 4.53 (0.97) 0.003* 1>2
HDL-C (mmol/L) 1.24 (0.35) 1.51 (0.40) <0.001* 1>2
LDL-C (mmol/L) 2.97 (1.01) 2.49 (0.81) <0.001* 1>2
TG (mmol/L) 1.44 (0.72) 1.13 (0.50) 0.002* 1>2
Mean (SD)
Table 8.6.1. Summary of clinical data
Parameter Baseline follow up P-value
TMH (mm) 0.30 (0.10) 0.27 (0.08) 0.074
NIKBUT
First (s) 10.08 (7.08) 10.29 (6.72) 0.875
Average (s) 11.92 (6.71) 12.14 (6.53) 0.849
REDNESS
Bulbar temp. 0.86 (9.36) 0.86 (0.44) 0.952
bulbar nasal 0.99 (0.47) 0.93 (0.41) 0.451
Limbal temp. 0.57 (0.32) 0.57 (0.39) 0.948
limbal nasal 0.71 (0.33) 0.62 (0.32) 0.082
MGD
Superior loss % 22.12 (11.73) 18.64 (10.88) 0.062
Inferior loss % 16.99 (9.94) 14.39 (11.06) 0.181
NAFL staining % 1.76 (2.46) 2.73 (4.53) 0.333
Lissamine staining % 12.10 (9.32) 11.03 (4.72) 0.372
Mean (SD)
Table 8.6.2. Results of anterior eye measures
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Hypercholesterolemia is considered to be related to MGD854. One study reported that patients with 
moderate to severe MGD had significantly higher total cholesterol than the controls854 It was 
suggested that the increased concentration of cholesterol increased viscosity and induced 
meibomian plugging, aggravating MGD599 848. It is well known that severe MGD can induce dry eye 
symptoms328. In addition Hypercholesterolemia was associated with dry eye disease in the Beaver 
Dam Eye Study331 and in the Taiwan nationwide population- based survey569. Further population-
based studies have found that dry eye syndrome was more prevalent with a decreased BMI338. 
There have been a few studies that looked at diet intervention on ocular surface disease but human 
studies are scarce. There was a single case study that reported gradual improvement in tear volume 
in a subject on a calorie restricted diet for approximately eight years855 but this is not really feasible 
and cannot translate into today’s world. Whole-body hydration may be an important consideration 
for the tear film. One study concluded that religious fasting has no effect on tear stability and 
volume856, while others showed an increased tear secretion rate following the pre-dawn meal during 
Ramadan857. Experimental rodents fed on calorie-restricted diets for 6 months showed increased 
tear volume and lacrimal gland acinar density as well as decreased ocular surface staining and 
lacrimal gland inflammatory cell density858.  
8.8 Conclusion 
In conclusion, the results showed no effect of bariatric surgery on anterior eye and ocular surface 
health. This is perhaps due to the cohort having relatively good tear secretion as measured by TBUTs 
greater than 10 seconds and a TMH greater than 0.20mm. The meibomian glands lipid secretion 
allows the tears to stay on the ocular surface and prevent evaporation and is the reason why our 
participants’ had a longer TBUT. The staining of fluorescein and lissamine green was minimal to 
begin with and no change was noticed after the intervention. Although obesity is a possible risk 
factor for FES, this would have been indicated through increased bulbar redness and staining. 
Neither of which were present in the cohort.  
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9. Summary and conclusions  
Evaluating the importance of retinal and systemic vascular risk factors in terms of the aetiology 
stemming from overweight and obese individuals has been a research area of interest for some 
time. The scientific literature relating to this has been reviewed in Chapter 1 of this thesis.  However, 
it is still unclear how disturbances within the vasculature, affecting multiple vascular beds, may 
interrelate to increase the risk from overweight to obese persons, and whether weight management 
interventions can reduce the risk through augmented vascular reserve or improve endothelial 
function.  Further questions arise when considering how valid the assessment of vascular function at 
the ocular level may be as an indicator of endothelial dysfunction systemically.  
Revealing or confirming these relationships could not only enhance aetiological understanding of 
early CVD risk but also provides insight into the intervention outcomes. It could also potentially open 
up new diagnostic or therapeutic avenues for overweight and obese individuals. Therefore, this 
study was concerned with investigating the presence, impact, and interactions of ocular and 
systemic vascular alterations in healthy, overweight, and obese individuals to ascertain how they 
may relate to increases in CVD risk and whether weight-loss interventions can ameliorate a person’s 
risk profile.  
The findings of this work were: 
9.1 The relationship between retinal and peripheral vascular function in healthy individuals with 
low cardiovascular risk. 
The uses of predictive models are indicated as preliminary steps for assessing each individual’s CVD 
risk. However, such methods rely on measurements that are useful in predicting long-term risk 
assessment in populations and not in individuals with specific genetic and environmental influences. 
As a direct result, such risk calculators either over- or underestimate risks in more than 50% of 
individuals. Indeed, while there are various biomarkers offering a disease-specific individual biological 
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profile, none of these techniques enable non-invasive assessments in primary care settings while 
being sufficiently sensitive to enable early detection and prevention. It would be useful to know, 
however, that regardless of the microvascular bed assessed, that existing methods are equally 
sensitive to detecting signs of early CVD risk. Therefore, the aim of the present study was to investigate 
the relationship between retinal microvascular function and peripheral vascular reactivity in 
apparently healthy, normotensive, individuals with no known history of cardiovascular disease.  
Post dynamic retinal vascular analysis, impairments in peripheral microvascular reactivity also 
exhibit signs of impaired retinal vascular function demonstrated by an abnormal arterial MDRT, 
slopeAC, and DA responses. This behaviour was not demonstrated in individuals without peripheral 
microvascular function abnormalities. Furthermore, the dysfunction measured at the retinal 
microvascular level correlated with similar changes in the peripheral circulation. Causes of the 
retinal vascular alterations identified in this study can only suggest that ED, when present, is a 
general process and is detectable with accuracy regardless of the method used or location of the 
vascular bed. Identification of retinal vascular dysfunction in patients with peripheral microvascular 
abnormalities showed, for the first time that functional impairments within the ocular circulation as 
assessed by DVA were correlated. Correlating these two different vascular beds indicates that 
dynamic analysis of vascular function is a variable specific for each individual that could be used to 
predict, prevent and monitor cardiovascular health in individuals. 
 
9.2 The effects of physical training on retinal and systemic microvascular function. 
It has been demonstrated that a sedentary lifestyle is a risk factor for increased weight gain. Excess 
adipose tissue induces several metabolic changes, including dyslipidaemia, elevated BP, oxidative 
stress, increased inflammation, and in so doing, contributes towards atherosclerosis, increased 
arterial stiffness, and macro- and micro-vascular endothelial dysfunction. More recently researchers 
were able to predict midlife endothelial dysfunction based on factors such as, BMI and total 
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cholesterol and fitness level in children; noting that these predisposing factors in childhood lead to 
adult obesity and in turn risk factors for CVD development. Physical exercise has been recognized as 
an important modifiable lifestyle intervention, mainly due to its effects on energy expenditure, 
reduction of adiposity and increasing NO bioavailability.  As such the aim of this study was to 
investigate the presence of microvascular dysfunction in overweight individuals and to assess the 
effects the physical exercise on these measured clinical variables. It was hypothesised that, based on 
recent evidence highlighting the improvements in macrovascular function measured by FMD 
through exercise, that overweight patients would demonstrate improvements in retinal vascular 
reactivity to flicker light in conjunction with improvements in systemic vascular function post weight-
loss through exercise. 
The findings showed that after the exercise regimen, participants had lower arterial reaction times 
for maximum dilation for the first provocation and overall throughout the three flicker cycles 
compared to baseline. The minimum diameter was also lower on the first flicker cycle and was 
maintained throughout. The percent constriction from baseline was markedly increased for the first 
flicker cycle and throughout. Lower reaction times to constriction were also reduced which results in 
a shorter period of time required for the vasculature to return to baseline values. However, no 
differences were found for the peripheral vasculature.  Correlations were nevertheles found 
between the retinal and peripheral vascular parameters explored in this study. 
Physical exercise has positively modified the retinal microcirculation function and, moreover, for the 
first time, results showed that the retinal microvascular reactivity can be augmented through 
exercise. These findings indicate that subclinical signs of retinal vascular dysfunction appear to be 
present in overweight individuals and that these measured clinical variables can be improved with 
physical exercise.  The importance of considering retinal vascular function in the prevention and 
management of overweight patients has been highlighted and, furthermore, through the utilisation 
of this technique vascular function that contributes to increases of endothelial function.  
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9.3 The long-lasting effects of fasting during the month of Ramadan on retinal and peripheral 
vascular function. 
Having established that the manifestation of retinal vascular dysfunction can be improved through 
physical exercise in overweight individuals, an exploration into whether this could be accomplished 
through fasting was the next logical step.  Ramadan fasting is defined as periodic food and water 
deprivation during daylight hours and itself can cause a reduced caloric intake in which people 
usually resort to two instead of three meals a day. It has been indicated that participants who are 
under 36 years of age will benefit greatly during the period of abstinence with reductions in BMI, WC 
and BP. Furthermore, studies have also demonstrated favourable lipid profile enhancements which 
can suggest that decreased calorie intake through fasting can improve individual CVD risk profile.  
Endothelial dysfunction is first pre-clinically noted in microvasculature circulation. Thus 
interventions to target detection at the micro-vascular level in conjunction with macro vascular level 
could provide early anticipation of endothelial dysfunction that leads to a negative impact on an 
individual’s CVD risk profile. Therefore, the aim of our study was to measure, for the first time, 
endothelial function at the microvasculature level that can be observed non-invasively. Retinal and 
peripheral level of endothelial functions were examined to determine important information on the 
benefits of fasting. The hope was that this would clarify whether fasting can be used as an 
intervention for the improvement in micro-vascular function.  
The findings did not indicate any measureable changes in anthropometrics but higher arterial 
maximal diameters for the first flicker provocation were found and overall throughout the three 
flicker cycles compared to their non-fasting status were found. Similar results were found in the 
amount of dilation %, which shows that retinal arteries on average were able to dilate from baseline 
to MD significantly better during fasting than during non-fasting period.  For retinal, BCFR was 
notably stable during the fasting period compared to the non-fasting period that showed great 
variations in assessment. The study showed tendencies in individuals on average had better 
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peripheral vascular function during fasting but that these measured parameters were not significant 
during the non-fasting period.  These findings provide support for the concept that dietary 
restriction through fasting is another method that can improve endothelial function through 
enhancements of the microcirculation. Interestingly, the nature of the retinal vascular alterations 
identified in the fasting participants appear to differ from those of the previous chapter. Fasting 
individuals retinal vessels have a better capacity to maximally dilate while in individuals who 
exercised, it was distinguished that the retinal vessels were much faster at responding to 
provocations. This is a novel finding which would benefit from further investigation to clarify its 
significance and determine the fasting versus exercise approach of weight-loss and their effects on 
the retinal vessel profile.   
9.4 The effect of bariatric surgery on retinal vessels structure and systemic microvascular function 
The prevalence of individuals who are overweight or obese is increasing rapidly in the developed 
world. Although this has increased for both sexes and all age and racial/ethnic groups, certain 
disparities may exist. Obesity in childhood, which is dramatically increasing, is a strong predictor of 
obesity in adulthood and studies have demonstrated that being overweight in early adult years is 
associated with a substantial incidence of obesity by middle age. Obesity increases the risk of 
cardiovascular disease and is targeted when treating patients who have progressed to diseased 
state. Indeed, obesity plays a key role in endothelial dysfunction and involves either an increase (or a 
decrease) in any of the endothelial-related chemical messenger and/or by alteration in any of the 
structural or functional vascular changes. Thus, endothelial dysfunction is one of the earliest 
hallmarks of vascular abnormality and measurement of endothelial dysfunction is proposed to be an 
early stage increased risk for CVD and may help in early detection and management of individuals at 
risk of developing CVD.  As such the aim of this study was to assess the effects bariatric surgery on 
ocular and systemic vascular alterations in previously untreated morbidly obese patients.   It was 
hypothesised that, based on recent evidence and from the previous findings, weight-loss 
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interventions should improve ocular and systemic vascular dysfunction and reduce overall 
cardiovascular risk.  
Findings showed that participants had greatly reduced anthropometric measurements including a 
favourable drop in blood pressure. Interestingly, IOP was also reduced one year after surgery. 
Furthermore, changes in lipid profiles were prominent that also resulted in a decreased CVD risk as 
calculated by FRS. However, it should be noted that these decreases were substantially lower than 
initial baseline measurements but our cohort it still categorized as obese due to their BMI >30kg/m2. 
Arterial stiffness was reduced, and microvascular function improved possibly through an increase in 
NO bioavailability. Furthermore, increases in the area under the curve, is a marker of improved 
endothelial function because blood traveling through more elastic vessels takes a longer time. This is 
the first time DTM has been used for comparisons after bariatric surgery in morbidly obese 
individuals. The inter-relationships identified between the investigated ocular and systemic 
parameters provide support for the decreases in CVD risk and the improvements in endothelial 
function.   
Retinal vessel structural alterations in the arterioles had improved and were negatively correlated 
with the degree of systemic BP.  Additionally favourable lipid profile such as increases in HDL-c were 
also positively correlated with increases in arteriolar diameter. Interestingly the findings showed, for 
the first time increases in venule diameter, which is classically associated with obesity, after an 
intervention while other studies have reported decreases. Although these findings suggest 
favourable CVD risk profile outcomes after bariatric surgery, supplementary enhancements to 
participants’ habitual diet and exercise as well as advice on the psychology of sedentary behaviour 
must be reinforced to the patient. 
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9.5 Anterior eye health after weight reduction through bariatric surgery. Is there an improvement 
in anterior ocular health? 
The impact of obesity on health and its harmful effects on the body are well known. There have 
been studies which have tried to establish associations between obesity and ocular pathologies, 
such as glaucoma, cataracts, and diabetic retinopathy but these are mainly due to obesity related 
risks of systemic diseases that can manifest themselves through visual disorders of the posterior eye.   
However, less is known about the impact of obesity on the tear film and whether there are any 
association’s related to ocular surface health. Dry eye syndrome is a multifactorial disease of the 
ocular surface that can result in tear film instability. It can be brought upon by certain medications, 
and poor nutritional diets. More recently, Floppy Eyelid Syndrome (FES) has been associated with 
ocular surface disease resulting in dry eyes, this is important because the number one risk factor for 
the development of floppy eyelid syndrome is obesity. Additionally, elevated amounts of serum 
lipids was associated with dry eyes in the Beaver Dam eye study and in the Taiwan nationwide 
population based survey. Conversely, there have been studies that have also shown no relationship 
between serum lipid markers and ocular surface health.  
The exact mechanism for the association between dry eye syndrome and obesity has yet to be 
explained. Therefore, the aim of this study was to evaluate ocular surface health in obese individuals 
before and after bariatric surgery. Findings showed that bariatric surgery did not improve any of the 
measured clinical variables. However, there were tendencies for the reduction in the tear meniscus 
height which would suggest a negative finding, as well as, a trend for meibomian gland drop out to 
be reduced which suggests a positive finding but again, these were not significant. There were also 
no correlations between serum lipid markers and any of the measured ocular surface parameters 
even though previous studies had noted these findings. The participants were asymptomatic and the 
results show that obesity does not necessarily cause ocular health problems nor can it be 
ameliorated or improved through bariatric surgery.  
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